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ABSTRACT
BETHANY JABLONSKI HORTON: TEST-DEPENDENT SAMPLING
DESIGN AND SEMI-PARAMETRIC INFERENCE FOR THE ROC CURVE
(Under the direction of Dr. Haibo Zhou)
The receiver operating characteristic (ROC) curve and area under the ROC curve (AUC)
are used to describe the ability of a screening test to discriminate between diseased and
non-diseased subjects. As evaluating the true disease status can be costly, researchers can
increase study efficiency by allowing selection probabilities to depend on the screening test.
We consider a test dependent sampling (TDS) design where TDS inclusion depends on a
continuous screening test measure. Disease status is validated only for subjects in the SRS and
TDS components. To improve efficiency, this sampling design incorporates three components:
the simple random sample (SRS) component, TDS component, and the un-sampled subjects.
We propose semi-parametric empirical likelihood estimators for the AUC, partial AUC,
and the covariate-specific ROC curve. First, the AUC estimator allows us to summarize
the ability of the screening test to distinguish between diseased and non-diseased subjects.
Empirical likelihood methods are used to avoid making distributional assumptions for the
screening test variable. Second, the AUC estimator is adapted to estimate partial AUC when
a subset of false positive rates is more clinically relevant. Third, the covariate-specific ROC
curve is estimated using a binormal model for the screening test variable. Although parametric
assumptions are made for the screening test, distributional assumptions are avoided for the
covariates by using empirical likelihood methods. This ROC curve estimator allows us to
assess the influence covariates have on the accuracy of the diagnostic test.
This cost-effective sampling design allows for a more powerful study on the same budget.
Efficiency is gained in all three estimators by incorporating information from both the sampled
and un-sampled portions of the population.
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Chapter 1
Literature Review
1.1 Introduction and motivation
Using statistical tools to discriminate between different populations is beneficial in a wide
variety of areas. One such tool is the receiver operating characteristic (ROC) curve, which
was developed for electronic signal detection (Hanley, 1989). The diagnostic methods have
been expanded to be useful in a wide variety of medical applications: from medical imaging
techniques (Swets, 1979) and studying risk markers for cardiovascular disease (Yeboah et al.,
2012) to using prostate-specific antigen to detect prostate cancer (Dodd and Pepe, 2003b)
and applying time-dependent accuracy summaries in the setting of survival analysis models
(Heagerty and Zheng, 2005). There is also a wide variety of statistical methods proposed in
this area: from new summary measurements to methods of dealing with missing data in this
diagnostic setting and changing the way in which subjects are sampled into the study.
Receiver operating characteristic (ROC) curves and area under the ROC curve (AUC) are
summary measures used to describe the ability of a screening test to discriminate between
diseased and non-diseased subjects (Bamber, 1975). As evaluating the true disease status can
be costly, it is beneficial for researchers to increase study efficiency by allowing selection prob-
abilities to depend on the screening test (Wang et al., 2012). Increased efficiency translates
to cost and time savings for studies as well as decreased burden on subjects.
Consider screening for non-small-cell lung carcinoma (NSCLC) cancer recurrence. Lung
cancer is the most common cause of cancer death among men and women in the world
(Blanchon et al., 2006). Lung cancer is classified as either small-cell lung carcinoma (SCLC)
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or non-small-cell lung carcinoma (NSCLC), of which NSCLC accounts for approximately 80%
of all lung cancers. After surgical lung resection, a large proportion of stage 1 NSCLC patients
have cancer recurrence within five years (Bueno et al., 2012). When surgery is used as the
primary treatment for NSCLC, adjuvant chemotherapy may benefit patients who have a high
risk of cancer recurrence. Identifying patients who are at high risk of cancer recurrence
is important in order for treatment to be given to those who would benefit most. This is
an important area of study for patients, families, and doctors when making decisions on a
treatment plan.
We used data from the data from the CALGB 150807 study conducted by the Cancer and
Leukemia Group B (Bueno et al., 2012). This study is a subset of patients registered in the
CALGB 140202 study who have stage 1A or 1B non-small-cell lung cancer (NSCLC). Among
patients in the CALGB 150807 study, 1,061 patients were not censored before 12 months
and were used in this analysis. The Balcone risk score, outlined by Blanchon et al. (2006),
has been developed to identify patients who are at greatest risk of cancer recurrence. The
risk score is developed by considering factors such as age, gender, activity level at diagnosis,
histological type, and the tumor-node-metastasis staging system.
There are many interesting questions that can be explored in this study. AUC can be
used to investigate the ability of the Balcone risk score to predict cancer recurrence. Given
the need for an accurate test, partial AUC (pAUC) can be used to evaluate the performance
of the Balcone risk score where a specific range of FPRs or TPRs is considered. Because large
FPRs are less clinically relevant, we can restrict the range of interest to FPR∈ (0, 0.3), for
example. With the wealth of patient information available, a covariate-specific ROC would
allow us to evaluate the performance of the Balcone risk score, while accounting for covariates
that appear to be associated with cancer recurrence. This covariate-specific ROC estimator
can then be used to identify subsets of the population where the screening test is better at
distinguishing between subjects who have cancer recurrence and those who do not.
There have been many methods studied and proposed in the area of ROC and AUC
analysis. Bamber (1975) proposed a nonparametric AUC estimator, which is equivalent to
the Mann-Whitney U-statistic (Pepe, 2004). Parametric AUC estimators were developed by
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Swets and Pickett (1982) and Hanley et al. (1983). These methods use SRS for selection
into the study. Wang et al. (2012) proposed a nonparametric AUC estimator which utilizes
a biased sampling design in order to target subjects who contribute more information to the
study. McClish (1989) and Thompson and Zucchini (1989) introduced the idea of evaluating
only part of the AUC when a subset of FPRs are of interest. The pAUC can be interpreted
as the joint probability that YD > YD¯ and YD¯ fall within the FPR range of interest (Dodd
and Pepe, 2003a). Estimators similar to those given above for the AUC have been proposed
for the pAUC. A nonparametric pAUC estimator that uses SRS data was proposed by Dodd
and Pepe (2003a) and a nonparametric pAUC estimator using a biased sampling scheme
was proposed by Wang et al. (2012). Another discriminatory measure used to differentiate
between two populations when data are available over time is the C statistic (Rizopoulos,
2011; Pencina et al., 2012b; Heagerty and Zheng, 2005; Antolini et al., 2005). The C statistic
is a weighted average of the AUCs across multiple time points in the study. Heagerty and
Zheng (2005) suggested that the time specific AUCs can be plotted over time to assess changes
in accuracy across time for a time to event outcome.
Another important area of research the use of covariates in modeling ROC and in esti-
mating AUC and pAUC. The use of covariates allows us to better understand the influence
covariates have on accuracy of the screening test (Wang et al., 2013). Thompson and Zucchini
(1989) proposed nonparametric direct estimation of the AUC for specific level of a categorical
covariate. Wang et al. (2013) proposed ROC estimation which uses a biased sampling design
and a binormal model for screening test variable. Dodd and Pepe (2003a,b) proposed using
a generalized linear model framework for modeling the screening test, which can be used to
estimate AUC and pAUC.
The proposed work focuses on estimation of AUC, pAUC, and a covariate-specific ROC
curve using biased sampling methods and all available information, including incomplete
information available for un-sampled subjects. We consider a test dependent sampling (TDS)
design where TDS inclusion is dependent on a continuous screening test measure. Here,
the Balcone risk score is the measure used for the biased sampling scheme. This biased
sampling design incorporates a simple random sample (SRS), the TDS component, and the
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un-sampled subjects as opposed to a design using only a simple random sample of the same
size. The idea behind the supplemental sample is to target resources where the greatest
amount of information can be attained (Zhou et al., 2002). Cancer recurrence and other
covariate information are known only for those included in the SRS and TDS components.
The screening test measure and other baseline information are available for all subjects in the
study. Information from un-sampled subjects will also be utilized in the proposed methods.
Using the biased sampling design as well as incorporating observed information from the un-
sampled subjects can lead to efficiency improvements. This suggests that a smaller sample
size can be used with these methods, compared to existing methods, where a larger sample
size would be necessary to obtain the same level of efficiency in the estimator. A smaller
sample size translates to cost savings for the study and decreased subject burden. Using this
biased sampling design, we propose multiple approaches to studying these data that answer
different questions, which are helpful in understanding the utility of the screening test.
1.2 ROC Curves and Area under the ROC curve (AUC)
1.2.1 Unadjusted methods
There are many ways to approach the use of data in the area of medical decision making.
Methods have been proposed for a variety of types of estimators. Greenhouse and Mantel
(1950) suggested that to be considered an acceptable test, a screening test should be able to
correctly classify at least a pre-specified percentage of the diseased subjects and incorrectly
classify no more than a set percentage who are well. Other common measures include area
under the ROC curve (AUC) and partial AUC, where a particular interval of FPRs or TPRs
are of interest. A three dimensional extension of ROC and AUC was proposed by Skaltsa
et al. (2012), where instead of a two level outcome (diseased or not diseased) the outcome can
have more levels. This is beneficial for studying diseases such as Alzheimer’s disease. In this
case, the disease naturally presents with a transition state that falls between normal aging
and irreversible Alzheimer’s disease, which can be described as mild cognitive impairment. Yu
et al. (2011), Liu and Zhou (2011), and Long et al. (2011b,a) considered methods to account
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for a missing outcome or diagnostic screening variable without eliminating those subjects
from the analysis, limiting bias and loss in efficiency. Wang et al. (2012, 2013) suggested
an alternate approach to sampling subjects in order to target those who contribute more
information. With this biased sampling scheme, a smaller sample size can be used to attain
estimates that are as good as or better than alternative sampling methods, such as SRS.
ROC and AUC
The receiver operating characteristic (ROC) curve is a tool used to display how well a
screening test, Y , is able to indicate disease status, D. The ROC curve is constructed by
plotting the false positive rate (FPR, Pr (Y ≥ c|D = 0)) versus the true positive rate (TPR,
Pr (Y ≥ c|D = 1)), where c is the threshold for the screening test to indicate disease. The area
under the ROC curve (AUC) is a summary measure used to determine both the importance
of a difference between two populations and also describes the accuracy of discrimination
performance (Bamber, 1975). Figure 1.1 shows an ROC curve with corresponding AUC. The
FPR and TPR range from 0 to 1, and the AUC ranges from 0.5 to 1. An ROC curve with
intercept 1 and slope 0 indicates a perfect screening test that correctly identifies disease status
in every subject. An ROC curve with intercept 0 and slope 1, creating a 45o line, indicates
a screening test that is essentially as good as flipping a coin. A screening test with an ROC
curve that falls above the 45o line indicates some level of ability of the screening test to
discriminate between diseased and non-diseased subjects.
Another summary measure is the partial AUC (pAUC), shown in Figure 1.2. The pAUC
restricts the FPR (or TPR) to a range that is more clinically relevant. McClish (1989)
and Thompson and Zucchini (1989) introduced the idea of evaluating only part of the AUC
for certain FPR intervals that are of interest. The pAUC can be interpreted as the joint
probability that YD > YD¯ and YD¯ fall within the FPR range of interest (Dodd and Pepe,
2003a). There are downsides that must be considered when using the pAUC. The standard
error of the pAUC estimator increases and there is a loss in precision when a major restriction
is made on FPR (Walter, 2005).
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Figure 1.1: Area under the ROC curve Figure 1.2: Partial area under the ROC
curve
AUC and pAUC estimators
A binormal model for estimating AUC was proposed by Swets and Pickett (1982) and
Hanley et al. (1983). They compared the binormal model for estimating AUC to the non-
parametric AUC estimator. Swets and Pickett (1982) suggested that the method assum-
ing a binormal model for the screening test variable is superior to the nonparametric es-
timator because with the binormal model, the estimator is less affected by location and
spread of points that define the ROC. The area under the empirical ROC curve is given by
AˆSRS = 1nDnD¯
∑nD¯
j=1
∑nD
i=1
[
I
(
YDi > YD¯j
)
+ 12I
(
YDi = YD¯j
)]
, which is the Mann-Whitney U-
statistic (Bamber, 1975). Both of these approaches to estimating the AUC use data that are
sampled from the population with SRS.
Dodd and Pepe (2003a) extended this AUC estimator in the SRS setting for pAUC. The
proposed pAUC estimator restricts the FPR (or TPR) and is given by
AˆSRSt =
1
nDnD¯
n∑
i=1
n∑
j=1
Di (1−Dj) I (Yi > Yj , Yj ∈ (q0, q1))
where q0 = FPR
−1 (t1) and q1 = FPR−1 (t0). This estimator is nonparametric and shows
great improvements compared to other estimators, such as being more robust while losing
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only moderate efficiency compared to parametric estimators. For the FPR component of the
estimator, they found that using the estimated quantiles instead of the true quantiles gave
improved efficiency for estimating pAUC (Dodd and Pepe, 2003a).
An empirical likelihood method for estimating AUC was proposed by Qin and Zhou (2006).
This estimator showed improved small sample properties compared to assuming a normal ap-
proximation. A confidence interval for the AUC was also developed. The empirical likelihood
methods made it possible to obtain estimates for parameters without specifying a distribution
for the screening test. To obtain confidence intervals, they showed that their proposed AUC
estimator followed a scaled chi-square distribution, giving asymptotically correct coverage
probability. Although these methods were derived for a SRS, the methods can be extended
to account for a stratified sampling design. McNeil et al. (1984) developed methods when a
fixed FPR or TPR are of interest. These methods assumed normality of the screening test
variable.
TDS methods
Wang et al. (2012) proposed estimators for both AUC and pAUC that improve efficiency by
using a biased sampling design. These estimators are nonparametric and show improvement
over the simple random sampling setting when using the standard AUC estimator and the
pAUC estimator proposed by Bamber (1975) and Dodd and Pepe (2003a), respectively. The
form of these estimators is similar to that of the SRS estimators, but weights are incorporated
that account for the biased sampling design. The AUC and pAUC estimators proposed by
Wang et al. (2012) are given by:
AˆTDS =
∑n
i=1
∑n
j=1 pipjDi (1−Di) I (Yi > Yj)∑n
i=1
∑n
j=1 pipjDi (1−Di)
Aˆt
TDS
=
∑n
i=1
∑n
j=1 pipjDi (1−Di) I
(
Yi > Yj , Yj ∈ ˆFPR
)
∑n
i=1
∑n
j=1 pipjDi (1−Di)
where the false positive rate is estimated by ˆFPRj =
∑
i pˆi(1−Di)I(Yi>Yj)∑
i pˆi(1−Di) . In Wang et al.
(2012), the TDS methods described for AUC and pAUC were used in evaluating the survival
benefit of celecoxib, a COX-2 inhibitor, for patients with positive COX-2 expression. COX-2
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is a protein that is over-expressed with lung cancer. Its intensity ranges from 0 to 10, and it
stratified into three groups to obtain the TDS portion of the sample: negative (COX-2 < 2),
moderate (2 ≤ COX-2 < 4), and positive (COX-2 ≥ 4). Preliminary data showed that the
proportions of patients falling into these categories were approximately 60%, 13%, and 27%,
respectively. In order to study the relationship between COX-2 value and survival, a range of
COX-2 values needs to be seen. Because treating and tracking outcomes for subjects is costly,
a sample is usually taken in order to complete the study on a fixed budget. The TDS method
for sampling was implemented in order to select enough subjects with moderate and positive
COX-2 to study this relationship. Define D = 1 as patients who survive less than 6 years
and D = 0 otherwise. Targeting a small range for the FPR can be important as false positive
results add increased cost and burden on subjects. With this in mind, the FPR interval of
interest was (0, 0.1). More details in the biased sampling component for this estimator are
given later in the Outcome-Dependent-Sampling portion of the literature review.
1.2.2 Covariate adjusted methods
Methods have been developed which consider the effect of covariate information on ROC
curves. This can be accomplished in many ways, such as estimating the covariate effect
on the screening test, directly estimating the AUC, and directly estimating the covariate
specific ROC curve. Tosteson and Begg (1988) proposed modeling the effect of covariates on
the screening test, Y . Here, a distribution function was assigned for Y , and the resulting
covariate effect on the ROC curve was calculated. There are limitations here, as model
misspecification can lead to erroneous results. Thompson and Zucchini (1989) and Dodd and
Pepe (2003a) proposed directly estimating the AUC, and Dodd and Pepe (2003a) proposed
directly estimating pAUC, while accounting for covariates. Methods for directly estimating
the survival function or the ROC curve were proposed by Pepe (1997, 2000), Cai and Pepe
(2002), and Wang et al. (2013). Generalized linear modeling methods were used in Pepe
(1997, 2000). These results were extended to a semi-parametric approach by Cai and Pepe
(2002).
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Thompson and Zucchini (1989) proposed that estimation can be completed by specifying
a distribution function for Y or can be completed nonparametrically using the Wilcoxon
statistic: ˆAUCk = n
−1
D,kn
−1
D¯,k
∑nD,k
i
∑nD¯,k
i {I [Yj < Yi] + 0.5I [Y i = Yj ]}, where k = 1, . . . ,K
denotes the covariate level. Thompson and Zucchini (1989) also proposed an analysis of
variance (ANOVA) approach for modeling to compare the means of an accuracy index for
different combinations of variables. In this setting, images are read by multiple people and
these results are compared to see how ratings compare between readers. The model is given
by Yijk = µ+ αi + bj + (ab)ij + c+ eijk, where µ+ αi represents the mean level of Y for the
i-th combination of the variables. The variable bj is a random variable, allowing for variation
between image readers. Zheng and Heagerty (2007) proposed a semi-parametric estimate
of the survival function of the screening test over time. The ROC is constructed from this
estimated survival function, and AUC can be assessed over time. The added component of
following a subject’s screening test variable over time allows for the ability to assess diagnostic
accuracy at different intervals of time between measurement and diagnosis.
Methods to estimate the AUC and pAUC while adjusting for covariates provide useful
model interpretations for both discrete and continuous covariates (Dodd and Pepe, 2003a,b).
These methods are semi-parametric and take advantage of generalized linear model frame-
work. Dodd and Pepe (2003b) define the covariate specific AUC as Pr
(
Y Di > Y
D¯
j |XDi , XD¯j
)
=
θij . The regression model is given by g (θij) = X
T
ijβ, where β is a vector of parameters and
g is a monotone increasing link function. The proposed estimating function is given by
SN (β) =
∑nD
i
∑nD¯
j
∂θij
∂β v (θij)
−1 (Uij − θij) ≡
∑nD
i
∑nD¯
j Sij (β). Dodd and Pepe (2003a)
propose the covariate-specific pAUC given by
AUCX (t0, t1) = Pr
(
Y D > Y D¯, Y D¯ ∈ (q0, q1) |X
)
.
The general model is given by AUCX (t0, t1) = g
(
XTβ
)
for a specified link function g. For
the pAUC setting the estimating equation is given by
VnD,nD¯ (β) =
nD∑
i
nD¯∑
j
∂θX
∂β
v (θX)
−1
(
V
(q0,q1)
ij − θX
)
= 0
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where V
(q0,q1)
ij = I
(
Y Di > Y
D¯
j , Y
D¯
j ∈ (q1, q0)
)
. When using the logit link, exponentiated
model parameters can be interpreted as AUC or pAUC odds. For a binary covariate, the
exponentiated model parameter can be interpreted as the ratio of AUC or pAUC odds be-
tween the two levels of that covariate. For a continuous covariate, the exponentiated model
parameter can be used to describe how AUC or pAUC changes for diseased and not dis-
eased subjects as that covariate changes. Dodd and Pepe (2003b) used their proposed AUC
methods to study the ability of the distortion product otoacoustic emission (DPOAE) de-
vice in assessing impaired hearing. The DPOAE device is used at three different frequencies
and three intensity settings, creating nine combinations of settings. The severity of hearing
loss is also of interest in this setting. A behavioral test where subjects indicate the point
at which a sound is audible is the gold standard in assessing hearing loss. The model used
here is given by log
(
AUC
1−AUC
)
= β0 + β1intensity + β2frequency + β3severity. Results from
this analysis showed that DPOAE is able to discriminate between severely impaired ears and
normal ears better than mildly impaired and normal ears, which is not surprising. Also,
stimuli with lower intensities achieved greater accuracy. Dodd and Pepe (2003a) considered
the ability of prostate-specific antigen (PSA) to diagnose prostate cancer. The data came
from the α-Tocopheraol and β-Carotene Study (ATBC). Serum samples were collected and
stored at baseline and three years later. Adjusting for time was important here, especially
because the time from measurement to diagnosis varied greatly and it was expected that
PSA levels taken close to the time of diagnosis would be more predictive. Clinical evidence
showed a relationship between PSA levels and prostate cancer. Two methods of quantifying
PSA were considered, total PSA and the ratio of free to total PSA. The comparison of these
two methods was incorporated into the model. Ultimately, 240 subjects in the study were
diagnosed with prostate cancer during the eight year study follow-up period. Serum samples
were age matched for 237 non-prostate diagnosed subjects who were sampled for comparison.
They considered FPR values in (0, 0.4). The model was given by:
log
[
AUC (0, 0.4)
0.4−AUC (0, 0.4)
]
= β0 + β1test + β2time + β3test ∗ time
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The results showed that PSA accuracy improved when subjects were measured at times closer
to the time of diagnosis. Total PSA appeared to be a better diagnostic tool for prostate cancer
than the ratio.
Pepe (1997) proposed a regression design that directly modeled covariate effects on the
ROC curve. Denote D the binary indicator of disease status, Y the non binary diagnostic test,
Z the factors that potentially influence test accuracy, and X the vector of covariates. The
ROC curve associated with Z for a logistic model is given by ROCZ (t) =
exp{α0(t)+Xβ}
1+exp{α0(t)+Xβ} ,
where α0 (t) is a monotone function from (0, 1) to (−∞,∞), and t denotes the false positive
rate. No distributional assumptions are made for Y ; assumptions are made only for the
relationship between diseased and non diseased subjects through the ROC curve model. This
approach allows for examining the influence covariates have on the accuracy of a diagnostic
test in discriminating disease status. This method was applied to radiology data, the same
used in Thompson and Zucchini (1989), where images were constructed and then evaluated
by three readers. Here, there were 50 each of diseased and non diseased images and the
readers classified their evaluation of each image with an ordinal scale from 1 to 5. After
data collection, the 4th and 5th categories were collapsed due to sparse data. A logistic
type regression was fit to the data with the model ROCZ (t) =
exp{α0(t)+β1X1+β2X2+β3X3}
1+exp{α0(t)+β1X1+β2X2+β3X3} ,
where Xi corresponds to the evaluation made by the i
th reader. This technique allowed for
comparisons between readers, such as reader 3 rating images systematically lower than the
other two readers.
An ROC curve estimator was proposed by Wang et al. (2013), which uses test dependent
sampling (TDS), a biased sampling design. With this method, portions of the population
are oversampled to gain efficiency. A binormal model is assumed for the screening test, Y ,
such that Y = β0 + βDD + β
T
XX + β
T
DXDXD + σ (D) , where  ∼ N (0, 1) and σ (D) =
σ1I [D = 1] + σ0 [D = 0]. No distributional assumptions are needed for the covariates due to
the use of empirical likelihood methods. Estimates of the survival function were estimated
and combined for a covariate-specific ROC curve, given by: ROCX (t) = S1X
(
S−11X (t)
)
=
Φ
(
βD+β
T
DXXD+σ0Φ
−1(t)
σ1
)
. This method was applied to data from a study evaluating the
prognostic value of COX-2 for survival of patients with lung cancer, the same used in Wang
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et al. (2012). Covariates such as age and gender were included in the model. These covariates
not only have a relationship with cancer survival, but also on the COX-2 expression, so
ability to include these covariates in the study is valuable. Simulation studies showed that
the estimator will perform fairly well under mild misspecification of the binormal model.
Other summary measures
Another discriminatory measure used to differentiate between two populations is the C
statistic (Rizopoulos, 2011; Pencina et al., 2012b; Heagerty and Zheng, 2005; Antolini et al.,
2005). In situations such as survival analysis settings, time dependent ROC and AUC can
be used to evaluate the screening test over time. Rizopoulos (2011) described the C statistic
as a summary of the screening test variable over the study period. This weighted average
of the AUCs is given by C =
∫
AUCtPr(T ∗i >t)dt∫
Pr(T ∗i >t)dt
, where Pr (T ∗i > t) is the marginal survival
probability. The marginal survival probability takes into account censoring, since all time
points will not contribute equally. Heagerty and Zheng (2005) suggested that the time spe-
cific AUCs can be plotted over time to assess a change in accuracy across time. While the
methods proposed by Heagerty and Zheng (2005) and Rizopoulos (2011) are semiparametric,
the methods proposed by Antolini et al. (2005) are non-parametric making them more robust.
Missing data
Instead of focusing of new types of summary measures for discrimination between popula-
tions, Yu et al. (2011), Liu and Zhou (2011), and Long et al. (2011b,a) considered the common
issue of missing data. Long et al. (2011b,a) developed methods for missing screening test val-
ues. Loss of efficiency and, depending on the type of missingness, bias may be introduced
when only including subjects with complete data. Both missing at random and missing not at
random scenarios are considered. This AUC estimator was shown to work well under model
misspecification. Nonparametric imputation procedures were used in developing methods to
analyze ROC when the biomarker for screening was missing. In this case, other auxiliary
variables were present and were used in imputing the main biomarker of interest. Instead of
the absence of the screening test variable, Yu et al. (2011) and Liu and Zhou (2011) developed
methods where the gold standard (verification of disease status) was missing. Yu et al. (2011)
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combined multiple continuous tests together as a composite test to discriminate between two
populations. It was assumed that the test values are binormal, and a Bayesian latent disease
model was used, along with an MCMC algorithm for computation. Glomerular filtration rate
(GFR) is a measurement associated with the ability of the kidneys to filter. A reduced GFR
is a marker for chronic kidney disease. Chronic kidney disease is defined as kidney damage
or GFR measurement below a set threshold. There are different ways to estimate the GFR
and no true gold standard in defining chronic kidney disease. Methods proposed by Yu et al.
(2011) were used to assess the optimal way of measuring GFR to diagnose chronic kidney dis-
ease. Liu and Zhou (2011) developed a semiparametric ROC curve estimator where the gold
standard is missing for a subset of the study population. The missing at random assumption
was assumed in the development of these estimators. Weighted estimating equations were
used to account for the missing gold standard for a subset of the subjects.
Optimal threshold for Y
Another interesting and important research topic in the area of ROC and AUC is choos-
ing the best threshold value of the screening test to indicate disease. Different approaches
can be considered in finding the optimal threshold for the screening test and in assessing
improvement in the screening tests available. Molanes-Lo´pez and Leto´n (2011) used empir-
ical likelihood methods to assess the most appropriate cut-off value for the diagnostic test
using the Youden index. The nonparametric empirical likelihood methods were compared to
a newly developed parametric methods. Simulation studies showed that the nonparametric
method was competitive with other parametric methods and was superior. Pencina et al.
(2012a) evaluated the improvement in population discrimination using AUC. These methods
assume multivariate normality and use a linear discriminant analysis. The measures under
study reduce to a function of Mahalanobis distance, which helps to describe the magnitude of
improvement in estimation. Let M2p+q = δ
TΣ−1δ denote the Mahalanobis distance for p + q
cases. The first of the three estimators proposed was assessing the change in AUC, ∆AUC.
This estimator reduces to ∆AUC = Φ
(√
M2p+q
2
)
− Φ
(√
M2p
2
)
.
To evaluate competing events, Zheng et al. (2012) proposed a method that evaluates
13
the predictive accuracy of a marker for each type of event. Huang et al. (2011) proposed a
nonparametric procedure that optimizes the linear combination of diagnostic tests to max-
imize the AUC. Combining these diagnostics provides a combined score that can used to
estimate the AUC estimator. Four methods were considered in estimating AUC, including
cross-validation, bootstrap, sigmoid function smoothing, and approximated cross-validation
for variable selection. As these methods can be very computationally intensive, the cross-
validation methods are strongly suggested, in an effort to reduce computational cost.
ROC and AUC are discriminatory measures that can be used when the outcome has two
levels, such as diseased versus not diseased. When the outcome has more than two levels,
other approaches need to be considered. Skaltsa et al. (2012) developed methods to assess
the optimum threshold for this diagnostic setting. Consider Alzheimer’s disease. This disease
naturally presents with a transition state that can be described as mild cognitive impairment,
which falls between normal aging and irreversible Alzheimer’s disease. A three-dimensional
classification plot is constructed, which is similar to the ROC curve. Volume under the surface
of this three-dimensional plot gives a measure of accuracy that is similar to AUC. Different
weights can be used in the estimator that involve the cost of evaluation to aid in finding the
optimum threshold. Disease prevalence and classification cost are incorporated here, both of
which need to be considered when finding the cut-off for the optimal test.
1.3 Outcome dependent sampling
1.3.1 Methods for binary and discrete outcomes
Many study designs exist to help assess the relationship between disease and exposure.
Prospective studies are one such example, but these studies tend to be time consuming and
expensive. When a rare disease or event is of interest, the study population would have to
be quite large to observe enough subjects with disease in order to assess a relationship. Time
is also an important factor in this type of study design, especially if time from exposure to
observing the event is large. Retrospective studies are another way of studying disease and
exposure relationships.
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The case-control sampling design is a very beneficial design when exploring relationships
between covariates and a dichotomous disease (or outcome) status. Logistic regression is a
tool used to explore the relationship between the dichotomous disease outcome and multiple
variables of interest. The logistic model is expressed as log
(
p
1−p
)
= β0+β1x1+· · ·+βjxj = xβ
where p = Pr(y = 1|x) (Prentice and Pyke, 1979). This tool extends the ability to study the
relationship between disease and exposure status to include other covariates of interest. In
situations where subjects are selected using biased sampling methods, the sampling design
must be accounted for, and basic logistic regression cannot be used.
When there is interest in studying a rare disease or exposure, taking a random sample
of the population may not provide a sufficient number of diseased or exposed subjects to
obtain model estimates and understanding of the rare disease or exposure of interest. White
(1982) suggested a two-stage approach where disease and exposure status are found for a
large sample in the first stage, which can be time consuming and costly. This design offers
improvement over a one stage design because some groups would contribute small cells in the
stratum-specific table. In the second stage, covariate information is found for only a stratified
subsample of the first stage subjects. Sub-sampling in the second stage is accomplished by
separating subjects into four groups based on their disease and exposure status. Rare diseases
or exposures will have more representation in the study by using this approach. Ascertaining
exposure status and covariates can be expensive and also invasive for subjects, which can
be problematic since exposure is established in the first stage. Similar to the two-stage case
control design described above is the case-cohort design. Prentice (1986) suggested a two stage
design where the disease status is identified in the first stage. One or more subjects without
disease are then matched to a diseased subject, and a random sample is then selected from
the entire cohort, or study population, in the second stage. From here, covariate information
is ascertained for the selected cohort and case subjects.
Multi-level outcome and exposure
Discrete choice analysis was discussed in Manski and McFadden (1981). Instead of the
binary classification for outcome and exposure, the classification is generalized so that there
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can be many options of outcome and exposure indication. This structure is beneficial in
situations where instead of looking at non-diseased versus diseased, it may be more informative
to consider non diseased and multiple levels of disease severity. Hsieh et al. (1985) and
Scott and Wild (1986) developed a conditional maximum likelihood method for choice-based
sampling. Estimators for response probabilities (the probability of illness given exposure and
other covariates) were proposed. Breslow and Cain (1988) combined the two-stage sampling
framework with the conditional maximum likelihood developed by Hsieh et al. (1985) for
choice-based sampling. This modified logistic regression method adjusts for potential biased
caused by oversampling certain groups in the second stage. Fears and Brown (1986) used
a maximum likelihood estimation method that included stratum specific terms for the case-
control setting. This work was improved upon by Scott and Wild (1991) where the method
was made more computationally reasonable.
1.3.2 Methods for continuous outcomes
Zhou et al. (2002) proposed a semiparametric empirical likelihood method using outcome
dependent sampling design for continuous outcomes. The information available for sam-
pled subjects is a continuous outcomes variable, Y , and a vector of covariates, X. For the
continuous outcome Y , consider splitting the variable into K mutually exclusive intervals,
Ck = (ak−1, ak], k = 1, ...,K, where a0 = −∞ < a1 < a2 < · · · < aK = ∞. The sampling
components consist of a SRS portion and an ODS portion. For the ODS portion, sampling
is targeted within the K intervals. The available data is given by {Yki, Xki}, where k indexes
the sampling group (k = 0 indicates the SRS sampling component) and i indexes the subject
within the kth sampling group. The sample size is n = n0 +n1 + · · ·+nK . Denote the density
of Y given X as fY |X (y|x, β) where β is the regression coefficient of interest. The cumulative
distribution of X is given by GX and the density function is given by gX . The likelihood of
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the observed data is given by
L (β,GX) =
{
n0∏
i=0
fβ (y0i|x0i) gX (x0i)
}
×
 K∏
k=1
nk∏
j=0
fβ (ykj , xkj |ykj ∈ Ck)

=
∏ fβ (y0i|x0i)×
K∏
k=1
nk∏
j=0
fβ (ykj |xki)
F (ak|xkj)− F (ak−1|xkj)

×
∏ gX (x0i)×
K∏
k=1
nk∏
j=0
F (ak|xkj)− F (ak−1|xkj)
F (ak)− F (ak−1)

= L1 (β)× L2 (β,GX) .
Without loss of generality, let K = 3. In order to get an estimate for β they first estimate
GX . The distribution of X is not defined. By fixing β, the empirical likelihood function
of GX can be found over all observed values of X. Denote pi1 = F (a1), pi3 = F¯ (a2), and
pi = gX (wi) where (w1, . . . , wn) = (x01, . . . , x0n0 , x11, . . . , x1n1 , x31, . . . , x3n3). The portion of
the likelihood that involves gX (wi) is given by L2 (β,GX) = L2 (β, {pi}) ∝
∏n
i=1 pipi
−n1
1 pi
−n3
3 .
To find {pˆi} that maximizes L2, they considered the following constraints:{
pi ≥ 0,
n∑
i=1
pi = 1,
n∑
i=1
pi {F (a1|wi)− pi1} = 0,
n∑
i=1
pi
{
F¯ (a2|wi)− pi3
}
= 0
}
From Qin and Lawless (1994), a unique maximum exists for {pi} under the above con-
straints if 0 is inside the convex hull of points {F (a1|w1)− pi1} , . . . , {F (a1|wn)− pi1} and{
F¯ (a2|w1)− pi3
}
, . . . ,
{
F¯ (a2|wn)− pi3
}
. The maximum over {pi} can be found by incorpo-
rating Lagrange multipliers:
H = logL2 (β, {pi}) + ρ
(
1−
n∑
i=1
pi
)
+ nλ1
n∑
i=1
pi {F (a1|wi)− pi1}
+nλ3
n∑
i=1
pi
{
F¯ (a2|wi)− pi3
}
From here, they find that ρ = n and pˆi =
1
n
[
1 + λ1 {F (a1|wi)− pi1}+ λ3
{
F¯ (a2|wi)− pi3
}]−1
.
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Plugging this estimate {pˆi} into the original likelihood function gives an empirical log likeli-
hood. An iterative procedure such as the Newton-Raphson algorithm can be used to obtain
estimates for β. This method proposed by Zhou et al. (2002) gives a method of estimation
that is not only efficient, but no distributional assumptions need to be made for the covariates
of interest.
Zhou et al. (2007) proposed the Horvitz-Thompson approach with inverse-probability
weights for the sampling design described in Zhou et al. (2002). The parameter β is esti-
mated without specifying G (X), where β is the vector of regression coefficients that links
the exposure and outcome, X and Y , respectively. This approach requires knowledge of the
sampling probabilities, unlike in Zhou et al. (2002). If all N subjects are observed, the log-
likelihood is given by
∑N
i=1 logP (yi|xi;β). The log-likelihood is estimated by weighting the
observed subjects with the inverse of their second-stage selection probability. The inverse
probability weighted estimator, βˆIPW , is found by solving
1
N
∑
k
∑
i∈Ck
1
pk
∂
∂β
Pβ(yi|xi)
Pβ(yi|xi) = 0,
where pˆk =
nk
Nk
. Simulation results show that for evaluating the linear relationship between
a continuous exposure and continuous outcome, using the ODS technique described is more
efficient than a simple random sample. This method reduces the number of subjects needed
to obtain the same level of accuracy compared to a SRS design. This weighted method is
only available if the weights are known or can be estimated, which can be difficult in some
circumstances. Gains in efficiency are found when the continuous outcome, Y , is stratified
into a large number of groups, defined by Ck.
Inclusion of non-validation data
Chatterjee et al. (2003) and Weaver and Zhou (2005) suggested methods for an outcome
dependent sampling design that allowed for the utilization of the un-sampled portion of the
data. Consider the sampling design detailed by Zhou et al. (2002). Let Y be a continuous
outcome variable of interest that is partitioned into K mutually exclusive intervals. The kth
stratum is given by Ck = (ak−1, ak] where a0 = −∞ < a1 < a2 < · · · < aK = ∞ and
k = 1, ...,K. Let the SRS and ODS components be referred to as the validation set, indexed
by V . The un-sampled portion of the population is referred to as the non-validation set,
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indexed by V¯ . The outcome variable must be known for all subjects in the population in
order to use the ODS design. However, the covariates of interest, X, are only ascertained for
the validation set. A sampling indicator is created to distinguish between the validation and
non-validation portions where Ri = 1 if Xi is observed and Ri = 0 if Xi is not observed. The
likelihood for the validation set where the variable information is complete is given by
LV (θ,GX) =
[∏
i∈V
f (Yi|Xi; θ)
][∏
i∈V
dGX (Xi)
][
K∏
k=1
pik (θ,GX)
−nk
]
(1.1)
where pik (θ,GX) =
∫
Pk (x; θ) dGX (x) and Pk (x; θ) dGX (x) =
∫
Ck
f (y|x; θ) dy. Here Pk (x; θ)
and pik (θ,GX) are the conditional and marginal probabilities that Y is in the k
th stratum.
Consider the use of all validation and non-validation subjects. The stratum sizes for the
non-validation set are calculated by taking the total number of subjects in Ck and sub-
tracting the number of validation subjects whose outcome variable fall within Ck, given by
nV¯ ,k = Nk − n0,k − nk. The stratum size follows a multinomial law where Pr
({
nV¯ ,k
})
=
(N−n0)!∏K
k=1 (Nk−n0,k)!
∏K
k=1 [pik (θ,GX)]
Nk−n0,k . Non-validation contribution to the likelihood is given
by
K∏
k=1
∏
j∈V¯k
fY (Yj ; θ)
pik (θ,GX)
, (1.2)
where fY (Yj ; θ) =
∫
f (Yj |u; θ) dGX (u). The full likelihood is found by combining (1.1) and
(1.2), and reduces to
LF (θ,GX) ∝
[∏
i∈V
f (Yi|Xi; θ)
]
×
[∏
i∈V
dGX (Xi)
]
×
∏
j∈V¯
f (Yi; θ)
 . (1.3)
The maximum estimated likelihood estimator (MELE) developed by (Weaver and Zhou,
2005) is similar to the pseudoscore estimator (PSE) proposed by Chatterjee et al. (2003).
The semiparametric estimator proposed by Chatterjee et al. (2003) relaxes the assumption
that all subjects have a positive probability of selection. By not requiring all subjects to
have a positive selection probability, it is possible to create a sampling framework for a
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case or control only design. Although much of the results are given for a discrete outcome,
exploring these methods for a continuous outcome is possible and would require nonparametric
regression methods. These two methods (MELE and PSE) were compared and found to be
more efficient than a semiparametric maximum likelihood estimator. The MELE is found by
replacing the unspecified marginal distribution function (such as GX in (1.3) above) with a
consistent estimator. The resulting likelihood incorporates the observed selection probability
p
′
k =
(n0,k+nk)
Nk
. To use the PSE estimator, function qθ (Xi) =
∑K
l=1 p
′
lPl (Xi; θ) is substituted
for the observed selection probability (p
′
k).
Restricted maximum likelihood
Song et al. (2009) proposed an estimation method using the ODS design described in
Weaver and Zhou (2005). Empirical likelihood methods similar to those used in Zhou et al.
(2002) and Weaver and Zhou (2005) were incorporated in developing the likelihood, which
gives
gˆi =
n−∑
j∈V¯
f (Yj |Xi; θ)∑
k∈V gˆkf (Yj |Xj ; θ)

−1
, (1.4)
where g (·) is the probability density function for X. It is noted that the number of con-
straints increases as the sample size increases, and the mixed Newton method for estimation
is suggested with the following steps:
1. Begin with initial estimates θ0 and g0i , i ∈ V .
2. Insert θ0 and g0i in to the right hand side of the score equations given above (1.4) and
solve the equations iteratively using the fixed-point algorithm until it converges, calling
the solution gci .
3. Take gci from the second step and plug into the likelihood to maximize the parametric
likelihood using Newton’s method to update θc.
4. Repeat the second and third steps until the proposed convergence criteria is met.
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Efficiency gains seen in simulation studies depends heavily on the proportion of subjects
sampled in the tails for the validation set.
OADS
Outcome and auxiliary dependent sampling is a biased method of sampling where a sub-
ject’s probability of selection depends on both the outcome and an auxiliary variable. A semi-
parametric empirical likelihood method was proposed by Wang et al. (2009). These methods
were applied to a lung cancer biomarker study where it was seen that subjects with epidur-
mal growth factor receptor (EGFR) mutations responded to EGFR inhibitor drugs differently
than those without the mutation. Because of the expense in testing for the EGFR mutation,
the predicted probability of a subject having the EGFR mutation was used as the auxiliary
variable for the ODS design. Logistic regression was used to obtain the predicted probability
with the model incorporating patient record information, including variables known to be
associated with EGFR mutation. The supplementary sample was made up of two groups:
those who responded to the inhibitor (Y , outcome) and those who did not respond to the
inhibitor but had predicted probability above a set threshold (W , auxiliary). The likelihood
was developed using a generalized linear model with known link function. Misspecification
of the distribution of the covariates, G (X|w = k), will lead to inconsistent results. Because
of this, empirical likelihood methods were used to estimate the distribution function of X,
similar to the approach described for Zhou et al. (2002). Simulation studies suggest that the
OADS design shows gains in efficiency when there is a moderate to high correlation between
the biomarker and the auxiliary variable. For rare disease, this method improves efficiency
compared to SRS.
ROC and AUC
Wang et al. (2012) used the ODS framework to estimate area under the receiver operating
characteristic curve. Consider a disease outcome D and a screening test Y , where it is of
interest to measure how well this screening test is able to indicate a subject’s disease status.
In this situation, the biased sampling design is completed using the screening test, which is
known, instead of the disease status outcome, which is unknown. For this reason, instead
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of an outcome dependent sample, a test-dependent sampling design is discussed. Similar
to Zhou et al. (2002), the empirical likelihood method was used to obtain an estimate for
pi = f (Yi, Di). An ROC curve estimator was proposed by Wang et al. (2013) that incorporates
other covariate information. A binormal model is assumed for the screening test, Y . No
distributional assumptions are needed for the covariates due to the use of empirical likelihood
methods.
1.4 Proposed research
1.4.1 AUC using test-dependent sampling
Motivated by the need to improve efficiency, a semi-parametric AUC estimator is proposed
that incorporates the test dependent sampling design and the of inclusion of information from
the un-sampled portion of the population. The TDS sampling design has three components:
the SRS component, TDS component, and non-validation set (un-sampled subjects). The
subjects sampled in the SRS and TDS components combined make up the validation set,
indexed by V , where true disease status is validated. The remainder of the population not
selected for sampling makes up the non-validation set, indexed by V¯ . The disease status, D,
is only ascertained for subjects who are in the validation set. These components are defined
by
SRS component (D0j , Y0j) j = 1, ..., n0
TDS1 component (D1j , Y1j |Y1j ∈ C1) j = 1, ..., n1
...
...
...
TDSK component (DKj , YKj |Y1j ∈ CK) j = 1, ..., nK
Non-validation component (Yv¯j |i 6= (0, 1, . . . ,K)) j = 1, ..., nV¯
where nv¯ = N−n0−
∑K
k=1 nk. The portion of the likelihood for the sampled subjects is given
by LV and the portion of the likelihood for the un-sampled portion of the subjects is given
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by LV¯ . These likelihood components are given below.
LV (fD) =
K∏
k=1
nk∏
j=1
Pr (Ykj ∈ Ck)−nk ×
K∏
k=0
f (Yij |Dkj)Pr (Dkj = d)
LV¯ (fD) =
(N − n0)!∏K
k=1 (Nk − n0,k)!
×
nV¯∏
j=1
1∑
d=0
f
(
YV¯ j |DV¯ j = d
)
Pr
(
DV¯ ,j = d
)
×
K∏
k=1
Pr (Ykj ∈ Ck)−nk . (1.5)
The full likelihood is given by L (fD) = LV (fD) × LV¯ (fD) where the distribution of the
screening test conditional on disease status, f (Yij |Dij = d), is not specified. Empirical like-
lihood inference is used to estimate the distribution of the screening test, Y , conditional on
disease status. This is desirable as model misspecification can introduce problems for full
or semi parametric estimators. The Newton-Raphson algorithm is used to obtain estimates
for model parameters, which are then used to estimate the expected disease status. The
estimated expected disease status is necessary in this design because true disease status is
missing for subjects in the non-validation component. The proposed AUC estimator is given
by
AˆPV,V¯ =
∑N
l 6=l′ D
∗
l
(
1−D∗l′
)
I (Yl > Yl′)∑N
l 6=l′ D
∗
l
(
1−D∗l′
) ,
where D∗l =

Dl if l ∈ V
Ê (Dl) =
pˆ
pˆ+eαˆ+βˆyl (1−pˆ) if l ∈ V¯
. (1.6)
Simulation studies show that the proposed AUC estimator improves efficiency over other
current methods, including a SRS only estimator proposed by Bamber (1975) and a method
proposed by Wang et al. (2012) that utilizes the TDS design without incorporating informa-
tion from the un-sampled portion of the population.
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1.4.2 Partial AUC using test-dependent sampling
It may be more clinically relevant to evaluate the utility of a screening test for a subset of
false positive rates. Using the likelihood development in (1.5), then we use empirical likelihood
methods to estimate pAUC without making assumptions of the distribution of the screening
test variable. The proposed pAUC estimator is given by
AˆPt:V,V¯ =
∑N
l 6=l′ D
∗
l
(
1−D∗l′
)
I
(
Yl > Yl′ , F̂PRl′ ∈ (t0, t1)
)
∑N
l 6=l′ D
∗
l
(
1−D∗l′
) ,
where F̂PRl′ =
∑N
l (1−D∗l ) I (Yl > Yl′)∑N
l
(
1−D∗l
)
and D∗l =

Dl if l ∈ V
Ê (Dl) =
pˆ
pˆ+eαˆ+βˆyl (1−pˆ) if l ∈ V¯
. (1.7)
Simulation studies show that efficiency is improved for the proposed pAUC estimator
compared to other current methods, including a SRS only estimator proposed by Dodd and
Pepe (2003a) and a method proposed by Wang et al. (2012) that utilizes the TDS design
without including information from the un-sampled portion of the population.
1.4.3 Covariate-specific ROC curve estimation using test-dependent sam-
pling
In evaluating a ability of the screening test to assign disease or outcome status correctly,
it may be beneficial to also evaluate covariate effects on diagnostic accuracy. We propose a
semi-parametric covariate-specific ROC curve estimator which incorporates a test-dependent
sampling design and inclusion of un-sampled subjects. A binormal model is used to describe
the relationship between the screening test, the disease status, and covariates. The sampling
components are the same as described for the AUC estimator. The screening test model is
given by
Y = Xβ + σ (D)  = β0 + β1D + β2X + β3XD + σ (D)  (1.8)
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where  ∼ N (0, 1) and σ (D) = σ1D + σ0 (1−D). The likelihood is given by
L (G, p,β, σ) ∝
3∏
i=0
ni∏
j=1
f (Yij |Xij , Dij) g (Xij |Dij = d)h (Dij)
×
nV¯∏
j=1
1∑
d=0
f
(
YV¯ j |XV¯ j , DV¯ j
)
g
(
XV¯ j |DV¯ j
)
Pr
(
DV¯ ,j = d
)
dX. (1.9)
Although the screening test distribution is specified, empirical likelihood methods are used in
maximizing the likelihood without specifying the distribution function for the covariates.
1.5 Outline of dissertation
In Chapter 2, notation and data structure are defined and AUC estimation is explored.
We develop a semi-parametric AUC estimator by using empirical likelihood methods. Sim-
ulation results and analysis of data from a lung cancer study and the Preterm Prediction
Study show that the proposed AUC estimator is unbiased and more efficient than other AUC
estimators compared.
In Chapter 3, partial AUC is considered. Similar to the AUC estimator proposed in Chap-
ter 2, a semi-parametric empirical likelihood estimator for the pAUC is proposed. Simulation
results and analysis of data from a lung cancer study and the Preterm Prediction Study show
that the proposed pAUC estimator is unbiased and more efficient than other pAUC estima-
tors compared.
In Chapter 4, the covariate-specific ROC curve estimator is proposed. This semi-parametric
estimator uses empirical likelihood methods to estimate the ROC curve without making as-
sumptions on the distribution of the covariates. Simulation studies show gains in efficiency
compared to current ROC curve estimators due to the TDS design and inclusion of un-sampled
subjects. Analysis of data for a lung cancer study and the Preterm Prediction Study show
the utility of this ROC curve estimator by showing that the screening test is more effective
for some covariate values than others.
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Chapter 2
AUC under Test-Dependent Sampling
2.1 Introduction
The receiver operating characteristic (ROC) curve and area under the ROC curve (AUC)
are summary measures used to describe the ability of a screening test to discriminate between
diseased and non-diseased subjects (Bamber, 1975). As evaluating the true disease status can
be costly, it is important for researchers to increase study efficiency by allowing selection
probabilities to depend on the screening test (Wang et al., 2012, 2013). Increased efficiency
translates to cost and time savings for studies as well as decreased burden on subjects. We
propose a semi-parametric AUC estimator which incorporates a test-dependent sampling
design and inclusion of un-sampled subjects. Simulation studies show that the proposed
AUC estimator is unbiased and improves efficiency compared to estimators using a simple
random sample (SRS) design and those that use only information from the sampled subjects.
Our research is motivated by the study of non-small-cell lung cancer where we identify
patients at high risk of cancer recurrence in order to adjust treatment plans to be most
effective. Using data from the Cancer and Leukemia Group B (CALGB) 150807 study, we
evaluate the ability of the Balcone risk score to identify patients who are at greatest risk of
non-small-cell lung cancer (NSCLC) recurrence by estimating the AUC. The ROC curve is
a tool used to graphically display the ability of the Balcone risk score to identify patients
who survive beyond 12 months by plotting the false positive rate (FPR, Pr (Y ≥ c|D = 0))
against the true positive rate (TPR, Pr (Y ≥ c|D = 1)). The AUC is a summary measure
used to describe the ability of the Balcone risk score to discriminate between patients who
26
survive beyond 12 months and those who do not. When surgery is used as the primary
treatment for NSCLC, adjuvant chemotherapy may benefit patients who have a high risk of
cancer recurrence. Identifying patients who are at high risk of cancer recurrence is important
in order for treatment to be given to those who would benefit most. This is an important
area of study for patients, families, and doctors when making decisions on a treatment plan.
The proposed methods are especially beneficial considering the length of time this type of
study will follow patients and cost of following a large number of subjects in this setting.
We also consider data from the Preterm Prediction Study in evaluating the utility of the
proposed AUC estimator (Goldenberg et al., 1996). Preterm birth (PTB), defined as delivery
at less than 37 weeks of gestation, contributes to neonatal morbidity and mortality. This is
an important area of study due to the negative impact of spontaneous PTB on maternal and
child health outcomes. Knowing the fetal fibronectin (FFN) measurement will not change the
incidence of spontaneous PTB, but it can affect the treatment plan. We evaluate the ability
of FFN to predict spontaneous PTB by estimating the AUC.
Previous research has explored multiple approaches to estimating AUC. A non-parametric
AUC estimator proposed by Bamber (1975) is equivalent to the Mann-Whitney U-statistic
(Pepe, 2004). Although the Bamber (1975) estimator is unbiased, the normal approximation-
based Mann-Whitney confidence interval has low coverage accuracy for high values of the
AUC when sample sizes for diseased and non-diseased subjects are small and unequal (Qin
and Zhou, 2006). A binormal model for estimating AUC was proposed by Swets and Pickett
(1982) and Hanley et al. (1983) where the estimator is less affected by the location and
spread of points that define the ROC. For both of these approaches, subjects are selected
by SRS from the population. An empirical likelihood method was proposed by Qin and
Zhou (2006) to estimate AUC, making it possible to obtain estimates for parameters without
specifying a distribution for the screening test. Qin and Zhou (2006) showed that their AUC
estimator followed a scaled chi-square distribution, giving asymptotically correct coverage
probability and a reliable alternative approach for constructing the confidence interval of the
AUC. Although these methods were derived for SRS, the methods can be extended to account
for a stratified sampling scheme. Under a test-dependent sampling (TDS) design, Wang et al.
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(2012) proposed a non-parametric estimator for the AUC. This sampling design includes SRS
and TDS components and improves efficiency over SRS-only designs. The TDS design is
related to outcome-dependent sampling (ODS). Zhou et al. (2002) used the ODS design and
empirical likelihood methods in regression modeling to develop parameter estimates where
inclusion in the sample depends on a continuous outcome variable. Weaver and Zhou (2005)
developed semi-parametric estimators for regression coefficients using the ODS framework
which utilize incomplete information for the un-sampled portion of the population. In the
design proposed by Weaver and Zhou (2005), the outcome which is used to develop the ODS
is observed for all subjects but covariates, which are observed for subjects selected in the
sample, are missing for the un-sampled portion of the population.
We propose the use of a test-dependent sampling (TDS) design in which TDS inclusion
depends on the continuous screening test measure, such as the Balcone risk score. The TDS
design incorporates an SRS component, a TDS component, and the remaining un-sampled
portion of the population. The TDS design allows investigators to over-sample subjects from
specified ranges of the screening test variable, allowing for a concentration of resources where
there is the greatest amount of information. All data are available for subjects sampled in
the study, but only the screening test value is available for the un-sampled portion of the
population. Wang et al. (2012) showed that the TDS design yields more efficient estimates
of AUC than the SRS design. We show that the efficiency of AUC estimation under the TDS
design can be further improved by utilizing information from both the sample and un-sampled
subjects.
Many screening tests define results in dichotomous terms, “positive” for a test value above
a threshold and “negative” for a test value below the threshold. Verification bias is a concern
for studies where all subjects whose test result is “positive” for the outcome have their disease
status verified (Pepe, 2004) but among subjects who test “negative” for the outcome, either
none or a subset of this group have their disease status verified. For the TDS design, subjects
are selected conditional on their test result, but only a subset of subjects within groups are
selected for ascertaining disease status. Accordingly, verification bias exists in the TDS design
(Wang et al., 2012, 2013). In the proposed design, all subjects are included in estimating
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the AUC. Although disease status is missing for subjects in the un-sampled portion of the
population, the inclusion of these subjects eliminates the bias typically associated with the
TDS design.
This chapter is organized as follows. In Section 2.2, we introduce existing AUC estimators,
propose use of empirical likelihood methods to develop a semi-parametric estimator for AUC.
In Section 2.3, asymptotic properties of the proposed AUC estimator are studied. In Section
2.4, we use simulation studies to compare the proposed estimator with existing methods. In
Section 2.5, we analyze data from the lung cancer study. In Section 2.6, we use the proposed
method to analyze data from the Preterm Prediction Study. We conclude with a discussion
in Section 2.7.
2.2 Semi-parametric empirical likelihood AUC (SPEL-AUC) estimation
2.2.1 Notation and data structure for the SPEL-AUC
Consider a continuous test variable, Y , and a binary disease indicator, D. The distribution
of Y can be divided into K mutually exclusive intervals defined by Ck = (ak−1, ak] where k =
1, . . . ,K. The sample size within each of the Ck intervals can be different. The TDS is made
up of three components: the SRS component, TDS component, and non-validation set (un-
sampled subjects). The subjects sampled in the SRS and TDS components combined make
up the validation set, indexed by V , where true disease status is validated. The remainder of
the population not selected for ascertainment of disease status makes up the non-validation
set, indexed by V¯ . The sample size of the validation set is given by nV = n0 +
∑K
k=1 nk, where
n0 is the sample size from the SRS component and nk is the sample size for the k
th TDS
component interval, k = 1, . . . ,K. The size of the non-validation set is given by nV¯ = N−nV .
To define subscripts, i indexes the sampling group where i = {0, 1, ...,K, V¯ } and j = {1, ..., ni}
denotes the individual in the ith sampling group. The test variable, Y , is observed for all
subjects in the dataset. The disease status, D, is only ascertained for subjects who are in the
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validation set. The data framework is given by
SRS component (D0j , Y0j) j = 1, ..., n0
TDS1 component (D1j , Y1j |Y1j ∈ C1) j = 1, ..., n1
...
...
...
TDSK component (DKj , YKj |Y1j ∈ CK) j = 1, ..., nK
Non-validation component
(
Yv¯j |i = V¯
)
j = 1, ..., nV¯ .
(2.1)
2.2.2 Existing AUC estimators
Two existing nonparametric AUC estimators are included in the simulation study to
compare with the proposed AUC estimator. These estimators are
1) the SRS only estimator (MW-AUC) proposed by Bamber (1975), denoted AˆSRSV , and
2) the empirical likelihood estimator (NPEL-AUC) proposed by Wang et al. (2012), de-
noted AˆTDSV .
First, we introduce the MW-AUC. This estimator utilizes a SRS design and is equivalent
to the Mann-Whitney U-statistic (Pepe, 2004), given by
AˆSRSV =
∑n
i=1
∑n
j=1Di (1−Di) I (Yi > Yj)∑n
i=1
∑n
j=1Di (1−Di)
. (2.2)
The second estimator under comparison, NPEL-AUC, was proposed by Wang et al. (2012)
for a TDS design where TDS inclusion depends on the test variable, Y. Empirical likelihood
methods were used to avoid making distributional assumptions on the screening test, Y. The
data structure is similar to the structure described in Section 2.2.1, except that non-validation
data are not included in the NPEL-AUC. The sample size within each of the Ck intervals is
equal. The sample size is given by n = n0 +
∑K
k=1 nk, where n0 is the sample size from the
SRS component and nk =
n−n0
K is the sample size for the k
th TDS interval, k = 1, . . . ,K.
The estimator is given by
AˆTDSV =
∑n
i=1
∑n
j=1 pˆipˆjDi (1−Di) I (Yi > Yj)∑n
i=1
∑n
j=1 pˆipˆjDi (1−Di)
, (2.3)
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where pˆi =
[
n0 +
∑K
k=1
nk
θˆk
I (yi ∈ Ck)
]−1
. The biased sampling scheme is accounted for by
incorporating the empirical probability masses pi and pj in the numerator and denominator.
The MW-AUC and NPEL-AUC use the same number of subjects to estimate the AUC and
differ in their allocation of subjects, where the MW-AUC uses only SRS to generate the
sample.
2.2.3 Semi-parametric empirical likelihood approach
Denote fY,D (Yij , Dij) the joint distribution of disease status (D) and screening test (Y ),
fY (Yij) the marginal distribution of Y , and fY,D (Yij , Dij |Yij ∈ Ck) the distribution of Y and
D conditional on Yij ∈ Ck, k = (1, 2, 3). For k = {1, 2, 3}, let Nk be the stratum size for
the kth strata in the population, Nk = n0,k + nk + nV¯ ,k, where n0,k =
∑ni
j=1 I(Y0j ∈ Ck),
nV¯ ,k =
∑ni
j=1 I(YV¯ j ∈ Ck), and nk is predetermined. The likelihood for the validation data
can be written as
LV (fD) =
n0∏
j=1
f (Y0j , D0j)×
K∏
k=1
nk∏
j=1
f (YkjDkj |Ykj ∈ Ck)
=
K∏
k=1
nk∏
j=1
Pr (Ykj ∈ Ck)−nk ×
K∏
k=0
f (Yij |Dkj)Pr (Dkj = d). (2.4)
The non-validation portion of the likelihood takes into account the missing data, where the
disease status is unknown, and is given by
LV¯ (fD) =
(N − n0)!∏K
k=1 (Nk − n0,k)!
K∏
k=1
Pr (Ykj ∈ Ck)Nk−n0,k
nV¯∏
j=1
Y ∈Ck
f
(
YV¯ j
)
Pr (Ykj ∈ Ck)
=
(N − n0)!∏K
k=1 (Nk − n0,k)!
×
nV¯∏
j=1
1∑
d=0
f
(
YV¯ j |DV¯ j = d
)
Pr
(
DV¯ ,j = d
)
×
K∏
k=1
Pr (Ykj ∈ Ck)−nk . (2.5)
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The full likelihood is found by combining the validation and non-validation portions of the
likelihood, 2.4 and 2.5, given by
L ({qij} , {rij} , p) = LV (fD)× LV¯ (fD)
∝
∏
k,j∈V
D=1
f (Ykj |Dkj = 1)Pr (Dij = 1)
∏
k,j∈V
D=0
f (Ykj |Dkj = 0)Pr (Dkj = 0)
×
nV¯∏
j=1
1∑
d=0
f
(
YV¯ j |DV¯ j = d
)
Pr
(
DV¯ j = d
)
=
∏
k,j∈V
D=1
qkjp×
∏
k,j∈V
D=0
rkj (1− p)×
nV¯∏
j=1
[
qV¯ jp+ rV¯ j (1− p)
]
, (2.6)
where p = Pr (D = 1), qij = f (Yij |Dij = 1), and rij = f (Yij |Dij = 0). We propose to non-
parametrically estimate {qij} and {rij} in (2.6). An interesting constraint between {qij} and
{rij}, given by rijqij = eα+βyij , was developed by Qin and Zhang (1997, 2003). To see this,
consider the standard logistic regression model where Pr (D = 1|Y ) = em
∗(Y )α
1+em
∗(Y )α = ψ (Y ).
The Bayes’ rule gives f (Y |D = 1) = f(Y )Pr(D=1|Y )Pr(D=1) = f(Y )ψ(Y )p . Similarly, f (Y |D = 0) =
f(Y )(1−ψ(Y ))
1−p . Consider the ratio
rij
qij
=
f (Y |D = 0)
f (Y |D = 1)
=
[
f (Y ) (1− ψ (Y ))
1− p
]
×
[
p
f (Y )ψ (Y )
]
=
p
1− p
(
1
1 + em∗(Y )α
)(
em
∗(Y )α
1 + em∗(Y )α
)
= em(Y )α,
which implies that rij = qije
m(Xij)α. Let m (Xij)α = α + βY . Applying this constraint to
the log-likelihood gives
l ({qij} , p, α, β) ∝
∑
ij
ln qij + nV,D=0α+ β
∑
i,j∈V
D=0
yij +
nV¯∑
j=1
ln
[
p+ eα+βyV¯ j (1− p)
]
.(2.7)
Without loss of generality, consider partitioning the screening test variable into three
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mutually exclusive intervals: C1 = (−∞, a1], C2 = (a1, a2], and C3 = (a2,∞). The TDS
consists of an SRS of size n0, a TDS component of size n1 + n2 + n3, and the non-validation
set of size N − nV , where nV = n0 + n1 + n2 + n3. Subjects are eligible to be sampled for
the TDS component based on their screening test result, Y. For example, if a subject’s test
result is less than or equal to a1 and n1 > 0, the probability of being selected in the TDS
component for C1 is greater than zero.
To develop the proposed SPEL-AUC estimator, we first estimate ({qij} , α, β) using em-
pirical likelihood methods outlined below. We then estimate the expected value of disease
for subjects in the non-validation set, whose true disease status is missing, using ({qˆij} , αˆ, βˆ)
and use this expected disease status estimate for those in the non-validation set to construct
the proposed SPEL-AUC estimator.
Estimation of ({qij} , α, β) is done using the profile likelihood approach by first fixing
(α, β) and obtaining {qij} from a constrained likelihood function. Specifically, we estimate
{qij} = f (Yij |Dij = 1) by maximizing a constrained likelihood function of (2.6) under the
following constraints:
qij ≥ 0, ∑
i∈(0,1,2,3,V¯ )
ni∑
j=1
qij = 1,
∑
i∈(0,1,2,3,V¯ )
ni∑
j=1
qij
{
eα+βyij − 1
}
= 0
 . (2.8)
A unique maximum for {qij} exists under the constraints given in (2.8) if 1 is inside the
convex hull of points eα+βyij for all (i, j) (Owen, 1988, 1990; Qin and Lawless, 1994). The
Lagrange multiplier method can be used to derive the maximum over {qˆij}. The logarithm
of the constrained likelihood is as follows:
H ∝
∑
ij
ln qij + nv,D=0α+ β
∑
i,j∈V
D=1
yij +
nV¯∑
j=1
ln
[
p+ eα+βyV¯ j (1− p)
]
+λ1
1−∑
ij
qij
+Nλ2∑
ij
qij
{
eα+βyij − 1
}
. (2.9)
Estimates {qˆij} and λˆ1 are found by taking the derivative of H with respect to qij and
setting the derivative equal to zero. The derivative of H is given by ∂H∂qij =
1
qij
− λ1 +
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Nλ2
{
eα+βyij − 1}. The estimate λˆ1 is found by evaluating ∑ij qij ∂H∂qij = N − λ1∑ij qij +
Nλ2
∑
ij qij
{
eα+βyij − 1} = 0. By setting the derivative of H equal to zero and solving for
qij , we have
qˆij =
1
N
[
1− λ2
(
eα+βyij − 1
)]−1
, (2.10)
for i ∈ (0, 1, 2, 3, V¯ ) and j ∈ (1, . . . , ni).
Profile log-likelihood
The empirical profile log-likelihood is obtained by plugging the estimates qˆij given by
(2.10) into (2.7). Denoting pl (ξ) as the natural logarithm of the empirical profile likelihood,
we have
pl (ξ) ∝ −
∑
ij
ln
[
1− λ2
(
eα+βyij − 1
)]
+ nV,D=0α+ β
∑
i,j∈V
D=0
Yij
+
nV¯∑
j=1
ln
[
p+ eα+βYV¯ j (1− p)
]
. (2.11)
The Newton-Raphson algorithm can be used to obtain ξˆ, where ξ = (α, β, λ2). These esti-
mators, ξˆ, are used in estimating the expected disease status. Disease status is unknown for
the non-validation portion of the population. For these subjects, an estimate of the expected
disease status is used in place of the true disease status in the SPEL-AUC. The expected
value of disease is given by
E (Dl) = 1 ∗ Pr (Dl = 1|Yl)
=
f (Dl = 1, Yl)
f (Yl)
=
f (Yl|Dl = 1)Pr (Dl = 1)
f (Yl|Dl = 1)Pr (Dl = 1) + f (Yl|Dl = 0)Pr (Dl = 0)
=
qlp
qlp+ rl (1− p)
=
p
p+ eα+βyij (1− p) . (2.12)
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An estimate of the expected disease status is found by plugging estimators ξˆ and pˆ into (2.12).
This estimate of expected disease status is given by
Ê (Dl) =
pˆ
pˆ+ eαˆ+βˆyl (1− pˆ)
. (2.13)
The SPEL-AUC uses the information from both the validation and non-validation portions
of the population. Estimated expected disease, given by (2.13), is used for non-validation
subjects where the true disease status is missing. Let l = 1, ..., N index the entire population.
The SPEL-AUC is given by
AˆPV,V¯ =
∑N
l 6=l′ D
∗
l
(
1−D∗l′
)
I (Yl > Yl′)∑N
l 6=l′ D
∗
l
(
1−D∗l′
) ,
where D∗l =

Dl if l ∈ V
Ê (Dl) =
pˆ
pˆ+eαˆ+βˆyl (1−pˆ) if l ∈ V¯
. (2.14)
2.3 Asymptotic properties of the SPEL-AUC
The asymptotic properties of the proposed SPEL-AUC estimator are established in The-
orem 1. Detail of the proof is provided in the appendix, including asymptotic results for
the components that make up the proposed SPEL-AUC estimator. Consider the U-process
UN (A, η) = RN (A, η)− E (RN (A, η)). Let RN (A, η) = 1N2
×∑i 6=j D′i (1−D′j) (Iij −A) where Iij = I (Yi > Yj , Yj ∈ (t0, t1)) and
D′l =
 Dl if l ∈ VÊ (Dl) = pp+eα+βyl (1−p) if l ∈ V¯ . Using this U-process, we show that
√
N
(
AˆPV,V¯ −A
)
= −
{
∂E [RN (A, η)]
∂A
}−1 ∑
i∈(0,1,2,3,V¯ )
ρin
−1/2
i
ni∑
j=1
Qij ,
where Qij (η) = E
(
R(ij)(ij)′ +R(ij)′(ij)
)
+ ρ−1i
∂ERN (A,η)
∂p
[
−1
n0
∂2lsrs(p)
p2
]−1
P0jI (i = 0)
+ ∂ERN (A,η)∂ξ
[
−1
N
∂2pl(ξ)
∂ξi∂ξi′
]−1
Hij (η).
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Theorem 1: Under general regularity conditions,
√
N
(
AˆPV,V¯ −A
)
d→ N (0,Σ), (2.15)
where Σ =
[
∂E[RN (A,η)]
∂A
]−2∑
i∈(0,1,2,3,V¯ ) ρivar (Qij).
We propose a variance estimator using the above asymptotic variance by replacing the
large sample quantities in Σ with their corresponding finite sample quantities. Specifically,
we have
Σˆ =
[
∂E [RN (A, η)]
∂A
]−2 ∑
i∈(0,1,2,3,V¯ )
ρˆivar
(
Qˆij
)
. (2.16)
2.4 Simulation study
We evaluate the behavior of the SPEL-AUC under various situations to examine its be-
havior. The simulation studies were conducted using R version 2.14. The data were generated
under the model
Y = β0 +Dβ1 + ,
where D = 1 for diseased subjects and D = 0 for non-diseased subjects. For the following
simulations, we generated data where  ∼ N (0, 1) and D ∼ Bernoulli (0.3). The population
size used in simulations is N = 2000 and the distribution of Y is partitioned into three
mutually exclusive sets given by C1 = (−∞, a1], C2 = (a1, a2], and C3 = (a2,∞). In the
following simulations, we consider the impact of 1) varying the cut points used to partition the
range of screening test values, {a1, a2} = {µY − ασY , µY + ασY }; 2) varying overall sample
size, nV ; 3) varying the proportion of SRS to TDS component sizes,
n0
nV
; and 4) varying model
parameter β1. The variations under consideration are: cut-point parameter (α) 1 and 1.5;
validation sample size (nV ) 120, 240, and 360; proportion of SRS subjects among validation
set ( n0nV ) 0.5 and 0.75; and model parameter for disease status (β1) 0.5 and 1. For simulation
results, the estimated means, standard errors, mean of the standard error estimates, and 95%
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nominal coverage probabilities for an estimator are obtained from 1000 independent runs.
Sample allocation for TDS
The SPEL-AUC uses the TDS design to target subjects on both tails of the distribution.
This sample consists of the following three components:
1) SRS component of size n0,
2) TDS component sample of size n1 + n2 + n3 where n1 subjects are sampled such that
Y1j ∈ C1 = (−∞, a1], n3 subjects are sampled such that Y3j ∈ C3 = (a2,∞), and
n1=n3, and
3) non-validation component of size N − nV , comprised of all subjects not sampled into
the SRS and TDS components.
Because the TDS component only over-samples from the tails, n2 = 0 where Y2j ∈ C2 =
(a1, a2]. Other sample allocations were considered and results are presented in the last two
lines of Table 2.2. The two-tailed allocation for the SPEL-AUC was chosen due to its con-
sistent estimation of the AUC and consistent reduction in standard error compared to other
sample allocations. For the NPEL-AUC, proposed by Wang et al. (2012), the sample con-
sists of the SRS and TDS components, except that in the TDS component, the subjects are
allocated equally across the three intervals, such that Yij ∈ Ci and n1 = n2 = n3.
Estimators to be compared
The SPEL-AUC, AˆP
V,V¯
in (2.14), is compared to three estimators in the simulation studies.
These estimators are given below. Specifically, under each setting, we compare the following
four estimators.
1) MW-AUC: the SRS only estimator (Bamber, 1975), denoted by AˆSRSV , is given by (2.2).
2) SPEL-AUC(SRS): the SRS with validation and non-validation data estimator, denoted
AˆSRS
V,V¯
, has the same form as the proposed estimator given in (2.14). The difference
between this estimator and the proposed estimator is the sampling design. This gives
a comparison of the SRS and TDS methods while incorporating non-validation data.
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3) NPEL-AUC: the TDS data only estimator (Wang et al., 2012), denoted AˆTDSV , is given
by (2.3).
4) SPEL-AUC: the proposed TDS with validation and non-validation data estimator, de-
noted AˆP
V,V¯
, is given by (2.14).
Results
Unbiasedness Simulation results are summarized in Tables 2.1 through 2.3. All four AUC
estimators yield unbiased estimates. To illustrate this, we simulated data using multiple
allocations, sample sizes, and cut-points. Tables 2.1 and 2.3 show that the averages of all
AUC estimators are close to or equal to the true value. Other allocation schemes were
considered for the SPEL-AUC in Table 2.2 by varying the proportion of subjects allocated to
the SRS component ( n0nV = (0.5, 0.75)), the cut-point defining the TDS component intervals
(α = (1, 1.5) where {a1, a2} = {µY − ασY , µY + ασY }), and the TDS component allocation
(one tail, both tails, and three intervals). In all of these variations, the SPEL-AUC continues
to be unbiased.
Efficiency Efficiency-wise, the proposed SPEL-AUC, AˆP
V,V¯
, is the most efficient among
all compared. The NPEL-AUC, AˆTDSV , is more efficient than the SRS estimators (SPEL-
AUC(SRS) and MW-AUC) and the MW-AUC is the least efficient among those compared.
This supports the idea that both the use of the TDS design and inclusion of non-validation
subjects create a more efficient alternative to the SRS design and validation-only estimators
while sampling the same number of subjects. For the SPEL-AUC, efficiency is similar when
the cut-points, µY ±ασY , are further from the mean (α = 1 versus α = 1.5) but performance
of the asymptotic standard error estimator (SˆE) is improved for α = 1. The asymptotic
standard error estimator is obtained using the proposed asymptotic variance estimator in
(2.16), by substituting finite sample quantities for large sample quantities. For example,
consider the results in Table 2.2 for nV = 360,
n0
nV
= 0.75, and allocation (270,45,0,45,1640).
For both α = 1 and α = 1.5 SE=0.024 with SˆE = 0.23 for α = 1 compared to SˆE = 0.22
for α = 1.5. We show a similar result when comparing the proportion of SRS subjects
within the TDS sample for n0nV = 0.75 versus 0.5. In Table 2.2, for nV = 360 and α = 1,
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we have SE=0.024 for both n0nV = 0.75 and
n0
nV
= 0.5 but the asymptotic standard error is
underestimated in the case of n0nV = 0.5 (SˆE = 0.21 versus SˆE = 0.23 when
n0
nV
= 0.75).
Table 2.2 shows that the estimated standard errors are very close to their true values. The
last two lines of Table 2.2 show that for the SPEL-AUC, allocation to only one tail gives
results that are less efficient than the two-tailed allocation.
Robustness The SPEL-AUC does not require model specification for the screening test, Y.
To explore the SPEL-AUC’s robustness, simulation studies were generated using both Normal
and Chi-squared distributions for the screening test. Simulation results reported in Table 2.3
show that across multiple sample sizes (120, 240, and 360) the simulation study gives similar
results. All estimators are unbiased and the SPEL-AUC is more efficient than the MW-AUC,
SPEL-AUC(SRS), and NPEL-AUC estimators.
2.5 Analysis of the lung cancer study data
We used the SPEL-AUC to analyze non-small-cell lung cancer (NSCLC) data from the
CALGB 150807 study conducted by the Cancer and Leukemia Group B (Bueno et al., 2012).
This study is a subset of patients registered in the CALGB 140202 study who have stage 1A
or 1B non-small-cell lung cancer (NSCLC), have not received preoperative chemotherapy or
radiation, and are not missing histological, demographic, clinical, and follow-up information
of interest. Among patients in the CALGB 150807 study, 1,061 patients were not censored
before 12 months and were used in this analysis.
Lung cancer is the most common cause of cancer death among men and women in the world
(Blanchon et al., 2006). Lung cancer is classified as either small-cell lung carcinoma (SCLC)
or non-small-cell lung carcinoma (NSCLC), of which NSCLC accounts for approximately 80%
of all lung cancers. After surgical lung resection, a large proportion of stage 1 NSCLC patients
have cancer recurrence within five years (Bueno et al., 2012). When surgery is used as the
primary treatment for NSCLC, adjuvant chemotherapy may benefit patients who have a high
risk of cancer recurrence. Identifying patients who are at high risk of cancer recurrence
is important in order for treatment to be given to those who would benefit most. This is
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an important area of study for patients, families, and doctors when making decisions on a
treatment plan.
The Balcone risk score, outlined by Blanchon et al. (2006), has been developed to identify
patients who are at greatest risk of cancer recurrence. To select the variables that are included
in the scoring algorithm, Blanchon et al. (2006) used a Cox model to identify variables that
were independently associated with mortality. The associated variables were then weighted to
create the Balcone risk index. The components of the risk score are given by: age (>70 years,
1 point); sex (male, 1 point); performance status at diagnosis (reduced activity, 3 points;
active >50%, 5 points; inactive >50%, 8 points; and total incapacity, 10 points); histological
type (large-cell carcinoma, 2 points); and tumour-node-metastasis (TNM) staging system
(IIA or IIB, 3 points; IIIA or IIIB, 6 points; and IV, 8 points). For the data used in this
analysis, the Balcone risk score ranges from 0 to 15.
The goal of this analysis is to summarize the ability of the Balcone risk score to distinguish
between patients who survive beyond 12 months and those who do not. This will allow us to
evaluate the benefit of using this risk score to identify patients at a higher risk of early cancer
recurrence. The outcome of interest is survival beyond 12 months and the screening test is
the Balcone risk score. Although all information is available for these patients, we illustrate
the utility of the proposed AUC estimator by sampling from the study data and evaluating
the estimated AUC. Table 2.4 gives descriptive statistics for the Balcone risk score, stratified
by survival at 12 months. Cut-points for the TDS component were defined by α = 1 standard
deviations from the mean of the Balcone risk score. A sample size of nV = 360 was used for
all estimators compared and details on sample allocation for each estimator are given in Table
2.5. The MW-AUC has an SRS of size n = 360. The SPEL-AUC(SRS) allocates 100% of the
sample to the SRS component and utilizes incomplete data from the non-validation set. The
NPEL-AUC allocates 50% of the validation sample to the SRS component and the remaining
50% are allocated equally between the three intervals, Ci, such that n1 = n2 = n3 = 60. The
SPEL-AUC allocates 75% of the sample to the SRS component and samples the remaining
25% from the tails, where n1 = n3 = 45 and n2 = 0, while utilizing incomplete data from the
non-validation set. Because all data has been obtained for these patients, we can apply the
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MW-AUC estimator on the full data (1,061 subjects) and we obtain an AUC of 0.657. Using
a sample size of n = 360, the AUC estimates and estimates of the standard error for the
methods compared are given by: MW-AUC 0.680 (0.051), SPEL-AUC(SRS) 0.670 (0.050),
NPEL-AUC 0.681 (0.046), and SPEL-AUC 0.724 (0.044). All estimators compared have an
estimated AUC that is similar to the best estimate we have for the true pAUC, which is 0.657,
found by using the complete data. We can also see that the proposed SPEL-AUC estimator
has the smallest estimated variance among the four AUC estimators compared.
2.6 Analysis of the Preterm Prediction Study data
We used the SPEL-AUC to analyze data from the Preterm Prediction Study, a multi-center
prospective study designed to study spontaneous preterm birth (Goldenberg et al., 1996). The
Maternal Fetal Medicine Units Network of the National Institute of Child Health and Human
Development carried out this study using ten centers to recruit women. There were 3073
women recruited between October 1992 and July 1994. Measurements were collected every
two weeks from 22 to 30 weeks’ gestation. Among the 3073 women recruited, 3001 had valid
measurements of interest for this analysis.
PTB, defined as delivery at less than 37 weeks of gestation, contributes to neonatal mor-
bidity and mortality which increases as gestational age decreases (McCormick, 1985). Bastek
and Elovitz (2013) combined results from multiple studies on this topic to gain a better un-
derstanding the relationship between biomarkers and PTB. The results were not definitive
for most biomarkers with the exception of fetal fibronectin (FFN).
Fetal fibronectin (FFN) is a protein that is produced by the fetal membrane. Knowing
the FFN measurement will not change the incidence of spontaneous PTB but it will effect
the treatment plan. Deshpande et al. (2013) found that FFN has moderate accuracy in
predicting PTB. Although many studies are concerned with the ability to predict spontaneous
PTB, Bastek and Elovitz (2013) suggest that the ability to predict those who will not have
spontaneous PTB is also valuable. Because FFN typically has a high negative predictive value
(proportion of true negatives over all who test negative), a negative FFN test is widely used
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in clinical practice to send patients home. Measurable levels of FFN are considered to be
abnormal between 20 and 37 weeks’ gestation. Lockwood et al. (1991) show that in 588 FFN
samples from uncomplicated pregnancies, a higher percentage of subjects were positive for
FFN (level above 0.05 µg/mL) before 22 and after 37 weeks’ gestation compared to between
22 and 37 weeks’ gestation. For example the percentage of cervical samples with positive
FFN for <22, 22 to 37 and >37 weeks’ gestation were 24%, 4%, and 32%, respectively. This
is an important area of study due to the negative effects of spontaneous PTB on maternal
and child health outcomes.
In our analysis, the outcome of interest is spontaneous PTB at less than 37 weeks’ gestation
and the screening test considered in FFN. Table 2.6 gives descriptive statistics for FFN,
stratified by spontaneous PTB. Because the standard deviation is large compared to the
mean, the cut-points for the TDS component were defined using α = 0.15. A sample size
of nV = 360 was used for all estimators compared and details on sample allocation for each
estimator are given in Table 2.7. The MW-AUC has an SRS of size n = 360. The SPEL-
AUC(SRS) allocates 100% of the sample to the SRS component and utilizes incomplete data
from the non-validation set. The NPEL-AUC allocates 50% of the validation sample to
the SRS component and the remaing 50% are allocated equally between the three intervals,
Ci, such that n1 = n2 = n3 = 60. The SPEL-AUC allocates 75% of the sample to the
SRS component and samples the remaining 25% from the tails, where n1 = n3 = 45 and
n2 = 0, while utilizing incomplete data from the non-validation set. Because the outcome of
spontaneous PTB is known for all patients, we can apply the MW-AUC estimator on the full
data (3,001 patients) and we obtain an AUC of 0.576. The estimates from each estimator are:
MW-AUC 0.522, SPEL-AUC(SRS) 0.536, NPEL-AUC 0.575, and SPEL-AUC 0.591. These
results show that all estimators accurately estimate the AUC.
2.7 Discussion
We have proposed a semi-parametric estimator for area under the ROC curve (AUC),
which allows us to summarize the ability of a screening test to discern between diseased and
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non-diseased subjects. This estimator incorporates a TDS design and includes both validation
and non-validation data. The use of empirical likelihood methods allows us to estimate the
AUC without specifying a distribution for the screening test. We establish the asymptotic
properties of the proposed estimator under general regularity conditions and show that this
estimator has good finite sample properties.
The proposed design is motivated by the need to improve efficiency in estimating AUC.
Ascertaining true disease status can be costly and invasive for subjects. Although disease
status is missing for the non-validation set, the proposed estimator takes advantage of all
information available for a larger number of subjects than the validation-only estimators.
Although all estimators are unbiased, the proposed estimator was shown to be the most
efficient, compared to three competing AUC estimators. This suggests that to obtain the
same variability less subjects would be needed when the proposed method is used, reducing
study cost and subject burden. These results support the idea that both the use of the TDS
design and inclusion of non-validation subjects create a more efficient alternative to the SRS
design and the validation-only estimators while sampling the same number of subjects. For
example, with a sample size of 240, the standard error of the proposed estimator is 0.03
compared to 0.034 and 0.035 in the competing methods (Table 2.1). In this case, we have
an estimated standard error of 0.029 which gives coverage proportion of 0.945. The proposed
method is also robust in its ability to estimate AUC under varying distributions. Simulation
studies show that when the screening test is simulated from a Chi-squared distribution, the
AUC estimators are unbiased and the SPEL-AUC continues to be the most efficient AUC
estimator under comparison.
Care should be taken when choosing the sample allocation and cut-points for the test-
dependent sample. If data are skewed with a long tail the standard error could be quite
large, as in the case of the Preterm Prediction Study and simulation studies where screening
test data are generated from a Chi-squared distribution. The proportion of subjects selected
for the SRS component and the TDS allocation of subjects within the intervals defined by
cut-points will largely depend on the characteristics of the data used.
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Table 2.1: Comparison of SPEL-AUC and competing methods
nV = 120 nV = 240 nV = 360
Method Mean SE Mean SE Mean SE
YD=1 ∼ N (1, 1), YD=0 ∼ N (0, 1) and True AUC= 0.7601
AˆSRSV 0.761 0.049 0.758 0.035 0.760 0.028
AˆSRS
V,V¯
0.761 0.049 0.760 0.034 0.760 0.026
AˆTDSV 0.762 0.048 0.759 0.034 0.759 0.027
AˆP
V,V¯
0.765 0.045 0.762 0.030 0.761 0.024
YD=1 ∼ N (0.5, 1), YD=0 ∼ N (0, 1) and True AUC= 0.6380
AˆSRSV 0.639 0.055 0.635 0.040 0.638 0.033
AˆSRS
V,V¯
0.639 0.055 0.638 0.038 0.637 0.031
AˆTDSV 0.637 0.051 0.640 0.037 0.637 0.030
AˆP
V,V¯
0.637 0.045 0.639 0.033 0.637 0.027
Cutpoints for the TDS component are defined by (a1, a2) =
(µY − ασY , µY + ασY ) where α = 1. AˆSRSV denotes the MW-
AUC which uses SRS; AˆSRS
V,V¯
denotes the SPEL-AUC(SRS)
which uses SRS and utilizes information for both validation and
non-validation data; AˆTDSV denotes the NPEL-AUC which uses
TDS; and AˆP
V,V¯
denotes the proposed SPEL-AUC which uses
TDS and utilizes information from both validation and non-
validation data. All estimators sample the same number of sub-
jects.
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Table 2.2: Asymptotic results for SPEL-AUC
nV
n0
nV
α (n0, n1, n2, n3, nV¯ ) Mean SE ŜE CP
n1 = n3 and n2 = 0
120 0.75 1 (90, 15, 0, 15, 1880) 0.765 0.045 0.043 0.936
240 0.75 (180, 30, 0, 30, 1760) 0.762 0.030 0.029 0.945
360 0.75 (270, 45, 0, 45, 1640) 0.761 0.024 0.023 0.938
n1 = n2 = n3
120 0.75 1 (90, 10, 10, 10, 1880) 0.764 0.047 0.045 0.921
240 0.75 (180, 20, 20, 20, 1760) 0.761 0.032 0.030 0.937
360 0.75 (270, 30, 30, 30, 1640) 0.760 0.025 0.024 0.946
n1 = n3 and n2 = 0
360 0.5 1 (180, 90, 0, 90, 1640) 0.761 0.024 0.021 0.922
360 0.75 1.5 (270, 45, 0, 45, 1640) 0.761 0.024 0.022 0.931
n1 6= n3 and n2 = 0
360 0.75 1 (270, 90, 0, 0, 1640) 0.760 0.025 0.024 0.944
360 0.75 1 (270, 0, 0, 90, 1640) 0.761 0.026 0.022 0.901
The true AUC is 0.7601. Screening test data is simulated assuming
YD=1 ∼ N (1, 1) and YD=0 ∼ N (0, 1). The fraction n0nV is the propor-
tion of subjects allocated to the SRS component out of the total num-
ber of validation subjects sampled. Cutpoints for the TDS component
are defined by (a1, a2) = (µY − ασY , µY + ασY ). The sample allocation,
(n0, n1, n2, n3, nV¯ ), gives the number of subjects allocated to the SRS com-
ponent, three intervals of the TDS component, and the non-validation set,
respectively.
Table 2.3: Comparison of SPEL-AUC and competing methods for Chi-Squared Distributed
Data
nV = 120 nV = 240 nV = 360
Method Mean SE Mean SE Mean SE
AˆSRSV 0.802 0.044 0.802 0.032 0.802 0.026
AˆSRS
V,V¯
0.790 0.044 0.790 0.032 0.790 0.025
AˆTDSV 0.804 0.048 0.802 0.034 0.803 0.027
AˆP
V,V¯
0.790 0.041 0.789 0.029 0.789 0.023
The true AUC is 0.8023. Screening test data is sim-
ulated assuming YD=1 ∼ χ (4, 3) and YD=0 ∼ χ (3).
Cutpoints for TDS component are defined by (a1, a2) =
(µY − ασY , µY + ασY ) where α = 1.
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Table 2.4: Descriptive statistics for the Balcone risk score
N Minimum Q1 Median Q3 Maximum
Overall 1076 0 1 1 3 10
Survival beyond 12 months 965 0 1 1 3 10
Survival less than 12 months 111 0 1 2 5 9
Table 2.5: Sample allocation for the non-small-cell lung cancer data
Component MW-AUC SPEL-AUC(SRS) NPEL-AUC SPEL-AUC
SRS 360 360 180 270
TDS (n1, n2, n3) (0, 0, 0) (0, 0, 0) (60, 60, 60) (45, 0, 45)
non-validation 0 701 0 701
Table 2.6: Descriptive statistics for FFN
N Minimum Q1 Median Q3 Maximum Mean St.Dev.
Spontaneous PTB 309 0 0.88 4.48 17.08 924.56 43.64 123.86
Not PTB 2692 0 0.28 2.61 7.22 2151.44 13.35 83.73
Table 2.7: Sample allocation for the Preterm Prediction Study
Component MW-AUC SPEL-AUC(SRS) NPEL-AUC SPEL-AUC
SRS 360 360 180 270
TDS (n1, n2, n3) (0, 0, 0) (0, 0, 0) (60, 60, 60) (45, 0, 45)
non-validation 0 2641 0 2641
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Chapter 3
Partial AUC under Test-Dependent Sampling
3.1 Introduction
The receiver operating characteristic (ROC) curve and area under the ROC curve (AUC)
are summary measures used to describe the ability of a screening test to discriminate between
diseased and non-diseased subjects (Bamber, 1975). When it is clinically relevant to consider
only a subset of false positive rates (FPR) or true positive rates (TPR), the partial AUC
(pAUC) is another summary measure that should be considered. As evaluating the true
disease status can be costly, it is important for researchers to increase study efficiency by
allowing selection probabilities to depend on the screening test (Wang et al., 2012). Increased
efficiency translates to cost for studies as well as decreased burden on subjects. We propose
a semi-parametric pAUC estimator which incorporates a test-dependent sampling design and
inclusion of un-sampled subjects. Simulation studies show that the proposed pAUC estimator
is unbiased and improves efficiency compared to estimators using a simple random sample
(SRS) design and those that use only information from the sampled subjects.
Using data from the Cancer and Leukemia Group B (CALGB) 150807 study, we evaluate
the ability of the Balcone risk score to identify patients who are at greatest risk of non-small-
cell lung cancer (NSCLC) recurrence by estimating the AUC while restricting the FPR to be
within the interval (0.1, 0.3) (Bueno et al., 2012). The ROC curve is a tool used to graphically
display the ability of the Balcone risk score to identify patients who survive beyond 12 months
by plotting the false positive rate (FPR, Pr (Y ≥ c|D = 0)) against the true positive rate
(TPR, Pr (Y ≥ c|D = 1)). The pAUC is a summary measure used to describe the ability
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of the Balcone risk score to discriminate between patients who survive beyond 12 months
and those who do not while restricting the FPRs (or TPRs) to an interval that is clinically
relevant. When surgery is used as the primary treatment for NSCLC, adjuvant chemotherapy
may benefit patients who have a high risk of cancer recurrence. Identifying patients who are
at high risk of cancer recurrence is important in order for treatment to be given to those
who would benefit most. At the same time, we want a screening test that minimizes the
false positives to reduce the number of patients that are subjected to potentially dangerous
treatments that are unnecessary. The proposed methods are especially beneficial considering
the length of time this type of study will follow patients and the cost of following a large
number of subjects in this setting.
We also evaluate data from the Preterm Prediction Study to assess the utility of fetal
fibronectin (fFN) in predicting spontaneous preterm birth while restricting the FPRs (or
TPRs) to an interval that is clinically relevant (Goldenberg et al., 1996). Preterm birth
(PTB), defined as delivery at less than 37 weeks of gestation, contributes to neonatal mor-
bidity and mortality. The prevalence of adverse events increases as gestational age decreases
(McCormick, 1985). This is an important area of study due to the negative impact of spon-
taneous PTB on maternal and child health outcomes. Knowing the fFN measurement will
not change the incidence of spontaneous PTB, but it will affect the treatment plan.
Previous research has explored multiple approaches to estimating pAUC. McClish (1989)
and Thompson and Zucchini (1989) introduced the idea of evaluating only part of the AUC
for a specified FPR interval. A nonparametric pAUC estimator proposed by Dodd and Pepe
(2003a), which is similar to the AUC estimator proposed by Bamber (1975), incorporates
a restriction in the numerator for the FPR interval of interest. The estimator proposed by
Dodd and Pepe (2003a) uses an SRS design for sampling subjects. Wang et al. (2012) pro-
posed a nonparametric pAUC estimator using a test-dependent sampling (TDS) design. This
estimator uses empirical likelihood methods to avoid making assumptions on the distribution
of the screening test, Y. Weights are incorporated into the estimator to account for the biased
sampling design. The TDS design is related to outcome-dependent sampling (ODS). Zhou
et al. (2002) used the ODS design and empirical likelihood methods in regression modeling
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to develop parameter estimates in which inclusion in the sample depends on a continuous
outcome variable. Weaver and Zhou (2005) developed a semi-parametric estimator for re-
gression coefficients using the ODS framework, which utilizes incomplete information for the
un-sampled portion of the population. In the design proposed by Weaver and Zhou (2005),
the outcome used to develop the ODS is observed for all subjects, but covariates are observed
for subjects selected in the sample.
We propose the use of a test-dependent sampling (TDS) design where TDS inclusion
depends on the continuous screening test measure fFN. The TDS design incorporates an SRS
component, a TDS component, and the remaining un-sampled portion of the population. The
TDS design allows investigators to over-sample subjects from specified ranges of the screening
test variable, allowing for a concentration of resources where there is the greatest amount of
information. All data are available for subjects sampled in the study, but only the screening
test value is available for the un-sampled portion of the population. The proposed method
gives improved estimates of the pAUC which are more efficient than those given by Dodd and
Pepe (2003a) and Wang et al. (2012).
Verification bias is associated with the TDS design described by Wang et al. (2012) in that
both designs generate bias. Many screening tests define results in dichotomous terms, “posi-
tive” for a test value above a threshold and “negative” for a test value below the threshold.
Verification bias is a concern, mostly for cohort studies, where all subjects whose test result is
“positive” for the outcome have their disease status verified (Pepe, 2004) but among subjects
who test “negative” for the outcome, either none or a subset of this group have their disease
status verified. For the TDS design described by Wang et al. (2012), subjects are selected
conditional on their test result, but only a subset of subjects within groups are selected. In
the proposed design, all subjects are included in estimating the AUC. Although disease sta-
tus is missing for subjects in the un-sampled portion of the population, the inclusion of these
subjects eliminates the bias typically associated with the TDS design.
This chapter is organized as follows. In Section 3.2, we introduce existing pAUC estima-
tors, propose use of empirical likelihood methods to develop a semi-parametric estimator for
pAUC. In Section 3.3, asymptotic properties of the proposed pAUC estimator are explored.
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In Section 3.4, we use simulation studies to compare the proposed estimator with existing
methods. In Section 3.5, we analyze data from the lung cancer study. In Section 3.6, we use
the proposed method to analyze data from the Preterm Prediction Study. We conclude with
a discussion in Section 3.7.
3.2 Semi-parametric empirical likelihood pAUC (SPEL-pAUC) estimation
3.2.1 Notation and data structure
Consider a continuous test variable, Y , and binary disease indicator, D. The distribution
of Y can be divided into K mutually exclusive intervals defined by Ck = (ak−1, ak] where
k = 1, . . . ,K. The sample size within each of the Ck intervals may be different. The TDS is
made up of three components: the SRS component, TDS component, and the non-validation
set (un-sampled subjects). This set of subjects sampled in the SRS and TDS components
combined make up the validation set, indexed by V , where the true disease status is validated.
The remainder of the population not selected for sampling makes up the non-validation set,
indexed by V¯ . The sample size of the validation set is given by nV = n0 +
∑K
k=1 nk, where
n0 is the sample size from the SRS component and nk is the sample size for the k
th TDS
interval, k = 1, . . . ,K. The size of the non-validation set is given by nV¯ = N −nV . To define
subscripts, i indexes the sampling group where i =
(
0, 1, ...,K, V¯
)
and j = {1, ..., ni} denotes
the individual in the ith sampling group. The test variable, Y , is observed for all subjects in
the dataset. The disease status, D, is only ascertained for subjects who are in the validation
set. The data framework is given by
SRS component (D0j , Y0j) j = 1, ..., n0
TDS1 component (D1j , Y1j |Y1j ∈ C1) j = 1, ..., n1
...
...
...
TDSK component (DKj , YKj |Y1j ∈ CK) j = 1, ..., nK
Non-validation component (Yv¯j |i 6= (0, 1, . . . ,K)) j = 1, ..., nV¯ .
(3.1)
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3.2.2 Existing pAUC estimators
Two existing pAUC estimators are included in the simulation study to compare with the
proposed pAUC estimator. These estimators are
1) the SRS only estimator (NP-pAUC) proposed by Dodd and Pepe (2003a), denoted
AˆSRSt:V , and
2) the nonparametric empirical likelihood estimator (NPEL-pAUC) proposed by Wang
et al. (2012), denoted AˆTDSt:V .
First, we introduce the NP-pAUC proposed by Dodd and Pepe (2003a). This nonpara-
metric estimator utilizes an SRS structure and is given by
AˆSRSt:V =
∑n
i=1
∑n
j=1Di (1−Di) I (Yi > Yj , Yj ∈ (q0, q1))∑n
i=1
∑n
j=1Di (1−Di)
. (3.2)
where q0 = F
−1
Y |D=0 (1− t1) = FPR−1 (t1) and q1 = F−1Y |D=0 (1− t0) = FPR−1 (t0).
The second estimator under comparison, NPEL-pAUC, was proposed by Wang et al.
(2012) and uses a TDS design, incorporating the SRS and TDS components where TDS
inclusion depends on the continuous screening test variable, Y. Empirical likelihood methods
were used to avoid making distributional assumptions on the screening test, Y. The data
structure is similar to the structure described in Section 3.2.1, except that non-validation
data are not included in the NPEL-pAUC. The sample size is given by n = n0 +
∑K
k=1 nk,
where n0 is the sample size from the SRS component and nk =
n−n0
K is the sample size for
the kth TDS interval, k = 1, . . . ,K. This pAUC estimator incorporates a restriction for the
FPR interval of interest, (t0, t1), given by F̂PRj =
∑
i pˆi(1−Di)I(Yi>Yj)∑
i pˆi(1−Di) . The pAUC estimator
is given by
AˆTDSt:V =
∑n
i=1
∑n
j=1 pˆipˆjDi (1−Di) I
(
Yi > Yj , F̂PRj ∈ (t0, t1)
)
∑n
i=1
∑n
j=1 pˆipˆjDi (1−Di)
, (3.3)
where pˆi =
[
n0 +
∑K
k=1
nk
θˆk
I (yi ∈ Ck)
]−1
. The biased sampling scheme is accounted for by
incorporating weights pi and pj in the numerator and denominator. Empirical likelihood
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methods were used in developing the estimator proposed by Wang et al. (2012).
3.2.3 Semi-parametric empirical likelihood approach
To develop the likelihood, denote fY,D (Yij , Dij) the joint distribution of disease status and
screening test. The marginal distribution of the screening test variable is given by fY (Yij).
The distribution of disease status and screening test, conditional on Yij falling in the interval
Ck, is given by fY,D (Yij , Dij |Yij ∈ Ck), k = (1, . . . ,K). Consider stratum sizes in the popula-
tion Nk = n0,k +nk +nV¯ ,k, where ni,k =
∑ni
j=1 I(Yi ∈ Ck) for i =
{
0, V¯
}
and k = {1, . . . ,K}.
The validation portion of the likelihood is given by
LV (fD) =
n0∏
j=1
f (Y0j , D0j)×
K∏
k=1
nk∏
j=1
f (YkjDkj |Ykj ∈ Ck)
=
K∏
k=1
nk∏
j=1
Pr (Ykj ∈ Ck)−nk ×
K∏
k=0
f (Yij |Dkj)Pr (Dkj = d). (3.4)
The non-validation portion of the likelihood takes into account the missing data, where the
disease status is unknown, and is given by
LV¯ (fD) =
(N − n0)!∏K
k=1 (Nk − n0,k)!
K∏
k=1
Pr (Ykj ∈ Ck)Nk−n0,k
nV¯∏
j=1
Y ∈Ck
f
(
YV¯ j
)
Pr (Ykj ∈ Ck)
=
(N − n0)!∏K
k=1 (Nk − n0,k)!
×
nV¯∏
j=1
1∑
d=0
f
(
YV¯ j |DV¯ j = d
)
Pr
(
DV¯ ,j = d
)
×
K∏
k=1
Pr (Ykj ∈ Ck)−nk . (3.5)
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The full likelihood is found by combining the validation and non-validation portions of the
likelihood, (3.4) and (3.5), given by
L ({qij} , {rij} , p) = LV (fD)× LV¯ (fD)
∝
∏
k,j∈V
D=1
f (Ykj |Dkj = 1)Pr (Dij = 1)
∏
k,j∈V
D=0
f (Ykj |Dkj = 0)Pr (Dkj = 0)
×
nV¯∏
j=1
1∑
d=0
f
(
YV¯ j |DV¯ j = d
)
Pr
(
DV¯ j = d
)
=
∏
k,j∈V
D=1
qkjp
∏
k,j∈V
D=0
rkj (1− p)
nV¯∏
j=1
[
qV¯ jp+ rV¯ j (1− p)
]
, (3.6)
where p = Pr (D = 1), qij = f (Yij |Dij = 1), and rij = f (Yij |Dij = 0). The probability of
having disease, p, is estimated from the SRS component of the TDS. Due to the relationship
between qij and rij and the need to decrease computational load, Qin and Zhang (1997,
2003) propose a constraint given by
rij
qij
= eα+βyij . Consider the standard logistic regression
model where Pr (D = 1|Y ) = em
∗(Y )α
1+em
∗(Y )α = ψ (Y ). The Bayes’ rule gives f (Y |D = 1) =
f(Y )Pr(D=1|Y )
Pr(D=1) =
f(Y )ψ(Y )
p . Similarly, f (Y |D = 0) = f(Y )(1−ψ(Y ))1−p . Consider the ratio
rij
qij
=
f (Y |D = 0)
f (Y |D = 1)
=
[
f (Y ) (1− ψ (Y ))
1− p
]
×
[
p
f (Y )ψ (Y )
]
=
p
1− p
(
1
1 + em∗(Y )α
)(
em
∗(Y )α
1 + em∗(Y )α
)
= em(Y )α,
which implies that rij = qije
m(Xij)α. Let m (Xij)α = α + βY . Applying this constraint to
the log-likelihood gives
l ({qij} , p, α, β) ∝
∑
ij
ln qij + nV,D=0α+ β
∑
i,j∈V
D=0
yij +
nV¯∑
j=1
ln
[
p+ eα+βyV¯ j (1− p)
]
.(3.7)
Without loss of generality, the continuous screening test variable is partitioned into three
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mutually exclusive intervals: C1 = (−∞, a1], C2 = (a1, a2], and C3 = (a2,∞). The TDS
consists of an SRS of size n0, a TDS component of size n1 + n2 + n3, and the non-validation
set of size N −nV , where nV = n0 +n1 +n2 +n3. Subjects are eligible to be sampled for the
TDS groups based on their screening test result. For example, if a subject’s test result is less
than or equal to a1 and n1 > 0, the probability of being selected in the TDS component for
C1 is greater than zero.
In order to develop the semi-parametric empirical likelihood pAUC estimator (SPEL-
pAUC), we first need to obtain estimates for {qij}, α, and β. We accomplish this by using
empirical likelihood methods outlined below. Once we have these parameter estimates, we
estimate the expected value of disease for subjects in the non-validation set and we estimate
the false positive rate for all subjects. We can then use this expected disease status and false
positive rate estimates in the SPEL-pAUC for the non-validation subjects where the true
disease status is missing.
To obtain estimates for α and β the profile likelihood must be constructed. The distri-
bution of the screening test conditional on disease status, f (Yij |Dij = 1), is not known or
assumed. A robust estimator for the pAUC can be constructed without making these dis-
tributional assumptions by fixing α and β and obtaining the empirical likelihood function of
F (Yij |Dij = 1), with support at the observed values of Y . To maximize the likelihood, we
estimate {qˆij} = f (Yij |Dij = 1) under the following constraints:qij ≥ 0, ∑
i∈(0,1,2,3,V¯ )
ni∑
j=1
qij = 1,
∑
i∈(0,1,2,3,V¯ )
ni∑
j=1
qij
{
eα+βyij − 1
}
= 0
 . (3.8)
A unique maximum for {qij} exists under the constraints given in (3.8) if 1 is inside the
convex hull of points eα+βyij for all (i, j) (Owen, 1988, 1990; Qin and Lawless, 1994). Lagrange
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multipliers, λ1 and λ2, are used to derive the maximum over {qˆij}. Consider the function
H ∝
∑
ij
ln qij + nv,D=0α+ β
∑
i,j∈V
D=1
yij +
nV¯∑
j=1
ln
[
p+ eα+βyV¯ j (1− p)
]
+λ1
1−∑
ij
qij
+Nλ2∑
ij
qij
{
eα+βyij − 1
}
. (3.9)
Estimates {qˆij} and λˆ1 are found by taking the derivative of H with respect to qij , where H
is given by (3.9), and setting the derivative equal to zero. The derivative of H is given by
∂H
∂qij
= 1qij − λ1 + Nλ2
{
eα+βyij − 1}. The estimate λˆ1 is found by evaluating ∑ij qij ∂H∂qij =
N −λ1
∑
ij qij +Nλ2
∑
ij qij
{
eα+βyij − 1} = 0. By setting the derivative of H equal zero and
solving for qij , we have
qˆij =
1
N
[
1− λ2
(
eα+βyij − 1
)]−1
, (3.10)
for i ∈ (0, 1, 2, 3, V¯ ) and j ∈ (1, . . . , ni).
Profile log-likelihood
The empirical profile log-likelihood is obtained by plugging the estimates qˆij , given in
(3.10), into (3.7). Denoting pl (ξ) as the natural logarithm of the empirical profile likelihood,
we have
pl (ξ) ∝ −
∑
ij
ln
[
1− λ2
(
eα+βyij − 1
)]
+ nV,D=0α+ β
∑
i,j∈V
D=1
yij
+
nV¯∑
j=1
ln
[
p+ eα+βyV¯ j (1− p)
]
. (3.11)
The Newton-Raphson algorithm can be used to obtain ξˆ, where ξ = (α, β, λ2). These estima-
tors, ξˆ, are used in estimating the expected disease status. Disease status is unknown for the
non-validation portion of the population. For these subjects, an estimate for the expected
disease status is used in place a true disease status in the SPEL-pAUC. The expected value
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of disease is given by
E (Dl) = 1 ∗ Pr (Dl = 1|Yl)
=
f (Dl = 1, Yl)
f (Yl)
=
f (Yl|Dl = 1)Pr (Dl = 1)
f (Yl|Dl = 1)Pr (Dl = 1) + f (Yl|Dl = 0)Pr (Dl = 0)
=
qlp
qlp+ rl (1− p)
=
p
p+ eα+βyij (1− p) , (3.12)
since rl = qle
α+βyl . An estimate of the expected disease status is found by plugging estimators
ξˆ and pˆ into (3.12). This estimate of expected disease status is given by
Ê (Dl) =
pˆ
pˆ+ eαˆ+βˆyl (1− pˆ)
. (3.13)
The pAUC measures the area under the ROC curve where we are interested only in the
region where the FPR falls within (t0, t1), such that 0 < t0 < t1 < 1. This restriction
is accounted for in the estimator by incorporating an estimate of the FPR along with the
chosen t0 and t1 bounds. The false positive rate is estimated by
F̂PRl′ =
∑N
l (1−D∗l ) I (Yl > Yl′)∑N
l
(
1−D∗l
) . (3.14)
The SPEL-pAUC uses the information from both the validation and non-validation por-
tions of the population. Estimated expected disease, give by (3.13), is used for non-validation
subjects where true disease status is missing. Let l = 1, ..., N index the entire population.
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The SPEL-pAUC is given by
AˆPt:V,V¯ =
∑N
l 6=l′ D
∗
l
(
1−D∗l′
)
I
(
Yl > Yl′ , F̂PRl′ ∈ (t0, t1)
)
∑N
l 6=l′ D
∗
l
(
1−D∗l′
) ,
where F̂PRl′ =
∑N
l (1−D∗l ) I (Yl > Yl′)∑N
l
(
1−D∗l
)
and D∗l =

Dl if l ∈ V
Ê (Dl) =
pˆ
pˆ+eαˆ+βˆyl (1−pˆ) if l ∈ V¯
. (3.15)
3.3 Asymptotic properties of the SPEL-pAUC
In this section we give the asymptotic properties of the SPEL-pAUC. Theorem 1 es-
tablishes the asymptotic normality of the SPEL-pAUC. Further detail is provided in the
appendix, including asymptotic results for the components that make up the SPEL-pAUC.
Consider the U-process UN (At, η) = RN (At, η)− E (RN (At, η)). Let RN (At, η) = 1N2
×∑i 6=j D′i (1−D′j) (It:ij −At) where It:ij = I (Yi > Yj , Yj ∈ (t0, t1)) and
D′l =
 Dl if l ∈ VÊ (Dl) = pp+eα+βyl (1−p) if l ∈ V¯ . Using this U-process, we show that
√
N
(
AˆPt:V,V¯ −At
)
= −
{
∂E [RN (At, η)]
∂At
}−1 ∑
i∈(0,1,2,3,V¯ )
ρin
−1/2
i
ni∑
j=1
Qij ,
where Qij (η) = E
(
R(ij)(ij)′ +R(ij)′(ij)
)
+ ρ−1i
∂ERN (At,η)
∂p
[
−1
n0
∂2lsrs(p)
p2
]−1
P0jI (i = 0)
+ ∂ERN (At,η)∂ξ
[
−1
N
∂2pl(ξ)
∂ξi∂ξi′
]−1
Hij (η).
Theorem 1: Under general regularity conditions,
√
N
(
AˆPt:V,V¯ −At
)
d→ N (0,Σt), (3.16)
where Σ =
[
∂E[RN (At,η)]
∂At
]−2∑
i∈(0,1,2,3,V¯ ) ρivar (Qij).
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The asymptotic variance estimator
Σˆt =
[
∂E [RN (At, η)]
∂At
]−2 ∑
i∈(0,1,2,3,V¯ )
ρˆivar
(
Qˆij
)
(3.17)
is obtained by replacing the large sample quantities in Σt with their corresponding finite
sample quantities.
3.3.1 Alternative estimation of the variance of the SPEL-pAUC
Standard error estimates were generated using the bootstrap method (Efron and Tibshi-
rani, 1993). The following algorithm was applied to each of 1,000 iterations of the simulation.
1) From the generated sample population, we drew B independent bootstrap samples
s1, s2, ..., sB of size nV with replacement, following the proposed sampling design in
Section 3.2.
2) For each bootstrap sample we then computed the SPEL-pAUC, denoted θˆb and given
in (3.15), resulting in B values of the SPEL-pAUC.
3) The average of these bootstrap ROC estimators is given by
¯ˆ
θb =
1
B
∑B
b=1 θˆb with variance
Vˆ
(
θˆb
)
= 1B
∑B
b=1
(
θˆb − ¯ˆθb
)2
and standard deviation given by
√
Vˆ
(
θˆb
)
.
4) We repeated these steps 1,000 times in generating the simulation results.
The ŜE displayed in the simulation results was found by taking the average of the standard
deviation estimates across 1,000 independent iterations of the simulation.
3.4 Simulation study
We evaluate the behavior of the SPEL-pAUC under many situations to better examine
its robustness. The simulation studies were conducted using R version 2.14. The data were
generated under the model Y = β0 +Dβ1 + , where D = 1 for diseased subjects and D = 0
for non-diseased subjects. For the following simulations, we generate data where  ∼ N (0, 1)
and D ∼ Bernoulli (0.3). The population size used in simulations is N = 2000 and the
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distribution of Y is partitioned into three mutually exclusive sets given by C1 = (−∞, qˆ0] ,
C2 = ( qˆ0, qˆ1] , and C3 = ( qˆ1,∞) . The values qˆ0 and qˆ1 are the empirical quantiles of the SRS
component in the TDS data. Here, qˆ1 corresponds to (1− t1)× 100% of the SRS component
data falling below qˆ1. In the following simulations, we consider the impact of 1) varying
overall sample size, nV ; 2) varying proportion of SRS to TDS component sizes,
n0
nV
; and
3) varying model parameter β1. The variations under consideration are: validation sample
size (nV ) 120, 240, and 360; proportion of SRS subjects among validation set (
n0
nV
) 0.25,
0.5, and 0.75; and FPR intervals. For simulation results, the estimated means, standard
errors, mean of the standard error estimates, and 95% nominal coverage probabilities for an
estimator are obtained from 1000 independent runs. Estimated standard errors were obtaining
with bootstrapping, using 50 replicate samples.
Sample allocation for TDS
The SPEL-pAUC uses the TDS design to target subjects on the left tail of the distribution.
This sample consists of the following three components:
1) the SRS component of size n0,
2) the TDS component of size n − n0 where all subjects are sampled from the left-most
interval, depending on the FPR interval of interest, and n0nV = 0.5. For example, if we
are interested in FPR ∈ (0, 0.1), then n1 = 0 subjects are sampled such that Y1j ∈ C1,
n2 =
1
2nV subjects are sampled such that Y2j ∈ C2, and n3 = 0 subjects are sampled
such that Y3j ∈ C3. Whereas, if we are interested in FPR ∈ (0.1, 0.2), then n1 = 12nV
subjects are sampled such that Y1j ∈ C1, n2 = 0 subjects are sampled such that
Y2j ∈ C2, and n3 = 0 subjects are sampled such that Y3j ∈ C3, and
3) the non-validation component of size N − nV , comprised of all subjects not sampled
into the SRS and TDS components.
For the NPEL-pAUC, proposed by Wang et al. (2012), the sample consists of the same SRS
and TDS components, except that in the TDS component, the subjects are allocated equally
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across all intervals. For interest in FPR ∈ (0, 0.1), n1 = 0 and n2 = n3 = 12 (n− n0). For
interest in FPR ∈ (0, 0.1), n1n2 = n3 = 13 (n− n0).
Estimators to be compared
The proposed estimator, SPEL-pAUC in (3.15), is compared to three estimators in the
simulation studies. These estimators are given below. Specifically, under each setting, we
compare the following four estimators.
1) NP-pAUC: the SRS only estimator Dodd and Pepe (2003a), denoted by AˆSRSt:V , is given
by (3.2).
2) SPEL-pAUC(SRS): the SRS with validation and non-validation data estimator, denoted
AˆSRS
t:V,V¯
, has the same form as the SPEL-pAUC in (3.15). The difference between this
estimator and the SPEL-pAUC is the sampling scheme. This gives a comparison of the
SRS and TDS designs while incorporating non-validation data.
3) NPEL-pAUC: the TDS data only estimator (Wang et al., 2012), denoted AˆTDSt:V , is given
by (3.3).
4) SPEL-pAUC: the proposed TDS with validation and non-validation data estimator,
denoted AˆP
t:V,V¯
, is given by (3.15).
Results
Unbiasedness All four AUC estimators yield unbiased estimates. To illustrate this, we
simulated data using multiple allocations, sample sizes, and FPR intervals. Tables 3.1 and
3.3 show that the average of all AUC estimators are close to or equal to the true value.
Other allocation schemes were considered for the SPEL-pAUC in Table 3.2 by varying the
proportion of subjects allocated to the SRS component ( n0nV = (0.25, 0.5, 0.75)) and the TDS
component allocation. In all of the allocations considered, the SPEL-pAUC continues to be
unbiased.
Efficiency The SPEL-pAUC is the most efficient among pAUC estimators compared and
the NP-pAUC is the least efficient among those compared. This supports the idea that both
the use of the TDS design and inclusion of non-validation subjects create a more efficient
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alternative to the SRS design and validation-only estimators while sampling the same number
of subjects. In most cases for the chosen allocation ( n0nV = 0.5 and allocation to left-most
interval), shown in Table 3.2, the bootstrapped standard errors are equal to the standard
error of the estimator. For FPR∈ (0, 0.2), for example, the first three lines of results show
that for sample sizes 120, 240, and 360, the bootstrapped standard errors are 0.014, 0.010,
0.008, respectively, which equals the standard error of the SPEL-pAUC estimator. For FPR∈
(0.1, 0.5), the first line gives results for nV = 120 with a bootstrapped standard error 0.027
compared to the standard error of 0.029. As the sample size increases, the bootstrapped
standard error does a better job of estimating the standard error of the SPEL-AUC. Table
3.2 shows that the standard error is only slightly effected for FPR∈ (0, 0.2) when alternate
allocations are considered. Whereas for FPR∈ (0.1, 0.5) the chosen allocation is the smallest
standard error at 0.015 for nV = 360, compared to 0.016, 0.017, and 0.018 for alternate
allocations.
Robustness The SPEL-pAUC does not require model specification for the screening test,
Y. To explore the SPEL-pAUC’s robustness, simulation studies were generated using both
Normal and Chi-squared distributions for the screening test. Simulation results reported
in Table 3.3 show that the simulation study gives similar results when the screening test
is generated using a Chi-squared distribution, as far as unbiasedness of the estimators and
efficiency of the SPEL-pAUC.
3.5 Analysis of the lung cancer study data
We used the SPEL-pAUC to analyze non-small-cell lung cancer (NSCLC) data from the
CALGB 150807 study (Bueno et al., 2012) conducted by the Cancer and Leukemia Group B.
This study is a subset of patients registered in the CALGB 140202 study who have stage 1A
or 1B non-small-cell lung cancer (NSCLC), have not received preoperative chemotherapy or
radiation, and are not missing histological, demographic, clinical, and follow-up information
of interest. Among patients in the CALGB 150807 study, 1,061 patients were not censored
before 12 months and were used in this analysis.
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Lung cancer is the most common cause of cancer death among men and women in the world
(Blanchon et al., 2006). Lung cancer is classified as either small-cell lung carcinoma (SCLC)
or non-small-cell lung carcinoma (NSCLC), of which NSCLC accounts for approximately 80%
of all lung cancers. After surgical lung resection, a large proportion of stage 1 NSCLC patients
have cancer recurrence within five years (Bueno et al., 2012). When surgery is used as the
primary treatment for NSCLC, adjuvant chemotherapy may benefit patients who have a high
risk of cancer recurrence. Identifying patients who are at high risk of cancer recurrence
is important in order for treatment to be given to those who would benefit most. This is
an important area of study for patients, families, and doctors when making decisions on a
treatment plan.
The Balcone risk score, outlined by Blanchon et al. (2006), has been developed to identify
patients who are at greatest risk of cancer recurrence. To select the variables that are included
in the scoring algorithm, Blanchon et al. (2006) used a Cox model to identify variables that
were independently associated with mortality. The associated variables were then weighted to
create the Balcone risk index. The components of the risk score are given by: age (>70 years,
1 point); sex (male, 1 point); performance status at diagnosis (reduced activity, 3 points;
active >50%, 5 points; inactive >50%, 8 points; and total incapacity, 10 points); histological
type (large-cell carcinoma, 2 points); and tumour-node-metastasis (TNM) staging system
(IIA or IIB, 3 points; IIIA or IIIB, 6 points; and IV, 8 points). For the data used in this
analysis, the Balcone risk score ranges from 0 to 15.
The goal of this analysis is to summarize the ability of the Balcone risk score to distinguish
between patients who survive beyond 12 months and those who do not when the FPR falls
within (0.1, 0.3). This FPR range allows us to assess the utility of the SPEL-pAUC when
the FPR is low. Clinicians may be less interested in the Balcone risk score at higher FPR
values because this would suggest that patients are being falsely identified as high risk for
cancer recurrence, leading to treatment plans that may be dangerous and unnecessary. The
outcome of interest is survival beyond 12 months and the screening test is the Balcone risk
score. Although all information is available for these patients, we illustrate the utility of
the proposed AUC estimator by sampling from the study data and evaluating the estimated
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AUC. Table 3.4 gives descriptive statistics for the Balcone risk score, stratified by survival at
12 months. A sample size of nV = 360 was used for all estimators compared and details on
sample allocation for each estimator are given in Table 3.5. The NP-pAUC has an SRS of
size n = 360. The SPEL-pAUC(SRS) allocates 100% of the sample to the SRS component
and utilizes incomplete data from the non-validation set. The NPEL-pAUC allocates 50%
of the validation sample to the SRS component and the remaing 50% are allocated equally
between the three intervals, Ci, such that n1 = n2 = n3 = 60. The SPEL-pAUC allocates
50% of the sample to the SRS component and samples the remaining 50% to the left tail,
where n1 = 180 and n2 = n3 = 0, while utilizing incomplete data from the non-validation
set. Because survival at 12 months is known for all subjects, we use the NP-pAUC estimator
to evaluate the pAUC using complete information, given by 0.150. The pAUC estimates are:
NP-pAUC 0.132, SPEL-pAUC(SRS) 0.158, NPEL-pAUC 0.149, and SPEL-pAUC 0.147. All
estimators compared have an estimated pAUC that is similar to the best estimate we have
for the true pAUC, which is 0.15, found by using the complete data.
3.6 Analysis of the Preterm Prediction Study data
We used the SPEL-pAUC to analyze data from the Preterm Prediction Study, a multi-
center prospective study designed to study spontaneous preterm birth (Goldenberg et al.,
1996). The Maternal Fetal Medicine Units Network of the National Institute of Child Health
and Human Development carried out this study using ten centers to recruit women. There
were 3073 women recruited between October 1992 and July 1994. Measurements were col-
lected every two weeks from 22 to 30 weeks’ gestation. Among the 3073 women recruited,
3001 had valid measurements of interest for this analysis.
PTB is defined as delivery at less than 37 weeks of gestation, contributes to neonatal
morbidity and mortality which increases as gestational age decreases (McCormick, 1985).
Bastek and Elovitz (2013) combined results from multiple studies on this topic to gain a
better understanding the relationship between biomarkers and PTB. The results were not
definitive for most biomarkers with the exception of fetal fibronectin (FFN).
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Fetal fibronectin (FFN) is a protein that is produced by the fetal membrane. Knowing
the FFN will not change the incidence of spontaneous PTB but it will affect the treatment
plan. Deshpande et al. (2013) found that FFN has moderate accuracy in predicting PTB.
Although many studies are concerned with the ability to predict spontaneous PTB, Bastek
and Elovitz (2013) suggest that the ability to predict those who will not have spontaneous
PTB is also valuable. Because FFN typically has a high negative predictive value (proportion
of true negatives over all who test negative), a negative FFN test is widely used in clinical
practice to send patients home. Measurable levels of FFN are considered to be abnormal
between 20 and 37 weeks’ gestation. Lockwood et al. (1991) show that in 588 FFN samples
from uncomplicated pregnancies, a higher percentage of subjects were positive for FFN (level
above 0.05 µg/mL) before 22 and after 37 weeks’ gestation compared to between 22 and 37
weeks’ gestation. For example the percentage of cervical samples with positive FFN for <22,
22 to 37 and >37 weeks’ gestation were 24%, 4%, and 32%, respectively. This is an important
area of study due to the negative effects of spontaneous PTB on maternal and child health
outcomes.
In our analysis, the outcome of interest is spontaneous PTB at less than 37 weeks’ gestation
and the screening test considered in FFN. Values of the screening test that are associated with
high FPRs are not of interest clinically and very low FPRs may not be realistic. Because
of this, we are interested in estimating the pAUC where we restrict the FPR interval to
(0.1, 0.5). Table 3.6 gives descriptive statistics for FFN, stratified by spontaneous PTB.
A sample size of nV = 360 was used for all estimators compared and details on sample
allocation for each estimator are given in Table 3.7. The NP-pAUC has an SRS of size
n = 360. The SPEL-pAUC(SRS) allocates 100% of the sample to the SRS component and
utilizes incomplete data from the non-validation set. The NPEL-pAUC allocates 50% of the
validation sample to the SRS component and the remaing 50% are allocated equally between
the three intervals, Ci, such that n1 = n2 = n3 = 60. The SPEL-pAUC allocates 50% of the
sample to the SRS component and samples the remaining 50% to the left tail, where n1 = 180
and n2 = n3 = 0, while utilizing incomplete data from the non-validation set. Because the
outcome of spontaneous PTB is known for all subjects, we use the NP-pAUC estimator to
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evaluate the pAUC using complete information, given by 0.177. The pAUC estimates are:
NP-pAUC 0.189, SPEL-pAUC(SRS) 0.133, NPEL-pAUC 0.157, and SPEL-pAUC 0.126. All
estimators compared have an estimated pAUC that is similar to the best estimate we have
for the true pAUC, which is 0.177, found by using the complete data.
3.7 Discussion
We have proposed a semi-parametric estimator for the partial area under the ROC curve
(pAUC), which allows us to summarize the ability of a screening test to discern between
diseased and non-diseased subjects while restricting the FPR to a range that is clinically
relevant. This estimator incorporates a TDS design and includes both validation and non-
validation data. The use of empirical likelihood methods allows us to estimate the pAUC
without specifying a distribution for the screening test. We use bootstrapping to estimate
the standard error and simulation studies show good coverage probabilities when using the
standard error estimated using bootstrap methods.
The proposed design is motivated by the need to improve efficiency in estimating pAUC.
Ascertaining true disease status can be costly and invasive for subjects. Although disease
status is missing for the non-validation set, the proposed estimator takes advantage of all
information available for a larger number of subjects than the validation-only estimators.
Although all estimators are unbiased, the proposed estimator was shown to be the most
efficient, compared to three competing pAUC estimators. This suggests that to obtain the
same variability less subjects would be needed when the SPEL-pAUC is used, reducing study
cost and subject burden. These results support the idea that both the use of the TDS design
and inclusion of non-validation subjects create a more efficient alternative to the SRS design
and the validation-only estimators while sampling the same number of subjects. For example,
with a sample size of 120 and FPR interval of (0, 0.02), the standard error of the proposed
estimator is 0.014 compared to 0.018 and 0.016 in the competing methods (Table 3.1). In
this case, we have an estimated standard error of 0.014 which gives coverage proportion
of 0.952. The SPEL-pAUC is also robust in its ability to estimate pAUC under varying
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distributions. Simulation studies show that when the screening test is simulated from a Chi-
squared distribution, the pAUC estimators are unbiased and the SPEL-pAUC continues to
be the most efficient pAUC estimator under comparison.
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Table 3.1: Comparison of SPEL-pAUC and competing methods
nV = 120 nV = 240 nV = 360
Method Mean SE Mean SE Mean SE
FPR∈ (0, 0.2) and True pAUC=0.0727
AˆSRSt:V 0.076 0.018 0.074 0.013 0.074 0.010
AˆSRS
t:V,V¯
0.074 0.016 0.073 0.011 0.073 0.008
AˆTDSt:V 0.074 0.016 0.075 0.012 0.074 0.009
AˆP
t:V,V¯
0.074 0.014 0.073 0.010 0.073 0.008
FPR∈ (0.1, 0.5) and True pAUC=0.2646
AˆSRSt:V 0.265 0.033 0.263 0.023 0.265 0.019
AˆSRS
t:V,V¯
0.266 0.030 0.265 0.021 0.264 0.016
AˆTDSt:V 0.266 0.030 0.263 0.022 0.264 0.018
AˆP
t:V,V¯
0.266 0.029 0.265 0.018 0.263 0.015
Screening test data is simulated assuming YD=1 ∼ N (1, 1)
and YD=0 ∼ N (0, 1). AˆSRSt:V denotes the NP-pAUC which
uses SRS; AˆSRS
t:V,V¯
denotes the SPEL-pAUC(SRS) which uses
SRS and utilizes information for both validation and non-
validation data; AˆTDSt:V denotes the NPEL-pAUC which uses
TDS; and AˆP
t:V,V¯
denotes the proposed SPEL-pAUC which
uses TDS and utilizes information from both validation and
non-validation data. All estimators sample the same num-
ber of subjects.
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Table 3.2: Properties of the SPEL-pAUC
nV
n0
nV
(n0, n1, n2, n3, nV¯ ) Mean SE ŜE CP
FPR∈ (0, 0.2) and True pAUC=0.0727
n1 = n3 = 0
120 0.5 (60, 0, 60, 0, 1880) 0.074 0.014 0.014 0.952
240 0.5 (120, 0, 120, 0, 1760) 0.073 0.010 0.010 0.944
360 0.5 (180, 0, 180, 0, 1640) 0.073 0.008 0.008 0.950
n1 = n3 = 0
360 0.25 (90, 0, 270, 0, 1640) 0.072 0.009 0.010 0.951
360 0.75 (270, 0, 90, 0, 1640) 0.073 0.008 0.008 0.948
n1 = n2 = n3
360 0.5 (180, 0, 90, 90, 1640) 0.073 0.008 0.008 0.950
FPR∈ (0.1, 0.5) and True pAUC=0.2646
n2 = n3 = 0
120 0.5 (60, 60, 0, 0, 1880) 0.265 0.029 0.027 0.926
240 0.5 (120, 120, 0, 0, 1760) 0.265 0.018 0.018 0.953
360 0.5 (180, 180, 0, 0, 1640) 0.263 0.015 0.016 0.955
n2 = n3 = 0
360 0.25 (90, 270, 0, 0, 1640) 0.263 0.018 0.018 0.957
360 0.75 (270, 90, 0, 0, 1640) 0.265 0.016 0.017 0.962
n1 = n2 = n3
360 0.5 (180, 60, 60, 60, 1640) 0.265 0.017 0.016 0.937
Screening test data is simulated assuming YD=1 ∼ N (1, 1) and YD=0 ∼
N (0, 1). The fraction n0nV is the proportion of subjects allocated to
the SRS component out of the total number of validation subjects
sampled. The sample allocation, (n0, n1, n2, n3, nV¯ ), gives the number
of subjects allocated to the SRS component, three intervals of the TDS
component, and the non-validation set, respectively.
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Table 3.3: Comparison of SPEL-pAUC and competing methods for Chi-Squared Distributed
Data
FPR∈ (0, 0.2) FPR∈ (0.1, 0.5)
Method Mean SE Mean SE
AˆSRSt:V 0.092 0.018 0.291 0.032
AˆSRS
t:V,V¯
0.096 0.016 0.286 0.026
AˆTDSt:V 0.092 0.017 0.293 0.029
AˆP
t:V,V¯
0.101 0.016 0.307 0.024
Screening test data is simulated assuming
YD=1 ∼ χ (4, 3) and YD=0 ∼ χ (3) and nV =
120. The true pAUC for FPR∈ (0, 0.2) is
0.0901 and for FPR∈ (0.1, 0.5) is 0.2921.
Table 3.4: Descriptive statistics for the Balcone risk score
N Minimum Q1 Median Q3 Maximum
Overall 1076 0 1 1 3 10
Survival beyond 12 months 965 0 1 1 3 10
Survival less than 12 months 111 0 1 2 5 9
Table 3.5: Sample allocation for the non-small-cell lung cancer data
Component MW-AUC SPEL-AUC(SRS) NPEL-AUC SPEL-AUC
SRS 360 360 180 180
TDS (n1, n2, n3) (0, 0, 0) (0, 0, 0) (60, 60, 60) (180, 0, 0)
non-validation 0 701 0 701
Table 3.6: Descriptive statistics for FFN
N Minimum Q1 Median Q3 Maximum
Spontaneous PTB 309 0 0.88 4.48 17.08 924.56
Not PTB 2692 0 0.28 2.61 7.22 2151.44
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Table 3.7: Sample allocation for the Preterm Prediction Study
Component NP-pAUC SPEL-pAUC(SRS) NPEL-pAUC SPEL-pAUC
SRS 360 360 180 180
TDS (n1, n2, n3) (0, 0, 0) (0, 0, 0) (60, 60, 60) (180, 0, 0)
non-validation 0 2641 0 2641
The FPR interval of interest is (0.1, 0.5).
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Chapter 4
Covariate-specific ROC Curve under Test-Dependent Sampling
4.1 Introduction
The receiver operating characteristic (ROC) curve is a summary measure used to describe
the ability of a screening test to discriminate between diseased and non-diseased subjects
(Bamber, 1975). Consider a screening test, Y, and disease or outcome, D, where D=1 indicates
presence of the disease and D=0 indicates no disease. The ROC curve is constructed by
plotting the false positive rate (FPR, Pr (Y ≥ c|D = 0)) against the true positive rate (TPR,
Pr (Y ≥ c|D = 1)), where c is the threshold for the screening test to indicate disease. As
evaluating the true disease status can be costly, it is important for researchers to increase
study efficiency by allowing selection probabilities to depend on the screening test (Wang
et al., 2012). Increased efficiency translates to cost and time savings for studies as well as
decreased burden on subjects. Incorporating covariates into the ROC curve estimator allows
for evaluation of the utility of the screening test for different subsets of a population. We
propose a semi-parametric covariate-specific ROC curve estimator, which incorporates a test-
dependent sampling design and inclusion of un-sampled subjects. Simulation studies show
that the proposed ROC curve estimator is unbiased and improves efficiency compared to
estimators using a simple random sample (SRS) design and those that use only information
from the sampled subjects.
Using data from the Cancer and Leukemia Group B (CALGB) 150807 study, we evaluate
the ability of the Balcone risk score to identify patients who are at greatest risk of non-
small-cell lung cancer (NSCLC) recurrence by estimating the covariate-specific ROC curve
(Bueno et al., 2012). When surgery is used as the primary treatment for NSCLC, adjuvant
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chemotherapy may benefit patients who have a high risk of cancer recurrence. Identifying
patients who are at high risk of cancer recurrence is important in order for treatment to be
given to those who would benefit most. We can evaluate the utility of the Balcone risk score
in predicting survival at 12 months for specific values of a covariate. Including covariates,
such as age and gender, in the model will help of identify subsets of the population where the
screening test is more effective at predicting survival at 12 months. This is an important area
of study for patients, families, and doctors when making decisions on a treatment plan. The
proposed methods are especially beneficial considering the length of time this type of study
will follow patients and the cost of following a large number of subjects in this setting.
We also use data from the Preterm Prediction Study to evaluate the ability of fetal fi-
bronectin (FFN) to predict spontaneous preterm birth by estimating the covariate-specific
ROC curve, while incorporating information from un-sampled subjects and including cervical
length, maternal age, and previous PTB (Goldenberg et al., 1996). Preterm birth (PTB),
defined as delivery at less than 37 weeks of gestation, contributes to neonatal morbidity
and mortality. The prevalence of adverse events increases as gestational age decreases (Mc-
Cormick, 1985). We can consider covariates, such a cervical length, when estimating the
ROC curve to identify subset of the study population in which FFN is a better predictor of
PTB. This is an important area of study due to the negative impact of spontaneous PTB
on maternal and child health outcomes. Knowing the FFN measurement will not change the
incidence of spontaneous PTB, but it will affect the treatment plan. The use of covariates
allows us to better understand the influence covariates have on accuracy of this screening test
(Wang et al., 2013).
Methods have been developed which consider the effect of covariate information on ROC
curves and summary measures area under the ROC curve (AUC) and partial AUC (pAUC).
Thompson and Zucchini (1989) and Dodd and Pepe (2003a) proposed direct estimation of the
AUC, and Dodd and Pepe (2003a) proposed direct estimation of the pAUC, while account-
ing for covariates. Pepe (2000) and Cai and Pepe (2002) used generalized linear modeling
methods to estimate the covariate-adjusted ROC curve. An alternative to direct ROC curve
estimation is to model the screening test variable as a function of covariates and the disease
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status. This approach has been used by Tosteson and Begg (1988) and Wang et al. (2013).
These methods make parametric assumptions for the screening test. Wang et al. (2013) pro-
posed the use of test-dependent sampling (TDS) in which inclusion in the sample depends
on the continuous screening test measure. The TDS design is related to outcome-dependent
sampling (ODS). Zhou et al. (2002) used the ODS design and empirical likelihood methods in
regression modeling to develop parameter estimates where inclusion in the sample depends on
a continuous outcome variable. Weaver and Zhou (2005) developed a semi-parametric estima-
tor for regression coefficients using the ODS framework, which utilizes incomplete information
for the un-sampled portion of the population. In the design proposed by Weaver and Zhou
(2005), the outcome used to develop the ODS is observed for all subjects, but covariates are
missing for the un-sampled portion of the population.
We propose the use of a test-dependent sampling (TDS) design in which TDS inclusion
depends on the continuous screening test measure. The TDS design incorporates an SRS
component, a TDS component, and the remaining un-sampled portion of the population.
The TDS design allows investigators to over-sample subjects from specified ranges of the
screening test variable, allowing for a concentration of resources where there is the greatest
amount of information. All data are available for subjects sampled in the study, but only the
screening test value and covariates are available for the un-sampled portion of the population.
The proposed method gives improved estimates of the covariate-specific ROC curve which are
more efficient than methods which utilize only the sampled subjects.
This chapter is organized as follows. In Section 4.2, we introduce an alternative covariate-
specific ROC curve estimator and propose use of empirical likelihood methods to develop a
semi-parametric estimator for the covariate-specific ROC curve. In Section 4.3, a variance
estimator for the proposed covariate-specific ROC curve estimator is described. In Section
4.4, we use simulation studies to compare the proposed estimator with competing methods. In
Section 4.5, we analyze data from the lung cancer study. In Section 4.6, we use the proposed
method to analyze data from the Preterm Prediction Study. We conclude with a discussion
in Section 4.7.
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4.2 Semi-parametric empirical likelihood ROC curve (SPEL-ROC) estima-
tion
4.2.1 Notation and data structure
Consider a continuous test variable, Y , a vector of covariates, X, and binary disease
indicator, D. The distribution of Y can be divided into K mutually exclusive intervals
defined by Ck = (ak−1, ak] where k = 1, . . . ,K. The sample size within each of the Ck
intervals may be different. The TDS is made up of 3 components: the SRS component, TDS
component, and the non-validation set (un-sampled subjects). The subjects sampled in the
SRS and TDS components combined make up the validation set, indexed by V , where the
true disease status is validated. The remainder of the population not selected for sampling
makes up the non-validation set, indexed by V¯ . The sample size of the validation set is given
by nV = n0 +
∑K
k=1 nk, where n0 is the sample size from the SRS component and nk is the
sample size for the kth TDS interval, k = 1, . . . ,K. The size of the non-validation set is given
by nV¯ = N−nV . To define subscripts, i indexes the sampling group where i =
(
0, 1, ...,K, V¯
)
and j = {1, ..., ni} denotes the individual in the ith sampling group. The test variable, Y ,
and covariates, X, are observed for all subjects in the dataset. The disease status, D, is only
ascertained for subjects who are in the validation set. The data framework is given by
SRS component (D0j , Y0j ,X0j) j = 1, ..., n0
TDS1 component (D1j , Y1j ,X1j |Y1j ∈ C1) j = 1, ..., n1
...
...
...
TDSK component (DKj , YKj ,XKj |YKj ∈ CK) j = 1, ..., nK
Non-validation component
(
Yv¯j ,Xv¯j |i = V¯
)
j = 1, ..., nV¯ .
(4.1)
4.2.2 Alternative ROC curve estimator
The alternative covariate-specific ROC estimator (LS-ROC) included in the simulation
studies uses a binormal ROC model, discussed in Pepe (2004) and Wang et al. (2013), and
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samples subjects with an SRS design. The model is given by
Y = Xβ + σ (D)  = β0 + β1D + β2X + β3XD + σ (D)  (4.2)
where  ∼ N (0, 1) and σ (D) = σ1D + σ0 (1−D). Parameter estimates are found using
the ordinary least squares method where βˆ =
[
XTX
]−1
XT y and the variances, σ21 and σ
2
0,
are found by calculating the sample variance for the respective outcome groups, D = 1 and
D = 0. The covariate-specific survival function is estimated for the diseased and non-diseased
groups for a chosen covariate value, giving Sˆ1X = Φ
(
µˆ1X−c√
vˆ1
)
and Sˆ0X = Φ
(
µˆ0X−c√
vˆ0
)
where
µˆ1X = βˆ0 + βˆD + βˆ
T
XX + βˆ
T
DXXD and µˆ0X = βˆ0 + βˆ
T
XX. The ROC curve is then estimated
by
R̂OC (t) = Sˆ1X
(
Sˆ−10X (t)
)
. (4.3)
The covariate-specific ROC curve can be generated by plotting Sˆ1X (t) against Sˆ0X (t) for
specified covariate values, X.
4.2.3 Semi-parametric empirical likelihood approach
To develop the likelihood, denote f (Yij |Xij , Dij) the distribution of the screening test con-
ditional on covariates and disease status. Denote g (Xij |Dij = d) the distribution of the co-
variates conditional on disease status. The joint distribution of disease status, covariates, and
screening test, conditional on Yij falling in the interval Ck is given by f (Yij , Dij ,Xij |Yij ∈ Ck),
k = (1, . . . ,K). Consider stratum sizes in the population Nk = n0,k + nk + nV¯ ,k, where
ni,k =
∑ni
j=1 I(Yi ∈ Ck) for i =
{
0, V¯
}
and k = {1, . . . ,K}. We use a binormal model to
describe the relationship between the screening test and the disease status and covariates,
given by
Y = Xβ + σ (D)  = β0 + β1D + β2X + β3XD + σ (D)  (4.4)
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where  ∼ N (0, 1) and σ (D) = σ1D + σ0 (1−D) (Pepe, 2004; Wang et al., 2013). Let
σ = (σ1, σ0).
The validation portion of the likelihood is given by
LV (G, p,β,σ)
=
n0∏
j=1
f (Y0j , X0j , D0j)×
K∏
k=1
nk∏
j=1
f (Ykj , Xkj , Dkj |Ykj ∈ Ck)
=
K∏
k=1
Pr (Ykj ∈ Ck)−nk
K∏
i=0
ni∏
j=1
f (Yij |Xij , Dij = d) g (Xij |Dij = d)Pr (Dij = d).(4.5)
The non-validation portion of the likelihood takes into account the missing data, where the
disease status is unknown, and is given by
LV¯ (G, p,β,σ)
=
(N − n0)!∏K
k=1 (Nk − n0,k)!
K∏
k=1
Pr (Ykj ∈ Ck)Nk−n0,k
nV¯∏
j=1
Y ∈Ck
f
(
YV¯ j ,XV¯ j
)
Pr (Ykj ∈ Ck)
=
(N − n0)!∏K
k=1 (Nk − n0,k)!
K∏
k=1
Pr (Ykj ∈ Ck)nk
×
nV¯∏
j=1
1∑
d=0
f
(
YV¯ j |XV¯ j , DV¯ j = d
)
g
(
XV¯ j |DV¯ j = d
)
Pr
(
DV¯ j = d
)
. (4.6)
The full likelihood is found by combining the validation and non-validation portions of the
76
likelihood, (4.5) and (4.6), given by
L ({qij} , {rij} , p,β,σ) = LV (G, p,β,σ)× LV¯ (G, p,β,σ)
∝
∏
i,j∈V
f (Yij |Xij , Dij) g (Xij |Dij)Pr (Dij = d)
×
nV¯∏
j=1
1∑
d=0
f
(
YV¯ j |XV¯ j , DV¯ j = d
)
g
(
XV¯ j |DV¯ j = d
)
Pr
(
DV¯ j = d
)
=
∏
i,j∈V
D=1
f (Yij |Xij , Dij = 1) qijp×
∏
i,j∈V
D=0
f (Yij |Xij , Dij = 0) rij (1− p)
×
nV¯∏
j=1
[
f
(
YV¯ j |XV¯ j , DV¯ j = 1
)
qV¯ jp+ f
(
YV¯ j |XV¯ j , DV¯ j = 0
)
rV¯ j (1− p)
]
, (4.7)
where p = Pr (D = 1), qij = g (Xij |Dij = 1), and rij = g (Xij |Dij = 0). The probability of
having disease, p, is estimated from the SRS component of the TDS. Due to the relationship
between qij and rij and the need to decrease computational load, Qin and Zhang (1997,
2003) propose a constraint given by
rij
qij
= em(Xij)α. Consider the standard logistic regression
model where Pr (D = 1|Y ) = em
∗(Y )α
1+em
∗(Y )α = ψ (Y ). The Bayes’ rule gives f (Y |D = 1) =
f(Y )Pr(D=1|Y )
Pr(D=1) =
f(Y )ψ(Y )
p . Similarly, f (Y |D = 0) = f(Y )(1−ψ(Y ))1−p . Consider the ratio
rij
qij
=
f (Y |D = 0)
f (Y |D = 1)
=
[
f (Y ) (1− ψ (Y ))
1− p
]
×
[
p
f (Y )ψ (Y )
]
=
p
1− p
(
1
1 + em∗(Y )α
)(
em
∗(Y )α
1 + em∗(Y )α
)
= em(Y )α,
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which implies that rij = qije
m(Xij)α. Applying this constraint to the log-likelihood gives
l ({qij} , p,α,β,σ)
∝
∑
ij
ln qij +
∑
ij∈V
f (Yij |Xij , Dij = d) +
∑
i,j∈V
D=0
m (Xij)α
+
nV¯∑
j=1
ln [ f
(
YV¯ j |XV¯ j , DV¯ j = 1
)
p+ f
(
YV¯ j |XV¯ j , DV¯ j = 0
)
em(Xij)α (1− p) ] . (4.8)
Without loss of generality, consider partitioning the screening test variable into three
mutually exclusive intervals: C1 = (−∞, a1], C2 = (a1, a2], and C3 = (a2,∞). The TDS
consists of an SRS component of size n0, a TDS component of size n1 + n2 + n3, and the
non-validation set of size N − nV , where nV = n0 + n1 + n2 + n3. Subjects are eligible to
be sampled for the TDS component based on their screening test result, Y. For example, if a
subject’s test result is less than or equal to a1 and n1 > 0, the probability of being selected
in the TDS component for C1 is greater than zero.
In order to develop the semi-parametric empirical likelihood ROC curve estimator (SPEL-
ROC), we first need to obtain estimates for {qij}, α, β, and σ. We estimate {qij} using
empirical likelihood methods outlined below. Parameters α, β, and σ are estimated using
the Newton-Raphson algorithm. Then we can use these parameter estimates in the ROC
curve equation, in (4.3), to obtain the SPEL-ROC.
To obtain estimates for α, β, and σ the profile likelihood must be constructed. The
distribution of the covariates conditional on disease status, g (Xij |Dij = 1), is not known
or assumed. A robust estimator for the covariate-specific ROC curve can be constructed
without making these distributional assumptions by fixing α and then obtaining the empirical
likelihood function of G (Xij |Dij = 1), with support at the observed values of X. To maximize
L ({qij} , p,α,β,σ), we estimate {qˆij} = g (Xij |Dij = 1) under the following constraints:qij ≥ 0, ∑
i∈(0,1,2,3,V¯ )
ni∑
j=1
qij = 1,
∑
i∈(0,1,2,3,V¯ )
ni∑
j=1
qij
{
em(Xij)α − 1
}
= 0
 . (4.9)
A unique maximum for {qij} exists under the constraints given in (4.9) if 1 is inside
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the convex hull of points em(Xij)α for all (i, j) (Owen, 1988, 1990; Qin and Lawless, 1994).
Lagrange multipliers, λ1 and λ2, are used to derive the maximum over {qˆij}. Consider the
function
H = l ({qij} , p,α,β,σ) + λ1
1−∑
ij
qij
+ nλ2∑
ij
qij
{
em(Xij)α − 1
}
∝
∑
ij
ln qij + λ1
1−∑
ij
qij
+Nλ2∑
ij
qij
{
em(Xij)α − 1
}
. (4.10)
Estimates {qˆij} and λˆ1 are found by taking the derivative of H with respect to qij , where H
is given by (4.10), and setting the derivative equal to zero. The derivative of H is given by
∂H
∂qij
= 1qij − λ1 + Nλ2
{
em(Xij)α − 1}. The estimate λˆ1 is found by evaluating ∑ij qij ∂H∂qij =
N −λ1
∑
ij qij +Nλ2
∑
ij qij
{
em(Xij)α − 1} = 0 and solving for λ1. By setting the derivative
of H equal zero and solving for qij , we have
qˆij =
1
N
[
1− λ2
(
em(Xij)α − 1
)]−1
(4.11)
for i ∈ (0, 1, 2, 3, V¯ ) and j ∈ (1, . . . , ni).
Profile log-likelihood
The empirical profile log-likelihood is obtained by plugging the estimates qˆij given in (4.11)
into the log-likelihood, given in (4.8). Define ξ = (α,β,σ, λ2). Denoting pl (ξ) as the natural
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logarithm of the empirical profile likelihood, we have
pl (ξ)
∝ −
∑
ij
ln
[
1− λ2
(
em(Xij)α − 1
)]
+
∑
ij∈V
ln f (Yij |Xij , Dij = d) +
∑
i,j∈V
D=0
m (Xij)α
+
nV¯∑
j=1
ln [ f
(
YV¯ j |XV¯ j , DV¯ j = 1
)
p+ f
(
YV¯ j |XV¯ j , DV¯ j = 0
)
em(XV¯ j)α (1− p) ]
∝ −
∑
ij
ln
[
1− λ2
(
em(Xij)α − 1
)]
+
∑
i,j∈V
D=0
m (Xij)α− 1
2
nv,D=1 lnσ
2
1
−
∑
i,j∈V
D=1
[
1
2σ21
(Yij −Xijβ)2
]
−
∑
i,j∈V
D=0
[
1
2σ20
(Yij −Xijβ)2
]
− 1
2
nv,D=0 lnσ
2
0
+
nV¯∑
j=1
ln
[
(2pi)−1/2σ−11 exp
{ −1
2σ21
(
YV¯ j −XV¯ j,D=1β
)2}
p
+(2pi)−1/2σ−10 exp
{ −1
2σ20
(
YV¯ j −XV¯ j,D=0β
)2}
em(XV¯ j)α (1− p)
]
.(4.12)
The Newton-Raphson algorithm can be used to obtain ξˆ.
The ROC curve is given by ROC = S1
(
S−10 (t)
)
and can be viewed by plotting S1 (t)
against S0 (t) for all possible screening test thresholds t, where Sd is the survival function of
the screen test for subjects with disease outcome d. For the SPEL-ROC, the screening test
is assumed to be normally distributed and the survival function can be estimated by
SˆD (t) = Φ
(
Xβˆ − t
σˆ (D)
)
,
(4.13)
where Φ denotes the standard normal cumulative distribution function, Xβ = βˆ0 + βˆ1D +
βˆ2X + βˆ3XD, and σˆ (D) = σˆ1D + σˆ0 (1−D). The estimated ROC curve is seen by plotting
Sˆ1 (t) against Sˆ0 (t) for all possible screening test values, t, and it is estimated by
R̂OC
P
V,V¯ (t) = Sˆ1
(
Sˆ−10 (t)
)
. (4.14)
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4.3 Variance estimation of the SPEL-ROC
Standard error estimates were generated using the bootstrap method (Efron and Tibshi-
rani, 1993). The following algorithm was applied to each of 1,000 iterations of the simulation.
1) From the generated sample population, we drew B independent bootstrap samples
s1, s2, ..., sB of size nV with replacement, following the proposed sampling design in
Section 4.2.
2) For each bootstrap sample we then computed the SPEL-ROC, denoted θˆb and given in
(4.14), resulting in B values of the SPEL-ROC.
3) The average of these bootstrap ROC estimators is given by
¯ˆ
θb =
1
B
∑B
b=1 θˆb with variance
Vˆ
(
θˆb
)
= 1B
∑B
b=1
(
θˆb − ¯ˆθb
)2
and standard deviation given by
√
Vˆ
(
θˆb
)
.
4) We repeated these steps 1,000 times in generating the simulation results.
The ŜE displayed in the simulation results was found by taking the average of the standard
deviation estimates across 1,000 independent iterations of the simulation.
4.4 Simulation study
We evaluate the behavior of the SPEL-ROC under many situations to better examine
its robustness. The simulation studies were conducted using R version 2.14. The data were
generated under the binormal model given by Y = Xβ + σ (D)  = β0 + βDD + βXX +
βXDXD + σ (D) , where  ∼ N (0, 1), X ∼ N (0, 2), σ (D) = σ1D + σ0 (1−D), and D ∼
Bernoulli (0.3) where D = 1 for diseased subjects and D = 0 for non-diseased subjects.
Model parameters are given by: β0 = 0.5, βD = 1, βX = 0.5, βXD = −0.3, σ21 = 1, and
σ20 = 2. The population size used in simulations is N = 1000 and the distribution of Y is
partitioned into three mutually exclusive sets given by C1 = (−∞, a1], C2 = (a1, a2], and
C3 = (a2,∞). In the following simulations, we consider the impact of 1) varying the sample
size, nV and 2) varying the proportion of SRS to TDS component sizes,
n0
nV
. The variations
under consideration are: validation sample size (nV ) 120, 240, and 360; and proportion of
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SRS subjects among validation set ( n0nV ) 0.25, 0.5, and 0.75. For simulation results, the
estimated ROC curve, standard errors, average of the standard error estimates, and 95%
nominal coverage probabilities for an estimator are obtained from 1000 independent runs.
Estimated standard errors were obtaining with bootstrapping, using 50 replicate samples.
Sample allocation for TDS
The SPEL-ROC uses the TDS design to target subjects in all three intervals of the screen-
ing test distribution with sampling fraction n0nV = 0.5. This sample consists of the following
three components:
1) SRS component of size n0,
2) TDS component of size n1 + n2 + n3 where n1 subjects are sampled such that Y1j ∈
C1 = (−∞, a1], n2 subjects are sampled such that Y2j ∈ C2 = (a1, a2], n3 subjects are
sampled such that Y3j ∈ C3 = (a2,∞), and n1 = n2 = n3, and
3) non-validation component of size N − nV , comprised of all subjects not sampled into
the SRS and TDS components.
Estimators to be compared
The SPEL-ROC, given by R̂OC
P
V,V¯ in (4.14), is compared to two estimators in the simu-
lation study. Under each setting, we compare the following three estimators.
1) LS-ROC: the SRS data only estimator, denoted R̂OC
SRS
V (t), given in Section 4.2.2.
2) SPEL-ROC(SRS): the SRS with validation and non-validation data estimator, denoted
R̂OC
SRS
V,V¯ , has the same form as the SPEL-ROC given in (4.14). The difference between
the SPEL-ROC(SRS) and the SPEL-ROC is the sampling scheme. Inclusion of this
estimator gives a comparison of the SRS and TDS designs while incorporating both
validation and non-validation data.
3) SPEL-ROC: the proposed TDS with validation and non-validation data estimator, de-
noted R̂OC
P
V,V¯ , is given by (4.14).
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Results
Unbiasedness All three ROC curve estimators yield unbiased estimates. To illustrate this,
we simulated data using multiple allocations and sample sizes. Table 4.1 shows that the
average of each ROC curve estimator is close to or equal to the true value. Other allocation
schemes were considered for the SPEL-ROC in Table 4.3 by varying the proportion of subjects
allocated to the SRS component ( n0nV = (0.25, 0.5, 0.75)). In all allocations and sample sizes,
the SPEL-ROC continues to be unbiased.
Efficiency The SPEL-ROC and SPEL-ROC(SRS) are more efficient than the LS-ROC.
For smaller sample sizes, nV = 120 in Table 4.1, the SPEL-ROC has smaller SE for lower
FPR values and the SPEL-ROC(SRS) has a smaller SE for a FPR of 0.5 or greater. With
a larger sample size, nV = 360, Table 4.1 shows that while the SPEL-ROC has smaller SE
for low FPRs (0.3 or less), and the SEs for this SPEL-ROC and the SPEL-ROC(SRS) are
the same when the FPR exceeds 0.3 For example, consider nV = 120 and FPR= {0.1, 0.3},
the SPEL-ROC has SEs of 0.057 and 0.069, respectively, compared to 0.060 and 0.070 for the
SPEL-ROC(SRS). Whereas, for nV = 360 and FPR= {0.1, 0.3}, the SPEL-ROC has SEs of
0.038 and 0.045, respectively, compared to 0.042 and 0.047 for the SPEL-ROC(SRS) and for
FPR= {0.5, 0.7, 0.9} both SPEL-ROC and SPEL-ROC(SRS) have SEs 0.031, 0.014, 0.002,
respectively. This supports the idea that both the inclusion of non-validation subjects creates
a more efficient alternative to the SRS design using the ordinary least squares method to
estimate the model parameters while sampling the same number of subjects. The simulation
studies suggest that for smaller values of the FPR, less than 0.5, the SPEL-ROC is the most
efficient out of the three ROC estimators. The bootstrapped standard errors estimated the
SE well, with coverage probabilities close to the nominal level of 0.95. For both nV = 120 and
nV = 360, the SE and SˆE are equal or very close to the same value. The greatest difference
can be seen for nV = 360 and
n0
nV
= 0.25, for a FPR of 0.3 we have SE of 0.048 and SˆE
slightly underestimates the SE, given by 0.045. In Table 4.3, for nV = 360 and
n0
nV
= 0.5,
the coverage probability declines (0.950, 0.941, 0.922, 0.910, 0.891) as the FPR increases (0.1,
0.3, 0.5, 0.7, 0.9). This trend was observed for all allocations considered in Table 4.3. Table
4.2 shows results similar to Table 4.1 in terms of efficiency of the covariate specific ROC
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curve estimators. Table 4.2 and Figure 4.1 show the utility of covariate-specific ROC curve
estimator by identifying covariate values where the screening test is more effective.
4.5 Analysis of the lung cancer study data
We used the SPEL-ROC to analyze non-small-cell lung cancer (NSCLC) data from the
CALGB 150807 study (Bueno et al., 2012) conducted by the Cancer and Leukemia Group B.
This study is a subset of patients registered in the CALGB 140202 study who have stage 1A
or 1B non-small-cell lung cancer (NSCLC), have not received preoperative chemotherapy or
radiation, and are not missing histological, demographic, clinical, and follow-up information
of interest. Among patients in the CALGB 150807 study, 1,061 patients were not censored
before 12 months and were used in this analysis.
Lung cancer is the most common cause of cancer death among men and women in the world
(Blanchon et al., 2006). Lung cancer is classified as either small-cell lung carcinoma (SCLC)
or non-small-cell lung carcinoma (NSCLC), of which NSCLC accounts for approximately 80%
of all lung cancers. After surgical lung resection, a large proportion of stage 1 NSCLC patients
have cancer recurrence within five years (Bueno et al., 2012). When surgery is used as the
primary treatment for NSCLC, adjuvant chemotherapy may benefit patients who have a high
risk of cancer recurrence. Identifying patients who are at high risk of cancer recurrence
is important in order for treatment to be given to those who would benefit most. This is
an important area of study for patients, families, and doctors when making decisions on a
treatment plan.
The Balcone risk score, outlined by Blanchon et al. (2006), has been developed to identify
patients who are at greatest risk of cancer recurrence. To select the variables that are included
in the scoring algorithm, Blanchon et al. (2006) used a Cox model to identify variables that
were independently associated with mortality. The associated variables were then weighted to
create the Balcone risk index. The components of the risk score are given by: age (>70 years,
1 point); sex (male, 1 point); performance status at diagnosis (reduced activity, 3 points;
active >50%, 5 points; inactive >50%, 8 points; and total incapacity, 10 points); histological
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type (large-cell carcinoma, 2 points); and tumour-node-metastasis (TNM) staging system
(IIA or IIB, 3 points; IIIA or IIIB, 6 points; and IV, 8 points). For the data used in this
analysis, the Balcone risk score ranges from 0 to 15.
The goal of this analysis is to summarize the ability of the Balcone risk score to distinguish
between patients who survive beyond 12 months and those who do not. This will allow us
to evaluate the benefit of using the Balcone risk score to identify patients at a higher risk
of early cancer recurrence. The outcome of interest is survival beyond 12 months and the
screening test is the Balcone risk score. The ROC curve is estimated at different ages to see if
the Balcone score is a more effective screening test at certain ages. Although all information
is available for these patients, we illustrate the utility of the proposed ROC curve estimator
by sampling from the study data and evaluating the estimated ROC curve by age. Table 4.4
gives descriptive statistics for the Balcone risk score and patient age, stratified by survival at
12 months. Cut-points for the TDS component were defined by α = 1 standard deviations
from the mean of the Balcone risk score. A sample size of nV = 360 was used for all estimators
compared and details on sample allocation for each estimator are given in Table 4.8. The LS-
ROC has an SRS of size n = 360. The SPEL-ROC(SRS) allocates 100% of the sample to the
SRS component and utilizes incomplete data from the non-validation set. The SPEL-ROC
allocates 50% of the validation sample to the SRS component and samples the remaining 50%
are allocated equally between the three intervals, Ci, such that n1 = n2 = n3 = 60, while
utilizing incomplete data from the non-validation set.
Table 4.6 and Figure 4.2 show the results from the analysis of the lung cancer study data.
We have modeled the Balcone risk score using information for the disease status and the
patient age. These results show that the Balcone risk score is a more effective screening test
for survival at 1 year for younger ages compared to older ages.
4.6 Analysis of the Preterm Prediction Study data
We used the SPEL-ROC to analyze data from the Preterm Prediction Study, a multi-
center prospective study designed to study spontaneous preterm birth (Goldenberg et al.,
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1996). The Maternal Fetal Medicine Units Network of the National Institute of Child Health
and Human Development carried out this study using ten centers to recruit women. There
were 3073 women recruited between October 1992 and July 1994. Measurements were col-
lected every two weeks from 22 to 30 weeks’ gestation. Among the 3073 women recruited,
3001 had valid measurements of interest for this analysis.
PTB is defined as delivery at less than 37 weeks of gestation and contributes to neonatal
morbidity and mortality which increases as gestational age decreases (McCormick, 1985).
Bastek and Elovitz (2013) combined results from multiple studies on this topic to gain a
better understanding the relationship between biomarkers and PTB. The results were not
definitive for most biomarkers with the exception of fetal fibronectin (FFN).
Fetal fibronectin (FFN) is a protein that is produced by the fetal membrane. Knowing
the FFN measurement will not change the incidence of spontaneous PTB but it will effect the
treatment plan. Other variables are important in studying the ability of FFN to distinguish
between PTB and not-PTB. Cervical length (CL) has been shown to be associated with PTB,
so a model that allows us to observe the estimated ROC curve at different CL measurements
may lead to a better understanding of population subgroups where FFN functions as a better
screening test. Other variables, such as maternal age and previous PTB, are also of interest
in this setting. Deshpande et al. (2013) found that FFN has moderate accuracy in predicting
PTB. Although many studies are concerned with the ability to predict spontaneous PTB,
Bastek and Elovitz (2013) suggest that the ability to predict those who will not have spon-
taneous PTB is also valuable. Because FFN typically has a high negative predictive value
(proportion of true negatives over all who test negative), a negative FFN test is widely used
in clinical practice to send patients home. Measurable levels of FFN are considered to be
abnormal between 20 and 37 weeks’ gestation. Lockwood et al. (1991) show that in 588 FFN
samples from uncomplicated pregnancies, a higher percentage of subjects were positive for
FFN (level above 0.05 µg/mL) before 22 and after 37 weeks’ gestation compared to between
22 and 37 weeks’ gestation. For example the percentage of cervical samples with positive
FFN for <22, 22 to 37 and >37 weeks’ gestation were 24%, 4%, and 32%, respectively. This
is an important area of study due to the negative effects of spontaneous PTB on maternal
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and child health outcomes.
In our analysis, the outcome of interest is spontaneous PTB at less than 37 weeks’ gestation
and the screening test considered in FFN. We include cervical length as a covariate in the
model. Because the standard deviation is large compared to the mean, the cut-points for
the TDS component were defined using α = 0.15. A sample size of nV = 360 was used for
all estimators compared. The LS-ROC has an SRS of size n = 360. The SPEL-ROC(SRS)
allocates 100% of the sample to the SRS component and utilizes incomplete data from the non-
validation set. The SPEL-ROC allocates 50% of the validation sample to the SRS component
and the remaing 50% are allocated equally between the three intervals, Ci, such that n1 =
n2 = n3 = 60, while utilizing incomplete data from the non-validation set. Table 4.9 and
Figure 4.3 show the results from the analysis of the Preterm Prediction Study data. We
have modeled the screening test using information for the disease status and the cervical
length. These results show that the screening test, FFN, is a more effective at screening for
spontaneous PTB when the cervical length is shorter.
4.7 Discussion
We have proposed a semi-parametric estimator for the covariate-specific ROC curve, which
allows us to summarize the ability of a screening test to discern between diseased and non-
diseased subjects for specified covariate values. This estimator incorporates a TDS design
and includes both validation and non-validation data. Although a binormal distribution is
assumed for the screening test variable, the use of empirical likelihood methods allows us to
estimate the ROC without specifying a distribution for the covariates.
The proposed design is motivated by the need to improve efficiency in estimating the
ROC curve and to develop methods to observe the utility of the screening test at different
covariate values. Ascertaining true disease status can be costly and invasive for subjects.
Although disease status is missing for the non-validation set, the proposed estimator takes
advantage of all information available for a larger number of subjects than the validation-only
estimators. Although all estimators are unbiased, the proposed estimator was shown to be
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the most efficient for low FPR values, compared to two competing ROC curve estimators. It
is unclear if the either the SPEL-ROC or SPEL-ROC(SRS) is superior at higher FPR values,
in terms of the standard error. These results suggest that to obtain the same variability less
subjects would be needed when the non-validation subjects are used to estimate the ROC
curve, reducing study cost and subject burden. These results support the idea that inclusion
of non-validation subjects creates a more efficient alternative to the validation-only estimators
while sampling the same number of subjects. For example, with a sample size of 360 and FPR
of 0.1, the standard error of the proposed estimator is 0.038 compared to 0.080 and 0.060 for
the LS-ROC and SPEL-ROC(SRS), respectively (in Table 4.1). In contrast, with a sample
size of 360 and FPR of 0.7, the standard error of the proposed estimator is 0.014 compared
to 0.016 and 0.014 for the LS-ROC and SPEL-ROC(SRS), respectively.
More simulation studies are needed to explore the robustness of the SPEL-ROC. Non-
normally distributed data should be simulated for both the screening test and the covariates.
The empirical likelihood methods allow for ROC curve estimation without specification of the
distribution of the covariates. Simulating covariates using non-normal distributions will allow
us to see how well the ROC curve estimator works for different types of data. Simulating
the screening test variable using non-normal distributions will allow us to see how well the
SPEL-ROC performs when the distribution of the screening test is mis-specified.
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Table 4.1: Comparison of SPEL-ROC and competing methods
R̂OC
SRS
V R̂OC
SRS
V,V¯ R̂OC
P
V,V¯
nV FPR True ROC Mean SE Mean SE Mean SE
120 0.1 0.208 0.212 0.080 0.200 0.060 0.200 0.057
0.3 0.602 0.600 0.092 0.582 0.070 0.581 0.069
0.5 0.841 0.838 0.063 0.826 0.046 0.824 0.048
0.7 0.959 0.955 0.029 0.952 0.021 0.950 0.023
0.9 0.998 0.996 0.005 0.996 0.006 0.996 0.004
360 0.1 0.208 0.212 0.048 0.208 0.042 0.207 0.038
0.3 0.602 0.605 0.054 0.600 0.047 0.599 0.045
0.5 0.841 0.842 0.036 0.839 0.031 0.839 0.031
0.7 0.959 0.958 0.016 0.958 0.014 0.958 0.014
0.9 0.998 0.997 0.002 0.997 0.002 0.997 0.002
Cutpoints for the TDS component are defined by (a1, a2) = (µY − ασY , µY + ασY )
where α = 1. R̂OC
SRS
V denotes the LS-ROC which uses SRS; R̂OC
SRS
V,V¯ denotes the
SPEL-ROC(SRS) which uses SRS and utilizes information for both validation and non-
validation data; and R̂OC
P
V,V¯ denotes the proposed SPEL-ROC which uses TDS and
utilizes information from both validation and non-validation data. All estimators sample
the same number of subjects. ROC curve estimates are calculated for the population
average of the covariate.
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Table 4.2: SPEL-ROC for specific covariate values
R̂OC
SRS
V R̂OC
SRS
V,V¯ R̂OC
P
V,V¯
FPR True ROC Mean SE Mean SE Mean SE
X = population average of the covariate
0.1 0.208 0.212 0.048 0.208 0.042 0.207 0.038
0.3 0.602 0.605 0.054 0.600 0.047 0.599 0.045
0.5 0.841 0.842 0.036 0.839 0.031 0.839 0.031
0.7 0.959 0.958 0.016 0.958 0.014 0.958 0.014
0.9 0.998 0.997 0.002 0.997 0.002 0.997 0.002
X = −0.5 0.1 0.246 0.260 0.054 0.257 0.049 0.255 0.043
0.3 0.649 0.664 0.054 0.662 0.050 0.658 0.046
0.5 0.870 0.877 0.033 0.876 0.030 0.874 0.029
0.7 0.969 0.970 0.013 0.971 0.011 0.970 0.011
0.9 0.998 0.998 0.002 0.998 0.001 0.998 0.001
X = 1 0.1 0.144 0.136 0.043 0.137 0.039 0.137 0.037
0.3 0.503 0.485 0.066 0.489 0.062 0.487 0.059
0.5 0.773 0.758 0.052 0.762 0.049 0.759 0.048
0.7 0.932 0.924 0.027 0.926 0.024 0.925 0.024
0.9 0.995 0.993 0.005 0.994 0.004 0.993 0.004
Cutpoints for the TDS component are defined by (a1, a2) = (µY − ασY , µY + ασY ) where
α = 1.
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Figure 4.1: Covariate-specific ROC Curve
The SPEL-ROC is calculated with a sample size of nV = 360 and allocation given by
(n0, n1, n2, n3, nV¯ ) = (180, 60, 60, 60, 640). The parameter c indicates all possible values of the screen-
ing test, Y. Cutpoints for the TDS component are defined by (a1, a2) = (µY − ασY , µY + ασY ) where
α = 1.
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Table 4.3: Properties of the SPEL-ROC
FPR
(n0, n1, n2, n3, nV¯ ) 0.1 0.3 0.5 0.7 0.9
nV = 120,
n0
nV
= 0.5
(60,20,20,20,880) R̂OC
P
V,V¯ 0.200 0.581 0.824 0.950 0.996
SE 0.057 0.068 0.048 0.023 0.004
ŜE 0.059 0.070 0.050 0.025 0.006
95% CP 0.942 0.936 0.938 0.929 0.941
nV = 360,
n0
nV
= 0.5
(180,60,60,60,640) R̂OC
P
V,V¯ 0.207 0.599 0.839 0.958 0.997
SE 0.038 0.045 0.031 0.014 0.002
ŜE 0.039 0.045 0.030 0.012 0.002
95% CP 0.950 0.941 0.922 0.910 0.891
nV = 360,
n0
nV
= 0.25
(90,90,90,90,640) R̂OC
P
V,V¯ 0.208 0.600 0.840 0.958 0.997
SE 0.040 0.048 0.033 0.014 0.002
ŜE 0.039 0.045 0.030 0.012 0.002
95% CP 0.930 0.934 0.913 0.892 0.869
nV = 360,
n0
nV
= 0.75
(270,30,30,30,640) R̂OC
P
V,V¯ 0.209 0.600 0.839 0.958 0.997
SE 0.041 0.048 0.032 0.014 0.002
ŜE 0.041 0.046 0.030 0.013 0.002
95% CP 0.940 0.931 0.924 0.913 0.909
The fraction n0nV is the proportion of subjects allocated to the SRS com-
ponent out of the total number of validation subjects sampled. Cutpoints
for the TDS component are defined by (a1, a2) = (µY − ασY , µY + ασY )
where α = 1. The sample allocation, (n0, n1, n2, n3, nV¯ ), gives the number
of subjects allocated to the SRS component, three intervals of the TDS
component, and the non-validation set, respectively. The standard error
estimators, SˆE, are found by bootstrapping.
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Table 4.4: Descriptive statistics for the Balcone risk score and age of patients
N Minimum Q1 Median Q3 Maximum
Balcone risk score (FFN)
Overall 1061 0 1 1 3 10
Survival beyond 12 months 965 0 1 1 3 10
Survival less than 12 months 111 0 1 2 5 9
Age
Overall 1061 23.9 61.9 69.3 75.5 95.1
Survival beyond 12 months 965 23.9 61.4 68.9 75.0 95.1
Survival less than 12 months 111 43.2 66.2 72.0 76.8 87.5
Table 4.5: Sample allocation for the non-small-cell lung cancer data
Component MW-AUC SPEL-AUC(SRS) NPEL-AUC SPEL-AUC
SRS 360 360 180 180
TDS (n1, n2, n3) (0, 0, 0) (0, 0, 0) (60, 60, 60) (60, 60, 60)
non-validation 0 701 0 701
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Table 4.6: Lung Cancer Study: Comparison of Covariate-specific ROC Curve Estimators
FPR R̂OC
SRS
V R̂OC
SRS
V,V¯ R̂OC
P
V,V¯
68.3 Years old (study average)
0.1 0.330 0.229 0.432
0.3 0.551 0.474 0.701
0.5 0.699 0.657 0.844
0.7 0.820 0.809 0.932
0.9 0.931 0.939 0.986
45 Years old 0.1 0.352 0.442 0.489
0.3 0.575 0.704 0.748
0.5 0.720 0.841 0.875
0.7 0.835 0.929 0.949
0.9 0.939 0.984 0.990
85 Years old 0.1 0.317 0.137 0.400
0.3 0.537 0.338 0.671
0.5 0.686 0.521 0.823
0.7 0.810 0.700 0.921
0.9 0.926 0.885 0.982
All estimators are calculated with a sample size of nV =
360. For the SPEL-ROC, cutpoints for the TDS com-
ponent are defined by (a1, a2) = (µY − ασY , µY + ασY )
where α = 1.
Table 4.7: Preterm Prediction Study: Descriptive Statistics for FFN and Cervical Length
N Minimum Q1 Median Q3 Maximum
Fetal fibronectin (FFN)
Overall 2987 0 0.37 2.80 7.68 2151.44
Spontaneous PTB 308 0 0.88 4.47 16.22 926.55
Not PTB 2679 0 0.28 2.60 7.20 2151.44
Cervical length (CL)
Overall 2987 0 30 35 40 70
Spontaneous PTB 308 0 26 33 38 58
Not PTB 2679 0 31 35 40 70
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Figure 4.2: Lung Cancer Study: SPEL-ROC by Age
The SPEL-ROC is calculated with a sample size of nV = 360 and allocation given by
(n0, n1, n2, n3, nV¯ ) = (180, 60, 60, 60, 701). Cutpoints for the TDS component are defined by (a1, a2) =
(µY − ασY , µY + ασY ) where α = 1.
Table 4.8: Sample allocation for the Preterm Prediction Study
Component LS-ROC SPEL-ROC(SRS) SPEL-ROC
SRS 360 360 180
TDS (n1, n2, n3) (0, 0, 0) (0, 0, 0) (60, 60, 60)
non-validation 0 2627 2627
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Table 4.9: Preterm Prediction Study: Comparison of Covariate-specific ROC Curve Estima-
tors
FPR R̂OC
SRS
V R̂OC
SRS
V,V¯ R̂OC
P
V,V¯
CL = 35.2mm (population average)
0.1 0.153 0.200 0.188
0.3 0.370 0.391 0.378
0.5 0.558 0.547 0.536
0.7 0.734 0.697 0.687
0.9 0.906 0.861 0.856
CL = 15mm 0.1 0.442 0.446 0.304
0.3 0.708 0.668 0.525
0.5 0.847 0.797 0.678
0.7 0.934 0.890 0.805
0.9 0.986 0.964 0.925
CL = 25mm 0.1 0.281 0.312 0.242
0.3 0.545 0.533 0.452
0.5 0.723 0.684 0.609
0.7 0.857 0.809 0.751
0.9 0.961 0.926 0.895
CL = 40mm 0.1 0.109 0.154 0.165
0.3 0.264 0.328 0.345
0.5 0.475 0.480 0.500
0.7 0.662 0.635 0.655
0.9 0.866 0.820 0.835
All estimators are calculated with a sample size of nV =
360. For the SPEL-ROC, cutpoints for the TDS component
are defined by (a1, a2) = (µY − ασY , µY + ασY ) where α =
1.
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Figure 4.3: Preterm Prediction Study: SPEL-ROC by Cervical Length
The SPEL-ROC is calculated with a sample size of nV = 360 and allocation given by
(n0, n1, n2, n3, nV¯ ) = (180, 60, 60, 60, 2627). CL indicates cervical length (mm) and c indicates
all possible values of the screening test, FFN. Cutpoints for the TDS component are defined by
(a1, a2) = (µY − ασY , µY + ασY ) where α = 1.
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Chapter 5
Conclusions
In this dissertation, we have used semi-parametric empirical likelihood methods to develop
estimators for the area under the ROC curve (AUC), partial AUC, and the covariate-specific
ROC curve. These tools help us study the ability of a screening test to discern between
diseased and non-diseased populations. We use a test-dependent sampling (TDS) design
where TDS inclusion depends on the continuous screening test measure. The TDS design
incorporates an SRS component, a TDS component, and the remaining un-sampled portion of
the population in which disease status is not validated. The TDS design allows investigators
to over-sample subjects from specified ranges of the screening test variable, allowing for a
concentration of resources where there is the greatest amount of information. This sampling
design is particularly useful in studies similar to the lung cancer study described by Bueno
et al. (2012), where the true disease status is expensive to ascertain due to the length of time
needed to observe the outcome or the invasive procedures needed to validate disease status.
In Chapters 2 and 3, we developed semi-parametric empirical likelihood estimators for
the area under the ROC curve (AUC) and the partial AUC, respectively. No distributional
assumptions are made for the screening test and the disease status is not validated for the
non-validation subjects in the un-sampled portion of the population. Simulation studies show
that both the use of the TDS design and the inclusion of non-validation subjects give a more
efficient alternative to the SRS designs and validation-only estimators when sampling the
same number of subjects. Although all estimators compared are unbiased, the proposed AUC
and pAUC estimators are shown to be the most efficient, compared to competing estimators.
This suggests that to obtain the same variability, fewer subjects would be needed when the
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proposed method is used, reducing study cost and subject burden. Analysis of data from the
lung cancer study and the Preterm Prediction Study show that the proposed AUC and pAUC
estimators are effective tools for discerning between the two outcome populations.
In Chapter 4, we developed a semi-parametric estimator for the covariate-specific ROC
curve. Empirical likelihood methods were used to estimate the ROC curve without making
assumptions on the distribution of the covariates. Normality of the screening test variable
is assumed for this estimator. Simulation studies support the idea that inclusion of the
un-sampled subjects, in which the disease status is not validated, improves efficiency com-
pared to the estimator which uses only sampled subjects will full data available. Analysis
of data from the lung cancer study and the Preterm Prediction Study show the utility of
the covariate-specific ROC curve estimator by showing that by including covariates in the
model, the screening test is more effective at discerning disease status for certain subsets of
the population.
The TDS design is shown to improve efficiency of the proposed estimators compared to
current estimators both in simulation studies and in analyzing data from the lung cancer
study described by Bueno et al. (2012) and data from the Preterm Prediction Study (Gold-
enberg et al., 1996). The proposed estimators utilize empirical likelihood methods to reduce
the distributional assumptions needed to estimate AUC, pAUC, and the covariate-specific
ROC curve. Future research for the covariate-specific ROC curve will include relaxation of
distributional assumptions of the screening test variable.
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APPENDIX A
Asymptotic results for the SPEL-AUC
In this section we develop the asymptotic distribution of the SPEL-AUC, given by AˆP
V,V¯
in (2.14). First we show the asymptotic distribution of η = (p, α, β, λ2) in Section A.1. Next,
we derive the asymptotic distribution of RˆN (A, η) in Section A.2, which is used to find the
asymptotic distribution of the proposed estimator, AˆP
V,V¯
.
A.1 Asymptotic properties of η = (p, β, α, λ)
A.1.1 Asymptotic distribution for ξ = (α, β, λ2)
The Newton-Raphson algorithm was used to construct estimators for ξ = (α, β, λ2). The
estimator for p was constructed independently of ξ. Consider the profile log-likelihood function
pl (ξ) ∝ −
∑
ij
ln
[
1− λ2
(
eα+βyij − 1
)]
+ nV,D=0α+ β
∑
i,j∈V
D=0
Yij
+
nV¯∑
j=1
ln
[
p+ eα+βYV¯ j (1− p)
]
. (A.1)
Define Hij (η) such that the derivative of the profile likelihood (A.1) is given by
∂pl(ξ)
∂ξ =∑N
l=1 Hij (η). As N → ∞, niN → ρi for i =
(
0, 1, 2, 3, V¯
)
. Consider the Taylor expansion of
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∂pl(ξ)
∂ξ |ξ=ξˆ at ξ:
∂pl (ξ)
∂ξ
|ξ=ξˆ = 0 =
∂pl (ξ)
∂ξ
+
(
ξˆ − ξ
) ∂2pl (ξ)
∂ξl∂ξl′
+ op(1)
⇒ N1/2
(
ξˆ − ξ
)
= N−1/2
[−1
N
∂2pl (ξ)
∂ξl∂ξl′
]−1
∂pl (ξ)
∂ξ
+ op(1)
= N−1/2
[−1
N
∂2pl (ξ)
∂ξl∂ξl′
]−1 ∑
i∈(0,1,2,3,V¯ )
ni∑
j=1
Hij (η) + op(1)
=
∑
i∈(0,1,2,3,V¯ )
ρ
1/2
i n
−1/2
i
[−1
N
∂2pl (ξ)
∂ξl∂ξl′
]−1 ni∑
j=1
Hij (η) + op(1). (A.2)
Lemma 1: Applying the central limit theorem to each term n
−1/2
i
[
−1
N
∂2pl(ξ)
∂ξi∂ξi′
]−1∑ni
j=1 Hij (η)
in (A.2), we have
√
N
(
ξˆ − ξ
)
d→ N (0, ψξ), (A.3)
where ψξ =
∑
i∈(0,1,2,3,V¯ ) ρ
1/2
i var
([
−1
N
∂2pl(ξ)
∂ξl∂ξl′
]−1
Hij (η)
)
.
A.1.2 Asymptotic properties of p
The estimate of p is found using the SRS portion of the test-dependent sample. Consider
the likelihood and log-likelihood for the subjects sampled in the SRS portion, given by
LSRS (fD) =
n0∏
j=1
f (Y0j , D0j)
=
∏
j:D=1
f (Y0j |D0j = 1) p×
∏
j:D=0
f (Y0j |D0j = 0) (1− p)
lSRS (fD) =
∑
j:D=1
{ln f (Y0j |D0j = 1) + ln p}+
∑
j:D=0
{ln f (Y0j |D0j = 0) + ln (1− p)}
∝ n0,D=1 ln p+ n0,D=0 ln (1− p) . (A.4)
Define P0j such that
dlSRS(p)
dp =
∑n0
j=1 P0j (p). Consider the Taylor expansion of
dlSRS(p)
dp |p=pˆ
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at p:
dlSRS (p)
dp
|p=pˆ = 0 = dlSRS (p)
dp
+ (pˆ− p) d
2lSRS (p)
dp2
+ op(1)
=
n0∑
j=1
P0j + (pˆ− p)
n0∑
j=1
d
dp
P0j + op(1)
⇒ n1/20 (pˆ− p) = n−1/20
[−1
n0
∂2lsrs (p)
p2
]−1 n0∑
l=1
P0j + op(1) (A.5)
Lemma 2: Applying the central limit theorem to A.5, we have
√
N (pˆ− p) d→ N (0, ψp), (A.6)
where ψp =
∑n0
j=1 ρ
1/2
i var
([
−1
n0
∂2lsrs(p)
p2
]−1
P0j
)
.
A.2 Asymptotic properties of RˆN (A, η)
In developing the asymptotic distribution of AˆP
V,V¯
, we assume that the U-statistic, UN (A, η) =
RN (A, η)−E (RN (A, η)) is stochastically equicontinuous. In this section we derive the asymp-
totic distribution of RN (A, η) and use this to develop the asymptotic distribution of the
SPEL-AUC, given by AˆP
V,V¯
. Suppose A is the true AUC value and η = (p, α, β, λ2). To show
asymptotic normality of AˆP
V,V¯
, consider the two-sample U-process, UN (A, η) = RN (A, η) −
E (RN (A, η)), where RN (A, η) =
1
N2
∑
i 6=j D
′
i
(
1−D′j
)
(Iij −A), Iij = I (Yi > Yj), and
D′l =
 Dl if l ∈ VÊ (Dl) = pp+eα+βyl (1−p) if l ∈ V¯ .
Now, consider the difference between the proposed AUC estimator and the true AUC.
Next, we use this difference to solve for RN (A, η), given by:
AˆPV,V¯ −A =
∑
i 6=j D
′
i
(
1−D′j
)
Iij∑
i 6=j D
′
i
(
1−D′j
) −A
=
N2RN (A, η)∑
i 6=j D
′
i
(
1−D′j
)
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⇒ RN (A, η) = 1
N2
∑
i 6=j
D′i
(
1−D′j
)
(Iij −A)
=
(
AˆPV,V¯ −A
)
× 1
N2
∑
i 6=j
D′i
(
1−D′j
)
. (A.7)
Let Rij = D
′
i
(
1−D′j
)
(Iij −A). From Asymptotic Statistics (Chapter 12, van der Vaart),
we know that
RˆN (A, η) =
1
N
N∑
i
E [Rij |Yi, Di] + 1
N
N∑
j
E [Rij |Yj , Dj ]
=
1
N
N∑
i
E [Rij |Yi, Di] + 1
N
N∑
i
E [Rji|Yi, Di]
=
1
N
N∑
i
E [Rij +Rji|Yi, Di]. (A.8)
Lemma 3: From Asymptotic Statistics (Chapter 12, van der Vaart), if
E
[(
D′i
(
1−D′j
)
(Iij −A)
)2]
< ∞ then √N
(
RN (A, η)− E [RN (A, η)]− RˆN (A, η)
)
p→ 0
and
√
N (RN (A, η)− E [RN (A, η)]) d→ N (0,Σ) (A.9)
where Σ = 4V ar (Rij).
Ultimately, we want to know the asymptotic distribution of
√
N
(
AˆP
V,V¯
−A
)
. This can
be accomplished by considering the Taylor expansion of
√
NRN
(
AˆP
V,V¯
, ηˆ
)
at (A, η) and using
the asymptotic distribution of RN (A, η), given in (A.9). We expand
√
NRN
(
AˆP
V,V¯
, ηˆ
)
at
(A, η). First, note that
√
NRN
(
AˆP
V,V¯
, ηˆ
)
=
(
AˆP
V,V¯
− AˆP
V,V¯
)
×∑i 6=j D′i (1−D′j) = 0. This
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Taylor expansion is given by:
√
NRN
(
AˆPV,V¯ , ηˆ
)
=
√
NRN
(
AˆPV,V¯ , ηˆ
)
±
√
NRN (A, η)±
√
NE [RN (A, η)]±
√
NE
[
RN
(
AˆPV,V¯ , ηˆ
)]
=
√
N
{
RN
(
AˆPV,V¯ , ηˆ
)
− E
[
RN
(
AˆPV,V¯ , ηˆ
)]}
−
√
N {RN (A, η)− E [RN (A, η)]}
+
√
NE
[
RN
(
AˆPV,V¯ , ηˆ
)]
−
√
NE [RN (A, η)] +
√
NRN (A, η)
=
√
NE
[
RN
(
AˆPV,V¯ , ηˆ
)]
−
√
NE [RN (A, η)] +
√
NRN (A, η) . (A.10)
Since we assume that the U-process, UN (A, η) =
√
n {RN (A, η)− E [RN (A, η)]} is equicon-
tinuous, then
√
N
{
RN
(
AˆPV,V¯ , ηˆ
)
− E
[
RN
(
AˆPV,V¯ , ηˆ
)]}
→ 0 and
√
N {RN (A, η)− E [RN (A, η)]} → 0.
Now that we have simplified
√
NRN
(
AˆP
V,V¯
, ηˆ
)
, we can expand E
[
RN
(
AˆP
V,V¯
, ηˆ
)]
at (A, η)
within (A.10), which gives us:
√
NRN
(
AˆPV,V¯ , ηˆ
)
=
√
NE
[
RN
(
AˆPV,V¯ , ηˆ
)]
−
√
NE [RN (A, η)] +
√
NRN (A, η)
=
√
N { E [RN (A, η)] + ∂E [RN (A, η)]
∂A
(
AˆPV,V¯ −A
)
+
[
∂E [RN (A, η)]
∂η
]T
1x4
(
ηˆP − η)
4x1
}
−
√
NE [RN (A, η)] +
√
NRN (A, η) + op (1)
=
√
N
{
∂E [RN (A, η)]
∂A
(
AˆPV,V¯ −A
)
+
[
∂E [RN (A, η)]
∂η
]T
1x4
(
ηˆP − η)
4x1
}
+
√
NRN (A, η) + op (1) . (A.11)
To derive the asymptotic distribution of
√
N
(
AˆP
V,V¯
−A
)
, we solve for
(
AˆP
V,V¯
−A
)
in the
final expression of
√
NRN
(
AˆP
V,V¯
, ηˆ
)
in (A.11). Then, we use (A.2) and (A.5) to estimate the
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asymptotic variance. We express
√
N
(
AˆP
V,V¯
−A
)
as:
√
N
(
AˆPV,V¯ −A
)
= −
{
∂E [RN (A, η)]
∂A
}−1√
N
[
RN (A, η) +
[
∂E [RN (A, η)]
∂η
]T
1x4
(ηˆ − η)4x1
]
= −
{
∂E [RN (A, η)]
∂A
}−1√
N
×
[
RN (A, η) +
∂E [RN (A, η)]
∂p
(pˆ− p) +
[
∂E [RN (A, η)]
∂ξ
]T
1x3
(
ξˆ − ξ
)
3x1
]
= −
{
∂E [RN (A, η)]
∂A
}−1 ∑
i∈(0,1,2,3,V¯ )
ρin
−1/2
i
ni∑
j=1
Qij .
We can re-express Rll′ = R(ij)(ij)′ so that the above express can be written as a double sum.
Define Qij as:
Qij (η) = E
(
R(ij)(ij)′ +R(ij)′(ij)
)
+ ρ−1i
∂ERN (A, η)
∂p
[−1
n0
∂2lsrs (p)
p2
]−1
P0jI (i = 0)
+
∂ERN (A, η)
∂ξ
[−1
N
∂2pl (ξ)
∂ξi∂ξi′
]−1
Hij (η)
and Qˆij = Eˆ
(
R(ij)(ij)′ +R(ij)′(ij)
)
+ ρˆ−1Eˆ
∂RN (A, η)
∂p
[
1
n0
∂2lsrs (p)
p2
]
|−1p=pˆP0j (pˆ)
+Eˆ
∂RN (A, η)
∂ξ
[−1
N
∂2pl (ξ)
∂ξi∂ξi′
]
|−1
ξ=ξˆ
Hl
(
ξˆ
)
.
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APPENDIX B
Asymptotic results for the SPEL-pAUC
In this section we develop the asymptotic distribution of the SPEL-pAUC, given by AˆP
t:V,V¯
in (3.15). First we show the asymptotic distribution of η = (p, α, β, λ2) in section B.1. Next,
we derive the asymptotic distribution of RˆN (At, η) in section B.2, which is used to find the
asymptotic distribution of the proposed estimator, AˆP
t:V,V¯
.
B.1 Asymptotic distribution for η = (p, β, α, λ)
B.1.1 Asymptotic distribution for ξ = (α, β, λ2)
The Newton-Raphson algorithm was used to construct estimators for ξ = (α, β, λ2). The
estimator for p was constructed independently of ξ. Consider the profile log-likelihood function
pl (ξ) ∝ −
∑
ij
ln
[
1− λ2
(
eα+βyij − 1
)]
+ nV,D=0α+ β
∑
i,j∈V
D=0
Yij
+
nV¯∑
j=1
ln
[
p+ eα+βYV¯ j (1− p)
]
. (B.1)
Define Hij (η) such that the derivative of the profile likelihood (B.1) is given by
∂pl(ξ)
∂ξ =∑N
l=1 Hij (η). As N → ∞, niN → ρi for i =
(
0, 1, 2, 3, V¯
)
. Consider the Taylor expansion of
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∂pl(ξ)
∂ξ |ξ=ξˆ at ξ:
∂pl (ξ)
∂ξ
|ξ=ξˆ = 0 =
∂pl (ξ)
∂ξ
+
(
ξˆ − ξ
) ∂2pl (ξ)
∂ξl∂ξl′
+ op(1)
⇒ N1/2
(
ξˆ − ξ
)
= N−1/2
[−1
N
∂2pl (ξ)
∂ξl∂ξl′
]−1
∂pl (ξ)
∂ξ
+ op(1)
= N−1/2
[−1
N
∂2pl (ξ)
∂ξl∂ξl′
]−1 ∑
i∈(0,1,2,3,V¯ )
ni∑
j=1
Hij (η) + op(1)
=
∑
i∈(0,1,2,3,V¯ )
ρ
1/2
i n
−1/2
i
[−1
N
∂2pl (ξ)
∂ξl∂ξl′
]−1 ni∑
j=1
Hij (η) + op(1). (B.2)
Lemma 1: Applying the central limit theorem to each term n
−1/2
i
[
−1
N
∂2pl(ξ)
∂ξi∂ξi′
]−1∑ni
j=1 Hij (η)
in (A.2), we have
√
N
(
ξˆ − ξ
)
d→ N (0, ψξ), (B.3)
where ψξ =
∑
i∈(0,1,2,3,V¯ ) ρ
1/2
i var
([
−1
N
∂2pl(ξ)
∂ξl∂ξl′
]−1
Hij (η)
)
.
B.1.2 Asymptotic distribution for p
The estimate of p is found using the SRS portion of the test-dependent sample. Consider
the likelihood and log-likelihood for the subjects sampled in the SRS portion, given by
LSRS (fD) =
n0∏
j=1
f (Y0j , D0j)
=
∏
j:D=1
f (Y0j |D0j = 1) p×
∏
j:D=0
f (Y0j |D0j = 0) (1− p)
lSRS (fD) =
∑
j:D=1
{ln f (Y0j |D0j = 1) + ln p}+
∑
j:D=0
{ln f (Y0j |D0j = 0) + ln (1− p)}
∝ n0,D=1 ln p+ n0,D=0 ln (1− p) . (B.4)
Define P0j such that
dlSRS(p)
dp =
∑n0
j=1 P0j (p). Consider the Taylor expansion of
dlSRS(p)
dp |p=pˆ
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at p:
dlSRS (p)
dp
|p=pˆ = 0 = dlSRS (p)
dp
+ (pˆ− p) d
2lSRS (p)
dp2
+ op(1)
=
n0∑
j=1
P0j + (pˆ− p)
n0∑
j=1
d
dp
P0j + op(1)
⇒ n1/20 (pˆ− p) = n−1/20
[−1
n0
∂2lsrs (p)
p2
]−1 n0∑
l=1
P0j + op(1) (B.5)
Lemma 2: Applying the central limit theorem to A.5, we have
√
N (pˆ− p) d→ N (0, ψp), (B.6)
where ψp =
∑n0
j=1 ρ
1/2
i var
([
−1
n0
∂2lsrs(p)
p2
]−1
P0j
)
.
B.2 Asymptotic distribution of RˆN (At, η)
In developing the asymptotic distribution of AˆP
t:V,V¯
, we assume that the U-statistic,
UN (At, η) = RN (At, η) − E (RN (At, η)) is stochastically equicontinuous. In this section
we derive the asymptotic distribution of RN (At, η) and use this to develop the asymptotic
distribution of the SPEL-pAUC, given by AˆP
t:V,V¯
. Suppose At is the true AUC value and
η = (p, α, β, λ2). To show asymptotic normality of Aˆ
P
t:V,V¯
, consider the two-sample U-process,
UN (At, η) = RN (At, η)−E (RN (At, η)), whereRN (At, η) = 1N2
∑
i 6=j D
′
i
(
1−D′j
)
(It:ij −At),
It:ij = I (Yi > Yj , Yj ∈ (t0, t1)), and D′l =
 Dl if l ∈ VÊ (Dl) = pp+eα+βyl (1−p) if l ∈ V¯ .
Now, consider the difference between the proposed pAUC estimator and the true pAUC.
Next, we use this difference to solve for RN (At, η), given by:
AˆPt:V,V¯ −At =
∑
i 6=j D
′
i
(
1−D′j
)
It:ij∑
i 6=j D
′
i
(
1−D′j
) −At
=
N2RN (At, η)∑
i 6=j D
′
i
(
1−D′j
)
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⇒ RN (At, η) = 1
N2
∑
i 6=j
D′i
(
1−D′j
)
(It:ij −At)
=
(
AˆPt:V,V¯ −At
)
× 1
N2
∑
i 6=j
D′i
(
1−D′j
)
. (B.7)
Let Rij = D
′
i
(
1−D′j
)
(It:ij −At). From Asymptotic Statistics (Chapter 12, van der
Vaart), we know that
RˆN (At, η) =
1
N
N∑
i
E [Rij |Yi, Di] + 1
N
N∑
j
E [Rij |Yj , Dj ]
=
1
N
N∑
i
E [Rij |Yi, Di] + 1
N
N∑
i
E [Rji|Yi, Di]
=
1
N
N∑
i
E [Rij +Rji|Yi, Di]. (B.8)
Lemma 3: From Asymptotic Statistics (Chapter 12, van der Vaart), if
E
[(
D′i
(
1−D′j
)
(It:ij −At)
)2]
<∞ then√N
(
RN (At, η)− E [RN (At, η)]− RˆN (At, η)
)
p→
0. Consequently,
√
N (RN (At, η)− E [RN (At, η)]) d→ N (0,Σ) (B.9)
where Σ = 4V ar (Rij).
Ultimately, we want to know the asymptotic distribution of
√
N
(
AˆP
t:V,V¯
−At
)
. This can
be accomplished by considering the Taylor expansion of
√
NRN
(
AˆP
t:V,V¯
, ηˆ
)
at (At, η) and us-
ing the asymptotic distribution of RN (At, η), given in ((B.9)). We expand
√
NRN
(
AˆP
t:V,V¯
, ηˆ
)
at (At, η). First, note that
√
NRN
(
AˆP
t:V,V¯
, ηˆ
)
=
(
AˆP
t:V,V¯
− AˆP
t:V,V¯
)
×∑i 6=j D′i (1−D′j) = 0.
109
This Taylor expansion is given by:
√
NRN
(
AˆPt:V,V¯ , ηˆ
)
=
√
NRN
(
AˆPt:V,V¯ , ηˆ
)
±
√
NRN (At, η)±
√
NE [RN (At, η)]±
√
NE
[
RN
(
AˆPt:V,V¯ , ηˆ
)]
=
√
N
{
RN
(
AˆPt:V,V¯ , ηˆ
)
− E
[
RN
(
AˆPt:V,V¯ , ηˆ
)]}
−
√
N {RN (At, η)− E [RN (At, η)]}
+
√
NE
[
RN
(
AˆPt:V,V¯ , ηˆ
)]
−
√
NE [RN (At, η)] +
√
NRN (At, η)
=
√
NE
[
RN
(
AˆPt:V,V¯ , ηˆ
)]
−
√
NE [RN (At, η)] +
√
NRN (At, η) . (B.10)
Since we assume that the U-process, UN (At, η) =
√
n {RN (At, η)− E [RN (At, η)]} is equicon-
tinuous, then
√
N
{
RN
(
AˆPt:V,V¯ , ηˆ
)
− E
[
RN
(
AˆPt:V,V¯ , ηˆ
)]}
→ 0 and
√
N {RN (At, η)− E [RN (At, η)]} → 0.
Now that we have simplified
√
NRN
(
AˆP
t:V,V¯
, ηˆ
)
, we can expand E
[
RN
(
AˆP
t:V,V¯
, ηˆ
)]
at
(At, η) within (1.23), which gives us:
√
NRN
(
AˆPt:V,V¯ , ηˆ
)
=
√
NE
[
RN
(
AˆPt:V,V¯ , ηˆ
)]
−
√
NE [RN (At, η)] +
√
NRN (At, η)
=
√
N { E [RN (At, η)] + ∂E [RN (At, η)]
∂At
(
AˆPt:V,V¯ −At
)
+
[
∂E [RN (At, η)]
∂η
]T
1x4
(
ηˆP − η)
4x1
}
−
√
NE [RN (At, η)] +
√
NRN (At, η) + op (1)
=
√
N
{
∂E [RN (At, η)]
∂A
(
AˆPt:V,V¯ −At
)
+
[
∂E [RN (At, η)]
∂η
]T
1x4
(
ηˆP − η)
4x1
}
+
√
NRN (At, η) + op (1) . (B.11)
To derive the asymptotic distribution of
√
N
(
AˆP
t:V,V¯
−At
)
, we solve for
(
AˆP
t:V,V¯
−At
)
in
the final expression of
√
NRN
(
AˆP
t:V,V¯
, ηˆ
)
in (B.11). Then, we use (B.2) and (B.5) to estimate
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the asymptotic variance. We express
√
N
(
AˆP
t:V,V¯
−At
)
as:
√
N
(
AˆPt:V,V¯ −At
)
= −
{
∂E [RN (At, η)]
∂A
}−1√
N
[
RN (At, η) +
[
∂E [RN (At, η)]
∂η
]T
1x4
(ηˆ − η)4x1
]
= −
{
∂E [RN (At, η)]
∂A
}−1√
N
×
[
RN (At, η) +
∂E [RN (At, η)]
∂p
(pˆ− p) +
[
∂E [RN (At, η)]
∂ξ
]T
1x3
(
ξˆ − ξ
)
3x1
]
= −
{
∂E [RN (At, η)]
∂A
}−1 ∑
i∈(0,1,2,3,V¯ )
ρin
−1/2
i
ni∑
j=1
Qij .
We can re-express Rll′ = R(ij)(ij)′ so that the above express can be written as a double sum.
Define Qij as:
Qij (η) = E
(
R(ij)(ij)′ +R(ij)′(ij)
)
+ ρ−1i
∂ERN (A, η)
∂p
[−1
n0
∂2lsrs (p)
p2
]−1
P0jI (i = 0)
+
∂ERN (A, η)
∂ξ
[−1
N
∂2pl (ξ)
∂ξi∂ξi′
]−1
Hij (η)
and Qˆij = Eˆ
(
R(ij)(ij)′ +R(ij)′(ij)
)
+ ρˆ−1Eˆ
∂RN (A, η)
∂p
[
1
n0
∂2lsrs (p)
p2
]
|−1p=pˆP0j (pˆ)
+Eˆ
∂RN (A, η)
∂ξ
[−1
N
∂2pl (ξ)
∂ξi∂ξi′
]
|−1
ξ=ξˆ
Hl
(
ξˆ
)
.
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